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ABSTRACT
Glutamic acid decarboxylase-65 (GAD-65) and the tyrosine phosphatase-like protein
IA-2 are major targets of autoimmunity in type I diabetes mellitus (type I DM), stiff-
man syndrome (SMS) and autoimmune polyendocrinc syndrome (I\PS). In this study,
the precise epitopes in GAD-65 of three different mouse monoclonal antibodies
(Mo Abs) (N-terminal MoAb within amino acid residues 4-17. C-h:nninal MoAb
within amino acid residues 572-585 and GAD-6). human monoclonal antibody
(b96.11 huAb) and polyclonal antibodies (SMS patients' sera) were investigated. The
precise cpitopes in IA-2 of two different MnAbs (7613 and 7()F) were also
investigated. These precise epitope investigations were performed lIsing two different
phage-displayed random peptide libraries with di Ilcrent characteristics (T7 phage
library gene X C9C and linear 9-mers, and M 13 filamentous phage library gene III
C7C and linear 12-mers and gene VIII 5C4C4).
Sequencing of N-terminal and C-terminal MoAb reactive peptidcs. which were
obtained from the successful biopanning using M 13 gene III linear 12-mers phage
library and were selected by high affinity binding in immnuo-blouing assay using
nitro-cellulose membranes and in capture ELISA. revealed that the 1110stsignificant
motif recognised was P-G-x-x-x-W-S-F and F-L-I-x-E-I/V/L-D-x-L. respectively.
which showed conservative substitutions and may correspond to the position 4-10
amino acids (aa) of GAD-65 (P-G-S-G-F-W-S-F) and to the position 573-581 aa of
CiAD-65 (F-L-I-E-E-I-E-R-L), respectively. To further detine the N-terminal MoAb
cpitope, sequencing of N-terminal MoAbs reactive peptides. which were obtained
trorn the successful biopanning using M 13 gene V III 5C4(,4 phage Iihrary and were
II
selected by high affinity binding in imrnnuo-blotting assay using nitro-cellulose
membrane and in capture ELISA. revealed a motif of SoT-Po which does not
correspond to 4-17 aa of GAD-65 and does not overlap with the previous motif of the
N-terminal MoAb. i.c. P-G-S-G-F-W-S-F (4-10 aa) of GAD-65. Therefore, the M13
pYIlI 5C4C4 worked with N-terminal MoAb by expressing a relevant sequence for
the N-terminal Mo Ab but which is unlike its epitopc in GAD-65. To further define the
N-terminal MoAb cpitope. sequencing of N-terminal Mo Ab reactive peptides, which
were obtained from the successful biopanning using T7 gene X linear 9-mers phage
library and were selected by high affinity binding in immnuo-blotting assay using
nitro-cellulose membrane. revealed a motif of P-X-X-G which may correspond to 4-7
aa ofGAD-65 (P-G-S-G). which overlaps with the previous motif P-(i-S-G-F-W-S-F
(4-10aa).
Sequencing of GAD-6 MoAb reactive peptides. which were obtained from the
successful biopanning using T7 gene X C9C phage library and were selected by high
affinity binding in immnuo-blotting assay using nitro-cellulose membrane and in
ELISA, revealed two different motifs of RlK-L/ A/I-x-K and Mvx-x-A. which showed
conservative substitutions and may correspond to the position 525-52X an of GAD-65
(R-L-S-K) and to the position 523-526 aa of GAD-65 (M-S-R-L). respectively, which
overlap with each other. To further define the GAD-6 epitope. sequencing of GAD-6
reactive peptides. which were obtained from the successful biopanning using T7 gene
X linear 9-mers phage library and were selected by high affinity binding in immnuo-
blottinu assay using nitro-cellulose membrane. revealed a motif of R-x-x-K, which
eo ~
may correspond to 525-528 aa of GAD-65 (R-L-S-K) and overlaps with the previous
motif of the GAD-Cl selected from T7 gene X C9C phage library. To further define the
III
(ii\IJ-() epitope. sequencing or GAD-6 reactive peptides. which were obtained from
the successful biopanniug using M 13 gene VIII 5('4('4 phage library and were
selected by high affinity binding in immnuo-blotting assay lIsing nitro-cellulose
membrane and in capture ELISA. revealed a motif or M-x-x-A which may correspond
to 523-526 aa of GAD-65 (M-S-R-L), and overlaps with the previous motif selected
from T7 gene X ('9(' phage library. Thus, the overall motif or GAD-6 may
correspond to 523-52X au of GAD-65 (M-S-R-L-S-K). To further define the GAD-6
cpitope, sequencing or (iAD-6 reactive peptides. which were obtained from the
successful biopanning using MI3 gene III C7C and linear l2-l11ers plwgc libraries, did
not show a clear motif and did not show reactivity with GAD-6 hy capture ELISA. A
possible explanation for this is that the peptides. which are specific to (;/\1)-6. are not
present in these M 13 pill phage libraries.
Sequencing of b96.11 huAb reactive peptides, which were obtained from the
successful biopanning US1l1gM 13 gene III linear l z-mers phage library and were
selected by moderate affinity binding in immnuo-blotting assay using nitro-cellulose
membrane. revealed two different motifs of IIV-T/S-A/G/L-T/S-i\!L and S-T/S-
CliAIL/I. which showed conservative substitutions and may correspond to the position
332-336 aa of GAD-()) (V -S-A-T-A) and to the position 338-340 aa or (IAD-65 (T-T-
V). respectively. Thus. the overall motif of b96.ll might correspond to .~32-340 aa of
( 'AD-65.
In a capture ELISA system for the detection of GAD-65 specific antibodies, b78
huAb bound slightly better with GAD-6 (rather than N-terminal Mo Ab ) as the capture
MoAb. but b96.1 I bound much better with GAD-6 as the capture Mo Ab. This might
IV
suggest that GAD-() docs interfere with b78 huAb binding to (iA[)-()) more than it
does with b96.11 hu Ah. However. it must also suggest that the (iAI )-() and b78 huAb
cpitopes are not directly overlapping.
Sequencing of SMS sera reactive peptides. which were obtained from the successful
biopanning using M I~ gene III linear 12-mers phage library and were selected by
moderate affinity binding in immnuo-blotting assay using nitro-cellulose membrane.
revealed two different motifs of L/A-A-x-T/S-R/H/K and of T/S-T-V/IIL-F-E-
UGlilY IA-H/K-L/Ci-x-K/R. which showed conservative substitutions and may
correspond to the position 371-375 aa ofGAD-65 (L-L-M-S-Rl and to the position
463-472 aa of GAO-65 (T-T-G-F-E-A-H-V-D-K). respectively. as public epitopes of
SMS patients' sera.
Sequencing of 76B and 76F MoAbs reactive peptides, which were obtained from the
successful biopanning using T7 gene X C9C and M 13 gene 111linear 12-mers phage
libraries and were selected by high affinity binding in immnuo-blotting assay using
nitro-cellulose membrane and in ELISA, revealed that the most significant motif
recognised was D-x-K-P-L-S and F-x-Y-Q, respectively. which may correspond to the
position 477-482 aa of IA-2 (D-Q-K-P-L-S) and to the position 626-()29 aa of IA-2
(F-E-Y-Q). respectively.
The studies described in this thesis have shown that the epitope mapping of different
antibodies on GAD-65 and IA-2 may help to understand the relationship between
antigenicity and structure in these autoantigens which are targets in ivpe I DM and
related disorders (c.g. SMS and APS).
CHAPTER ONE
GENERAL INTRODUCTION
Introduction
1. Introduction
1.1 Autoimmunity
1.1.1 The Spectrum of Autoimmune Diseases
Autoimmune disease occurs when a specific adaptive immune response is directed
against self. Human autoimmune diseases are divided into two major groups, organ-
or tissue-specific, and systemic. In organ- or tissue-specific autoimmune diseases,
autoimmune responses are directed against autoantigens present in a single organ or
tissue [e.g., type I diabetes mellitus (type 1 DM)l. On the other hand, in systemic
autoimmune diseases. autoantigens that are widespread throughout the body are the
target of autoimmune responses [e.g., nuclear antigens in systemic lupus
erythematosus (SLE)] (Table 1.1). Some autoimmune diseases are characterised by
autoimmune responses against both systemic and organ- or tissue-specific
autoantigens (e.g., Sjogren' s syndrome).
Autoantibodies or T cells can cause tissue damage in autoimmune diseases.
Autoantibodies to autoantigens on cell surfaces (e.g., autoimmune haemolytic
anaemia) or extracellular matrix (e.g., Goodpasture's disease) lead to tissue damage.
I' cells specfic to autoantigens can damage tissue cells directly or by activating
macro phages (e.g., in type 1 DM). Also, autoantibodies to receptors cause disease by
stimulating (e.g., thyroid-stimulating hormone receptor i11 Graves disease) or
blocking (e.g., acetylcholine receptor in myasthenia gravis) receptor function. On the
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other hand. chronic generation of immune complexes causes tissue damage III
systemic autoimmune diseases (e.g .. SLE).
Table 1.1 Classification of Autoimmune Diseases. Target Autoantigen Associations.
Autoimmune Diseases
Organ- or Tissue-Specific Diseases
Type I Diabetes Mellitus
Autoimmune Thyroiditis
Graves' Disease
Myasthenia Gravis
Pernicious Anaemia
Primary Biliary Cirrhosis
Goodpasture's Disease
Pemphigus Vulgaris
Bullous Pemphigoid
Addison's Disease
Systemic Diseases
Systemic Lupus Erythematosus
Systemic Sclerosis
Autoimmune Haemolytic Anaemia
Dermatomyositis
Rheumatoid Arthritis
Idiopathic Thrombocytopenic Purpura
Autoantigcns
Islet 13 cells
Thyroglobulin. Thyroid Peroxidase
Thyroid Stimulating Hormone Receptor
Acetylcholine Receptor
Intrinsic Factor
Bile Ducts of Liver
Glomerular Basement Membrane
Epidermal Cadherin
Epidermal Basement Membrane
Secretory Cells of Adrenal Cortex
DNA. Histories. Ribosomes
Nucleoli
Red Blood Cells. Rhesus Antigen
Soluble Nuclear Proteins
[gG
Platelet lntegrin
1.1.2 Mechanisms of Self-Tolerance Induction
There are two mechanisms involved in the induction of self-tolerance: primary and
secondary (regulatory).
1. 1.2. 1 Primary Mechanisms
Primary mechanisms include clonal deletion, clonal anergy and clonal indifference
(ignorance) which influence lymphocyte development and shaping or Ihi.' repertoire.
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1.1.2.1.1 Clonal Deletion
I and Bvccll lineages can be eliminated during their development and maturation in
central and peripheral lymphoid tissues. Also. clonal deletion includes receptor
editing (escaped deletion). resulting in synthesis or receptors lacking specificity for
the original self antigen; and propriocidal killing: deletion by apoptosis when the
lymphocytes are exposed to self antigen either early in development or when the self
antigen is present in multivalent form or at high concentrations or self antigens,
deleting particularly those lymphocytes with high affinity for the antigen.
I. 1.:1.1.1.1 B cells
B cells. like T cells. are susceptible to deletion at an early stage in their development.
13 cells obtained from tolerant double transgenic mice expressing multivalent self
antigens [e.g. major histocompatibility (MHC) class I or membrane hound hen egg
lysozyme (HEL)] are eliminated from peripheral lymphoid tissues ill the absence of
signal 2 for cell-cell interactions (Hartley et al., 19(1). Also. inducing tolerance in B
cells with specificity for natural self antigens by deletion has been confirmed by using
transgenic models expressing the genes for autoantibodies to double stranded DNA
(Chen et al., 1995). erythrocytes (Murakami et al., 19(2) and COX (Brombacher et al.,
1(91). In the case of the erythrocyte model, the Ig transgenic B cells correlated to the
B-1 rather than the 8-2 lineage, suggesting that the 8-1. like 8-2. cells arc susceptible
to deletion. and the deletion can occur in the periphery as well as the hone marrow.
Furthermore. in the case of the CD8 model, mature peripheral 13 cells may also be
eliminated.
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Self-reactive B cells may also be eliminated by receptor editing ( l'iL'gs et al., 1993;
Gay et al.. 19(3). Following engagement of Ig receptors on immature B cell,
recombinase activating genes are reinduced leading to receptors lacking specificity for
the original self antigen.
Administration of large amounts of soluble antigen to normal or transgenic mice leads
to apoptotic death in germinal centre B cells, particularly those with high affinity for
the inducing antigen. by interfering with the interaction of B cells with the follicular
dendritic cell network (Han et al., 1995; Pulendran et al., 19(5): this resembles
propriocidal killing of acutely activated T cells. This process is I cell and Fas
independent and inhibited by bcl-2.
1.1.2.1.1.2 TeeJls
Thymic stromal cells which include endogenous thymic epithelial cells mainly control
positive selection whereas bone marrow-derived stromal cells like macrophages and
dendritic cells mainly control negative selection (deletion) (Pardoll and Carrera. 1992:
Hugo et al., 1993 l.Early precursor thymocytes. which lack either I' cell receptor
(TCR) or accessory molecules, mature into TCR+ C04+ C08+ (double positive) cells
with the ability to interact with antigen-presenting stromal cells. The double positive
cells with higher avidity for self-peptide-MHC complexes are eliminated. while those
with lower avidity survive and differentiate into single positive ('04+ CD8- or C04-
(,D8+ T cells with anti-foreign specificity (Scollay and Godfrey. 19(5).
lntrathymic deletion of TCRa~+ single positive T cells recognising self peptide on
thymic APC is very efficient (Sprent, 19(5). There is evidence that f() I cells are also
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partially intrathymicallv deleted (Allison. 1993). Some (J.r~ lCR+ double negative T
cells are positively selected in the thymus and migrate to peripheral lvmphoid tissues
and the bone marrow (Dejbakhsh-Jones et al., 19(5). Within the thymus. apoptosis
can occur in double positive thymocytes via a Fas dependent pathwny (Arase et al..
19(4). while within the periphery those expressing the NK 1.1 marker appear to play
an immunoregulatory role through release of large amounts or Th2 cvtokines (lL-4
and IL-lO) (Bendalac. 19(5).
T-cc!l deletion is complete when massive doses of antigen arc used. For example.
inoculation of a peptide from lymphocytic choriomeningitis virus (I.CMY) in TCR
transgenic mice causes complete deletion of LCMY -specific l cells (Moskophidis et
al.. 1(93). In addition. Fas may playa role in maintaining self-tolerance in humans as
evident from the development of autoimmune lyrnphoprolifcrativc syndromes in
patients with Fas gene mutations (Fisher et al., 19(5). l-as-related molecules. such as
tumour necrosis factor receptor (TNFR). control the deletion or CDX+ T cells whereas
the Fas pathway also controls the deletion ofCD4+ T cells (Zhcng cl ;11.. 1(95).
1.1.2.1.2. Clonal Anergy
Clonal Anergy is characterised in both T- and Bvcell lineages hv a failure to
proliferate in response to antigen. down regulation of the antigen receptor complex
and/or cytokine receptors and costimulatory molecules and reversibility on exposure
to appropriate second signals.
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1I.:!.I.l.1 Bee/I.,·
Hoth mature and immature B cells can be rendered anergic. Thus. this mode of
tolerance occurs in peripheral lymphoid tissue as well as the bone marrow (Goodnow
et al., 1989). Although anergic B cells, which arc removed [rom the tolerant
environment, fail to respond to T-cell help or Tvindcpcudent stimuli such as
lipopolysaccharide (LPS), removal of the anergic B cells to an environment that lacks
tolcrogenic concentrations of antigen leads to uprcgulation 01" Igrvi and antibody
production (Adams et al., 1990). Thus, the anergic stall: is reversible: it does not
commit the B cell to death and may allow the development or autoimmunity to
soluble (oligovalent) self antigens. Anergic 8 cells from soluble I-lEL double
transgenic mice can retain the capacity to process antigen and to proliferate and
differentiate into antibody producing cells following exposure to C()40 ligand and the
cytokines IL-4 and IL-5. On the other hand. this state is ussociated with
downregulation of the [g receptor function and a reduction in tyrosine kinase activity
and calcium nux (Eris et al., 1994).
1.1.:!.1.2.2 T cells
l-cell anergy occurs when IL-2 is lacking, as for example. when the interaction
between pairs of costimulatory molecules like 87/(,D28 is blocked. I-cell anergy is
associated with inhibition of proliferation and secretion or 11.-2 and with
downregulation of T cell receptors for antigen and IL-2 or coreceprors. Also, it is
associated with a block in the transcription of the IL-2 gene by AI'-1. the activity of
which depends on signaling through the TCR-C03 and C028 pathways (Kang et al.,
19(2). A failure in activation of the Ras protein may block the production of IL-2,
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smcc the Ras protein transmits signals along the TCR-CD:; patlmay to AP-I and
influences early events in the CI)28 pathway (Li et al., 199(1).
Less antigen results in anergy whereas more antigen leads to deletion t lazekas de St.
Groth et al., 19(2). Murine and human C04+ T-cell clones can be rendered anergic in
vitro on encounter with peptide in the absence of CD2SIB7 signals (I >CSilva et al..
1()91). whereas naive T cells (e.g., from TCR transgenic mice) remain indifferent.
Blockade of the interaction between C028 and B7 in vivo does not necessarily lead to
anergy: so the T cells either remain indifferent (naive) or if blockade is incomplete.
partial activation may occur which may shift the cytokine profile lrom Th I to Th2
(Kearney et al., 19(5).
Exposure of C04+ T cells to intravenous peptide or superantigcn is accompanied by
an anergic state. because the avidity of binding to the TCR receptor docs not reach
that required for deletion.
1.1.2.1.3 Clonal Indifference (Ignorance)
T and B cells expressing anti-self receptors may persist in the host hut rail to interact
with antigen. There arc three reasons why these cells remain indi [Icrent to self
antigens. The first reason includes antigen related factors such as 10\\ concentration
and valency or inaccessibility (sequestration). The second reason is cellular factors
including low precursor frequency of naive T cells. low receptor avidity of
preswitched B cells or low functional activity of neonatal (early in lite) dendritic cells
and naive unprimed T cells which lack adhesion molecules required lor penetration of
nonlymphoid tissues. The third reason includes host or tissue related lactors such as
7
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low or absent expression of Mile. lack of costimulatory molecules Ill' lack of cytokine
secretion.
1.1.2.2 Secondary Mechanisms
1.1.2.2.1 Interclonal Competition and Follicular Exclusion
In the case of B cells. intcrclonal competition may occur between existing and newly
formed clones of cells for a range of rate-limiting processes. such as ~rowth factors.
On the other hand. tollicular exclusion is a way or relining the .uui-Iorcign B-cell
repertoire which can occur for two reasons: first. in HEL double trans~el1ic mice. the
presence of immune complexes within peripheral lymphoid tissue may block antigen
binding Ig receptors leading to interference by these immune complexes with normal
B-cell signalling (Fulcher and Basten. 1997). Second. a lack ofTvccll help leads to the
lack of the second signals and the failure of self-reactive B cells to enter the follicles
(Fulcher et al., 1996).
1.1.2.2.2 Suppression
Suppression can be mediated under different conditions by CD4+. ('1 )8+ and double
negative (,D4- CDX- T-cell subpopulations (Adelstein et al.. I t)l)()) ('()4+ T cells
suppression is not entirely clear although it can be associated with induction of a Th2
cytokine profile, Also. double negative T cells. including those expressing NK 1.1.
secrete large amounts of lL-4 and IL-IO and very little amounts of IL-2 or IFNy
(Bendalac, 1995). Suppression by this subset may be due to preferential induction of a
Th? response and immune deviation. In addition. CD8+ T cells exert their suppressive
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effect on development of experimental allergic encephalomyelitis (1'.\1':) via release
olthc inhibitory cytokinc, transforming growth factor-]) (T(iF-r~) (Miller et 1.11.. 1992).
1.1.2.2.3 Immune Deviation
Immune deviation describes the reciprocal relationship bctwccn Tvccll reactivity
[delayed type hypersensitivity (OTH)] and antibody production which can occur
following immunization with antigen in different physical forms or concentrations.
For example. administration of a small dose of antigen leads to a strong OTH
response with little or no antibody, whereas large doses lead to significant antibody
production and less DTH. Also. strong OTH responses occur when lh I cells secreting
1L-2 and IFNy are activated under the influence of macrophage derived IL-12. On the
other hand. production of most classes of antibodies is stimulated h\ Th2 derived IL-
4. Moreover. Th2 and Th 1 cells are inhibited by 1FNy and 1L-4/11.-1 O. respectively
(Mosmann et al., 1991 ) .
1.1.2.2.4 Vetoing
Iluman and mouse CDX+ T cells can recognise self peptide-Ml-lC class I complexes
present on other CDX-expressing T cells which then kill the original cell by apoptosis
(Miller, 1986). Vetoing depends on an interaction between the C[)X molecule on the
veto cell and the UJ domain of the MHC class I molecule on the recognising cell
(Fink et al., 1983). Human. not mouse, C04+ T cells can act as veto cells by
expressing HLA class II (Schwartz. 1993).
l)
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1.1.2.2.5 ldiotypc Network
Perinatal administration 01' certain anti-idiotype antibodies call lead to prolonged
inhibition of the corresponding idiotypes later in life by cross-link inu (II' Ig receptors
on immature B cells. which are then deleted in the absence 01' second siunals (Keanev
~ .
and Vakil. (986). The efficacy of pooled Ig in the treatment or certain autoimmune
diseases. such as immune thrombocytopenic purpura. may he related to its content of
anti-idiotype antibodies (Berkman et al., 1990).
1.1.3 Mechanisms of Induction of Autoimmunity
1. 1.3. 1 Release of Anatomically Sequestered Antigens
Antigens associated with peripheral tissues, especially those sequestered behind
anatomical barriers. may not be exposed to the developing T cell repertoire and,
therefore. tolerance may normally be unnecessary. However. evidence indicates that
exposure of previously sequestered antigens as a cause or organ-specific
autoimmunity can occur. For example, in sympathetic ophthalmia. damage to one eye
leads to a response to released sequestered antigen causing autoimmune damage to the
other eye.
1. 1.3.2 Cryptic Epitopes
Some tissue proteins are normally processed and presented to lymphocytes by
antigen presenting cells (APes), with tolerance being established to the dominant
epitopes. If. however. circumstances arise which cause the same components to be
degraded in an unusual or excessive manner, peptide fragments ll1a~ he generated
10
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which would normally be cryptic. and to which the immune system is not tolerant.
l.yrnphocytes can react against these cryptic epitopes. generating <Ill autoimmune
response. Epitope crypticity may result from various factors. including ineffective
processing or dominance of a flanking epitope that competes tor hindiru, to the same
human leukocyte antigen (I-ILA) molecule.
1.1.3.3 Peripheral Tolerance and Immunological Ignorance
Mature resting T cells specific for extrathymic antigens. which arc presented by non-
professional APes (other than dendritic cells and macrophages). may be induced to
undergo anergy due to the absence of appropriate second signals or costimulatory
Iactors (Schwartz. 19(0). An alternative possibility is that there is 110 induction of
anergy. but that the mature T cells are unable to recei ve appropriate signals and/or
help possibly due to the low amount of antigen presented. Therefore. the T cell will
ignore such antigens. Thus. if adequate antigen presentation and costimulation occurs
through professional APes. then these T cells may be activated and cause tissue
damage.
1. 1.3.4 Molecular Mimicry
Many peptide fragments of infectious agents are homologous with host proteins [e.g ..
coxsackie virus P2-C protein and glutamic acid decarboxylase ( i;\l)) (Kaufman et
al., 1992)]. Thus. the immune responses against these fragments or infectious agents
may cross-react with self antigens. Autoreactive T cells may be stimulated initially by
cross-reactive foreign antigens. not by the autoantigens themselves. due to the way in
which the foreign antigens are presented. i.e. their immunogcnicitv. The foreign
II
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antigens are normally presented by professional antigen presenting ccllx (APes) (i.e.
dendritic cells and macrophages) which express l ll.A class II ;lI1d costimulatory
adhesion molecules. Once T cells are activated by foreign antigens. Ihcsc effector T
cells may react against cross-reactive autoantigens.
1. 1.3.5 Molecular Modification
Some antigenic determinants are created on somatically mutated antibodies during the
maturation of the immune response. For example. in rheumatoid arthritis. rheumatoid
tactors (RFs) (anti-Igt i Fe autoantibodies) may be induced because modified
antigenic determinants are exposed on antigen-cornplcxed [g(i. Although these low
affinity autoantibodies (RFs) react better with multimeric Ig(j. they can bind to
monomeric [gG. However. glycosylation defects may also playa role in RF induction
( lsuchiya et al., 199]).
In addition, the carrier effect enables autoreactive B cells to receive T cell help when
a foreign determinant. e.g. drug or virus, becomes covalently linked to a self-
determinant which is recognised by the receptor (Ig) of autoreacrivc 13cell. TeR of
the helper T cells recognise the foreign determinant which is processed and presented
by MHC of self-reactive B cells. Then, these helper T cells cooperate with self-
reactive B cells to induce proliferation of these I~ cells and production of
autoantibodies (Reeves and Todd 1996).
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1.1.3.6 Failure of Natural Immune Tolerance to Autoantigens
l.rrors in central or peripheral tolerance at the "1"- or B-cell len: I have also been
suggested as causes of autoimmunity. which might be due 10 interference with
apoptosis during negative selection of reactive clones. Interactions between Fas and
las ligand (Fasl.) an: required for the initiation or apoptosis. and Sl.L-prone mice.
including Ipr (lyrnphoproliferation) and gld (generalised iyrnphoprnlitcrative disease)
mice, arc defective in the apoptosis-promoting Fas and Fasl.. respectively. The SLE-
prone MRL-lpr mice. rendered transgenic for TCR-recognising antigens in the context
or MHC class I or class II, show defects in peripheral T-cell tolerance with no defects
in thymic negative selection (Singer and Abbas 19(4). Fas-dcficicnt autoimmune
lyrnphoproliferative syndrome (FD-ALPS), also Known as the Canale-Smith
syndrome. is the human equivalent of the lymphoproliferative autoimmune disease of
t-vlRL-Ipr mice which is associated with inherited uenes encodinu detective versions
~ ~
or the Fas protein.
1.1.3.7 Po/yclonal Activation
Polyclonal T - and/or B-cell activation has also been suggested as an initiating
mechanism of autoimmunity. particularly in systemic diseases. I'olyclonal 8-cell
activators may induce autoantibodies because of the existence or non-deleted self-
reactive B cells and/or stimulating arrested anergised 13 cells which may become
active. Polyclonal Tvcell activators may also induce autoantibodies indirectly. The T
cells. which react with HLA class II-bound antigenic self-peptide» on B cells, may
stimulate self-antigen specific B cells. thereby leading to production or autoantibodies
(Theofilopoulos, 199~).
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1.1.3.8 Immunoregulatory Disturbances
Changes in Tvccll subsets and their cytokincs may be involved in initiating
autoimmune diseases. lor example, in type I DM, CD4+ T helper I cell (TH 1)-
derived IFN-y activates macrophages and CD8+ cytotoxic T cells ( It·) and inhibits
lH 2 cells, which might otherwise have suppressed the autoimmune response.
14
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1.2 Type 1 Diabetes Mellitus
lypc I diabetes mellitus (type 10M) is an autoimmune diseuse which is
characterised by destruction of insulin-producing pancreatic islet 1\ cells. This
autoimmune response to the islet p cells can damage these cells following cellular
infiltration of the islets by Th I cells. macrophages and COX+ cytotoxic T cells (TC).
Also, autoantibodies. e.g. to glutamate decarboxylase (GAD). lire produced to the
autoantigens of the islet I~cells. and these can be used as markers or the pathogenesis
of type 10M. These autoantibodies can also be produced in other diseases. such as
autoimmune polyendocrine syndrome (APS) and stiff-man syndrome (SMS).
There are two types of APS. type I (APS I) and type II (AI'S II). /\PS I is a rare
disorder with an autosomal recessive inheritance. The main common tcatures of APS
I are mucocutaneous candidiasis. hypoparathyroidism. adrenal failure and 5% of
patients develop type OM. APS II is a rare disorder with an autosomal dominant
inheritance. The main common features of APS II are thyroid disease. gastric
autoimmunity. adrenal failure and up to 50% of patients develop type I DM (Neufeld
et al., 1980).
SMS is a rare neurological disorder characterized by progressive rigidity and spasms
of skeletal muscles and a deficiency of gamma-ami no-butyric acid ( JABA). This is
associated with the binding of autoantibodies to CiAO. which is responsible for the
synthesis of GABA from glutamic acid in the brain and peripheral neurons and islet p
cells (Solimena et al.. 19(0). About 30% of SMS patients develop type I OM. but
most patients with type I DM do not have SMS (Solimcna et al.. 199(l)
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lnvironmcntal factors. such as specific viruses. and genetic factors. primarily HLA.
arc associated with the development of type 10M.
1.2.1 Immunopathogenesis of Type 1 Diabetes Mellitus
Islet [~ cells may express many autoantigens (for example. insulin and GAD). The
autoimmune reponsc against these autoantigcns involves humoral mediators
(autoantibodies} and cellular mediators. i.e. Te. TIL macrophagcs and other APCs.
such as dendritic cells (Benoist and Mathis 1997).
Islet 0 cell autoantigens are processed and presented by macrophagcs and/or other
APCs (particularly dendritic cells) in association with HLA class II molecules. which
are present on the surface of APCs. Ag-HLA class II complexes and co-stimulatory
adhesion molecules (87). which are present on the surface of macrophages, may
activate TH 1. Also. macrophages secrete interleukin-12 (IL-12) to lurther activate
1'1-11. Then. TH 1 produce lL-2 and interferon-y (IFN-y). IFN-y activates macrophages
and Te. while lL-2 activates TC only (Rabinovitch. 19(4). Also. IFN-y inhibits TH2
(Lord et al., 19(6) and may have direct cytotoxic effects on the islet [~cdls (Awata et
al .. 19(4). Furthermore. IFN-y upregulates the adhesion molecules 011 the islet p cells
(Awata et al., 1(94) and enhances their HLA class I expression to promote the
interaction ofTC with islet 0 cells (Awata et al. 1994: Hussain et ul .. 11)l)6). IFN-y in
combination with either tumour necrosis factor (TN F)-« or -0 or lyrnphotoxin induces
II LA class II expression on the islet J3 cells (Pujol-Borrell et al.. 1(87). The
macrophages, which are activated by IFN-y. secrete IL-lu.IL-I[1. I"NF-(J, (Hussain et
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al.. 19(6).11.-6 (Benoist and Mathis 1997), oxygen free radicals «)_:, ami H~(2) and
nitric oxide (NO) which are cytotoxic to islet p cells (Rabinovitch. I ()1)4), In contrast.
('(' can be elicited through bystander activation, but can home to and destroy the islet
1\ cells. by recognition of antigens (Benoist and Mathis. 199X), There is evidence that
perforin plays its role in islet 13 cell destruction (Benoist and Mathis 1(97), Also. the
interaction between I:as on islet B cells and Fas ligand on infiltrating cells might
trigger selective apoptotic f3-cell death in inflamed islets (Moriwak i et al., 1999).
Macrophage-derived IL-IB enhances expression of Fas (Cf)<)5) nil islet B cells
(Yamada et al., I 99() which facilitates Fas-Fax ligand interactions: Fas ligand
(C[)95L) is already expressed on islet p cells of normal individuals: interaction
between Fas and Fas ligand both expressed on islet 13 cells may induce apoptosis of
islet B cells (Loweth cl al.. 1998). In another study in NOD mice. laxl. was detected
on TH and TC and Fas expression was detected on 13 cells or syngeneic islet grafts
leading to autoimmune destruction of islet p cells. Fas expression correlates with
expression of IL-I u, TNFa and IFNy in islet grafts (Suarez-Pinzon, et ul., 1999). Islet
I~cell destruction and infiltration by leukocytes in autoimmune diabetes in NOD mice
involves Fast-mediated mechanisms (Suarez et al., 2(00), Also. TNF/TNFRI
interaction may play a role in the destruction of islet f3cells (Pakula et al.. 1(97).
Vascular endothelial cells may also respond to lL-1. TNF and IFN-y by expressing
II LA class II molecules to present islet p cell autoantigens to '1'111 (Rabinovitch,
19(4). and adhesion molecules to enhance the accumulation of mononuclear cells in
the islets (Hanninen et al., 19(2).
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lC secrete IFN-y and TNF-I~. which arc cytotoxic to islet I~cells. and the re interact
with Ag-HLA class I complexes. which are present on the surface lll' islet p cells
(Rabinovitch. 19(4) (Fig. I. I ).
Further damage to the islet r~cells may enhance the exposure of some proteins. which
arc normally kept sequestered within the islet [3 cells. such as heat-shock proteins.
proinsulin and cytoplasmic gaugliosides. The appearance of these proteins stimulates
the inflammatory T cells. particularly TC, and the secretion 01' inflammatory
mediators (TC-derived IFN-y). which promotes the attraction of macrophages. The
macrophages will present them to TH l. The remaining healthy I~cells must overwork
to supply the needed insulin. This hyperactivity exhausts the islet II cells and may
increase the release of the autoantigens and the killing of these islet II cells. Very few
islet p cells remain to supply insulin to the body. and the symptoms ot typc I DM will
appear (Atkinson and Maclaren 1990).
IX
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Figure 1.1 The role of TH I and TH2 subsets in autoimmune response 111 type I
diuhctes mellitus (Rabinovitch 19(4).
IThe autoimmune ('CSp~nsc in rn@
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1.:2.1 Environmental Factors
1.2.2. 1 Geographical Distribution and Incidence
The incidence of type 1 ()M has been shown to be increasing. llowcvcr. the incidence
of type 1 DM differs between populations, with a 60-fold difference between the
hiuhest and the lowest rates (Rewers et al., 1988: Green et al.. 1991: Karvonen et al.,
19(7). The highest incidence is found in Caucasoid populations. particularly in
northern Europe, and the lowest rates are found in Asia and South America (Karvonen
et al.. 1993: Karvonen et al.. 19(7).
The incidence of type 1 DM has increased by about 1% per year during the last 10
years (Bingley and Gale 1989: Dahlquist et al., 1(91). During Il)93-1995. the
incidence of type I DM was 8.1 per 100,000 a year. ranging in-between lower rates in
southern European countries and higher rates in northern Europe (Rosen bauer et al.,
19(9). In the Oxford region. the annual increase of the incidence or type 1 OM in
children aged 0-4.5-9 and 10-14 was 11%,4% and lolll. respectively. between the
year 1985-1996 (Gardner et al., 1997). In addition, in children aged under 5 years, the
incidence of type I DM was increased from 4.2 to 9.9 per 100.000 per year between
1973-4 and 1988. in England (Metcalfe and Baum 19(1). In Finnish children aged
under 15 years. the annual increase in the incidence of type I DM "as 2.4% between
the year 1965-1984 (Tuornilehto et al., 1992). By the year 20 10. it is estimated that
the incidence of type I DM will be 50 per 100,000 per year in Finland and it will
exceed 30 per 100.000 per year in many other populations (Onkamo et al., 1999). The
incidence of type I DM in Sardinia is almost as high as in Finland. 3().) per 100.000
per year in children aged ::;14 years between the year 199()-1l)l)4 (Karvonen et al..
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2()O()}. whereas most southern European countries have a lower incidence (Dorman et
ul.. 199(): Muntoni et al.. 19(2). Generally. a vcrv high incidence or type 1 DM
amongst children aged S 14 years between the year 19l)()-19<J4 (:2:2() per 100.000 per
year) was found in Sardinia. Finland. Sweden. Norway. Portugal. the lJ.K .. Canada
and New Zealand (Karvonen et al., 2000).
lhe differences in geographical incidence, as seen in type I DM. arc rare amongst
severe chronic diseases of childhood (Diabetes Epidemiology Research International
Group 1(88).
1.2.2.2 Viruses as Important Environmental Factors
!\ range of viruses has been implicated in type I DM. Enterovirus infections.
particularly with coxsackie virus B4 (CYB4). may playa role in activating the
immune response against islet 13 cells. Increased islet 13 cell autoantibody
(ICA)/insulin autoantibody (lAA) levels are associated with enterovi rus infections.
The levels of virus-specific IgM. IgG and IgA are increased in enterovirus infections
and the level of Cvfs-specific IgM is increased in newly diagnosed type 1 OM
patients (Hyoty et al., 1995: Kaufman et al., 19(2). Proliferative lymphocyte
responses to antigens from other viruses, such as eVB I. 86 and adenovirus with
homologies to GAD-65 are observed in newly diagnosed type 1 1)Ivl (Jones and
Crosby 1(96). The prevalence of coxsackie B serum antibodies is increased in recent-
onset type 1 DM (Helfand et al., 1(95) and in mothers of infants \\110 developed
early-onset type 1 DM (Dahlquist et al., 1995). Furthermore. the elevated levels of
eVB-specific IgM persist for a few months after infection. This has led to the
suggestion that ('VB infection may precipitate the onset of type 1 I)M in a pre-
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diabetic individual within a kw months. In contrast. diabetes may develop many
years after exposure to the virus. For example. initiation infections. such as congenital
rubella infection. occurs in utero but diabetes develops 5-20 years later. In culture. the
('VB4 and mumps viruses can infect human islet 1\ cells. leading to ovcrcxpression of
II LA class I (Parkkoncn et al.. 1992).
There are six amino acids. PEYKEK (260-265 amino acid residues of (iAO), identical
in P2-C protein of CYB4 and GAD65 (the 65 kDa isomer or GAD). while they differ
in only one amino acid. PEYKTK (Glu-e Thr), between P2-C protein of CYB4 and
(iA067 (the 67 kDa isomer of GAD) (Hou et al.. 19(4). The high similarity of the
amino acid sequences of GAD65/67 to the P2-C protein of CVB4. is consistent with
the possibility that molecular mimicry plays a role in the pathogenesis of type 10M.
Thus. it suggests that the immune response against P2-C protein of CVB4 may cross-
react with GAD of islet 1\ cells. leading to more destruction of islet 1\ cells and further
release of GAD from islet p cells (Kaufman et al., 1992: lIou er al., 1994).
Interestingly, MICA-I,O. human monoclonal antibody derived from a diabetic patient.
recognises an amino acid residue (E264) within this amino acid sequence of GAD.
PEVKEK. However. MICA-IO does not recognise the P2-C protein itself. indicating
that the linear homology region in P2-C does not acquire a conformation similar to
that ofGAD-65 (Schwartz et al., 1999).
In contrast to the above. Horwitz and colleagues showed that infection with CYB4,
which shows similarity with GAD, rapidly provoked diabetes in TeR transgenic mice
specific for a different islet autoantigen. This suggests that CYI34 induces diabetes as
an indirect result of local infection leading to inflammation. tissue damage and the
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release or sequestered islet antigens causing the stimulation or resting uutoreactive T
CL'IIs.Thus. eVB4 may induce type 1 OM through bystander damage and activation
(Horwitz et al., 19(8).
Congenital rubella infection may induce autoimmune islet I~cell destruction and
subsequently the development of type I OM (Pack et al.. 1(88). 201Y;) or individuals
with congenital rubella syndrome (CRS) develop type I OM while 110 case has been
reported of type 1 DM following postnatal rubella infection (Eisenbarth et al., 1994).
Pancreatic islet cell surface autoantibodies (ICSA) are found in 201Y() Ill' the total CRS
population. Also, the presence of HLA-OR3 and the absence of IILA-OR2 are
associated with the CRS patients who develop diabetes (Feellner et al., 1984).
lurthermore, there are signiticant correlations between 'I-ce!l clone responses to
rubella virus peptide V:; (RV El) (157 -176 amino acid residues) and a determinant of
(iA067 (274-286 amino acid residues) in patients with recent onset type 1 OM and
the response of another T cell clone cross-reactive with RVE 1 and a determinant of
(JAD67 (212-226 amino acid residues) in patients with late onset type I DM. Also,
there is significant correlation between T-cell clone responses to RVE2 (87-107
amino acid residues) and GA065 (274-286) (Ou et al., 2(00).
('VB infection and type I DM are more strongly associated with IILA-DR4 than.
IILA-DR3. while congenital rubella infection and type I DM are more strongly
associated with HLA-DR3 than HLA-OR4 (Eberhardt et al.. 1(85). In addition, a
tandem repeat of ORB 1*0404-A 11(3) andlor a tandem repeat or DRB 1*0404-
B35( 15) might predispose CRS patients to development or type I 1)[V1 (Ou et al.,
2000 ).
'p
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Cvtomcgalovirus (CivIY) may playa role in the pathogenesis or type I OM by
inducing islet r~cell destruction (Hiltunen et al., 19(5). High titres 0" ("MY-specific
Ig(i are associated with ICAs in healthy siblings or diabetic children t lliltunen et al.,
1995: Nicoletti et al.. 19(0). Also. anti-CMY antibodies can cross-relict with a 38
k ilodalton autoantigcn (38 kDa). which is expressed on the surface or islet I~cells. and
subsequently may be implicated in the autoimmune response to islet II cell destruction
(Hiltunen et al., 1995: Pack et al., 19(0). The molecular mimicry or amino acid
sequences of CMY proteins with islet P cell autoantigens may induce the islet p cell
destruction by molecular mimicry (Buesa-Gomez et al., 19(4).
It has recently been shown that monoclonal and polyclonal CiAD65 (24X-257 or 88-99
amino acid residues i-speci tic T cells from patients with type 1 I)M could be
stimulated by viral (human herpes virus) and bacterial peptidcs with Iittle apparent
sequence homology with autoantigenic epitopes (Bach et al.. 199X).
1,2.2.3 Dietary Factors
It has been proposed that breast milk may be important either to diminish exposure of
breast-fed infants to an unidentified diabetogenic agent. which mayor may not be a
virus (Elliott and Martin 1984: Stuart et al.. 19X4). or may be important for the
transmission of agents that prevent islet P cell destruction. Maternal IgA may prevent
viral infections which contribute to islet P cell destruction (Kassim et ul., 1987; Hjelt
et al., 1(85). Also. in breast-fed infants. there is evidence of increased IgA production
(Prentice 1987). increased IFN response to respiratory syncytial virus (Chiba et al.,
1(87). and increased B cell proliferation (Juto 19X5), On the other hand. the
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transmission of such viruses via breast milk may prevent the development of type I
I)i'vl by Tvlyrnphocvrc subset «('04+ TH cells) depletion. i.c. the tropism of the virus
ma\ alter the function of ('04+ TH cells which cause the autoimmune response
« ildstone 1(88). In addition. many anti-inflammatory agents. such as tree radical
scavengers. are present in human breast milk (Mayer et ~tI.. II)XXI: this may be
relevant since oxygen free radicals are cytotoxic to islet I~cells (Rahinovitch 1(94),
Altcmatively, early cessation of breast milk and replacement with cows milk
introduces foreign protein antigens into the immature infant. lntcrcstingly, bovine
serum albumin (BSA) is recognised by IgG and IgA anti-USA antibodies. which are
detected in all diabetic children. The ABBOS peptide. which is a region of the
albumin protein. shares a sequence homology with the ICA69 autoantigen (Dotta et
al.. 1(94).
1,2.2.4 Other Environmental Factors and Hygiene
l'hc increasing incidence of diabetes in many countries may be attributed to improved
standards of hygiene (Kolb and Eliot 1994). Children in Northern Iroland aged under
I:; years in areas with a high population density and household crowding were
observed to have the lowest incidence rates of type I DM. during the period 1989-
1994 (Patterson et al.. 1(96). Early contact with microbial antigens prevents diabetes
in animal models (Patterson et al., 1994). Social mixing in early infancy appears to
confer protection against the development of childhood diabetes. This may be
mediated through exposure to infectious agent(s). This indicates that early infectious
exposure may play a role in the development or imrnunorcgulutorv mechanisms
which protect against diabetes (McKinney et al.. 20()()). such ~IS modi lication of the
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lymphocytic response to late immunological challenges (Schwimmbcck et al., 1988)
and/or stimulation of the production of immunorcgulatory cytokincs that prevent
diabetes (Bach 19(4). The 'hygiene hypothesis' postulates that reduced exposure to
common microbial infections in early life may increase the risk or type I OM in
childhood.
Chemical toxins. such as alloxan. Chlorotocin, certain pesticides (Assail and Larger
19(3) and nitrosamines. such as streptozotocin . (Dulin and Sorer 1(17X) can poison
pancreatic r~cells directly or trigger an immune response which further damages these
cells. The incidence of childhood type I OM in northern England is associated with
higher nitrate levels ill domestic drinking water (Parslow et al.. 1(ilI7). Nitrate is
reduced to nitrite. the chemical precursor of nitrosamines (Choi I<iX5l. Furthermore,
the water does not contain nitrosation inhibitors. such as vitamin C r Virtanen et al.,
1994 ).
1.2.3 Genetic factors
1.2.3. 1 Human Leukocyte Antigens (HLA)
It has been estimated that about 50-60% of the risk for type 1 ()Mis genetic. the rest
being environmental. Family studies indicate that 60% of attributable genetic risk is
due to HLA (Van dcr Auwera et al., 1995), The HLA complex is a region of 3,500
kilo bases (kb) on the short arm of chromosome 6 (6p11.3).
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In l Il.A class I. 111./\-137. -8S. -8 IS and -818 are also positively associated with type
I [)M. There is a significant increase in the frequency of the I-ILI\-I37 allele in the
early-onset type I DM patients rather than in the intermediate and late-onset type
I)M patients (Dcmainc et al., 1995).
lhe presence of an aspartate residue (Asp) at position-57 of the D()(', chain (DQP57)
confers resistance to type I OM (Badenhoop et al.. 1989: Routsias and Papadopoulos
19(5). while the presence of serine (Ser), alanine (Ala) or valine (Val) at OQP57
confers susceptibility to type I OM (8adenhoop et al.. 19lN). Also. the presence of
arginine at OQ(152 confers susceptibility to type I DM. while the absence of arginine
at DQaS2 confers resistance to type I OM (Ilonen et al.. 19(6) (Table 1..2).
In HLA class II. I-lLA-DR3-DQ2 and HLA-OR4-DQ8. which have DQP57 Ala+
(Owerbach and Gabbay et al., 1996) and OQa52 Arg+ (Ilonen cl al.. 1996), are
strongly associated with type I OM (Oemaine et al., 1995: Erlich et al.. 1(96). The
presence of HLA-OR3 and HLA-OR4 in individuals with autoautobodics to GA065
((;AA65+) and complement-fixing islet cell autoantibodies (CF-IC/\+) will increase
the relative risk of type I DM (Aanstoot et al., 1994).
IlLA-DRI-DQ5. which has DQP57 Ser+ (Demaine et al.. 1(95). and IILA-DR9 are
positively associated with type I DM (Liparota et al., 19(5). In contrast. the HLA-
DR2-0Q6. which has DQP57 Asp+ and OQa52 Arg- (Toxi et al.. I ()l)4): HLA-DR7.
which has DQa52 Arg-: and HLA-OR5 are negatively associated with type 1 OM
(Toxi et al., 19(4). The protective allele (HLA-DR2-0Q6) is associated with high
litres of GAAs. It has been suggested that the high titres of (j!\!\s 111:1\· correlate with
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a CD4+TI-12 cell response. This indicates that the activation of a C[)4+ TH2 cell
response may he associated with the presence of IILA-DR2-!)()(). Also. there is no
association between I('A and I!LA-DR2-DQ6 (Pugliese et al.. Il)l)5). III addition. the
DPB 1*0301 allele is positively associated with type I DM and tlW~ interact with
I-ILA-DR4 to increase the overall risk of type 1 DM (Erlich et ul.. Il)l)()).
Some protective alleles. such as HLA-DRB I*040} or 407. haw DRI174 Glu+, while
the susceptible alleles. such as I-1LA-DR4. have DRrn4 Ala+ or Arg+ (Auwera et al..
19(5).
Table 1.2 Susceptible and Protective Amino Acid Residues in l ll.A Class II Loci
II LA class II locus Susceptible amino acid residue Protective amino acid residue
D<)I~57 Serine: e.g. HLA-DR I-DQ5 Aspartate: e.g. III.A-DR2-DQ6
Alanine: e.g. HLA-DR3-DQ2
HLA-DR4-DQ8
Valine
1)()a52 Arginine: e.g. HLA-DR3-DQ2 Absence of arguune: e.g. HLA-
HLA-DR4-DQ8 DR2-DQ6
DRln4 Arginine: e.g, HLA-DR4-DQ8 Glutamine: e.g. III.A- DRBI*0403
Alanine; e.g. HLA-DR4-DQ8 or 407
The HLA-DQB I *020 I allele is associated with high risk of diabetes among stiff-man
syndrome (SMS) patients. while the HLA-OQI3I *0602 allele (I-ILA-OR2-0Q6)
might be associated with a reduced prevalence of diabetes in SMS patients (Pugliese
cl al., 1993: Pugliese et al., 1994).
DR3 and OR4 have been shown to confer susceptibility to type 1 Dlvl. while OR2 has
been shown to confer protection from type 10M. As indicated above. this is due to
linkage disequilibrium of these alleles (OR2. OR3. and OR4) to various OQ alleles.
including OQ6. DQ2 and DQS (Owerbach et al., 19X3). An attractive hypothesis
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states that the diabetogenic peptideis) binds tighter to the resistant than to the
susccpti hie DQ molecules, leading to elimination or strongly autorcactjve T-cell
clones in the thymus. In the periphery, the protective DQ molecules compete with the
suscepti ble DQ molecules for binding to the peptidet s) (Ncpom I<)<)()). Other DO
molecules are not capable of binding such diabetogenic pcptidct s ). It has been
postulated that DQ molecules are the mediators of immunosuppression (Salgamme et
;11.. 19(1). The susceptible DQ molecules bind to diabetogenic pcptides and can
initiate the immune response by the presence or a hydrophilic lirst pocket in the
antigen-binding groove. a hydrophobic or amphiphilic [~49-56 dimerisation patch that
allows for spontaneous or T-ccll receptor-induced dimerisation. and the Arg-Gly-Asp
cell adhesion loop (Routsias and Papadopoulos 19(5).
The inheritance of liLA haplotypes influences which peptides arc selected for
presentation to TeR. The susceptiblity model depends on the binding of diabetogenic
pcptidcs to particular HLA molecules. If an individual inherits u disease associated
liLA gene, susceptibility occurs when the product of this gene is the 1110Stefficient
hinder of diabetogenic [\ cell peptides amongst the other class II molecules in that
individual. Conversely. an individual with disease associated Hl.A genes is resistant
10 type I DM when the products of other HLA class II genes art' more efficient
hinders of the diabetogenic p cell peptides (Nepom 1(90).
An alternative theory is the protective model which depends on the binding of
tolerogenic peptides to particular HLA molecules. Alleles which arc negatively
associated with type I DM. such as DR2, have a high affinity for iolcrogenic p cell
peptides which are necessary to induce tolerance. whereas those al leks which are
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positively associated with type I OM have a low affinity lor thcxc pcptides, or bind
them in the wrong orientation (Sheehy 1992).
lhe TAP2A (transporters associated with antigen processing) al le le is positively
associated with I-ILA-DR3+ and HLA-OR4+ type I I)M patients. III contrast. the
I'AP2B allele is negatively associated with type I DM patients (Lsposito et al.,
I9(5).The TAP 1. T;\P2 and LMP2 (low molecular-weight proteins: loci show little
effect on age at onset or type I DM (Liparota et al., 19(5).
In Hl.A class Ill. C-J. allotypes are associated with type I j)~1. such as C4A
(Badenhoop et al., 19X9: Demaine et al., 1995). The I-IL/\ /\ l-BX-DIU and HLA 862-
[)R4 are associated with the 5.5 and 10.5 kb TNF-u gene alleles. respectively
(Badenhoop et al.. 19X9). Also. TNF-P polymorphism is associated wirh type 1 OM
(Awata et al., 19(4). HSP70 locus shows little effect on age at onset or type 1 DM
(l.iparota et al., 1(95).
lhe key genetic factor in the development of autoimmune diabetes ill the non-obese
diabetic (NOD) mouse is the presence of major histocompatibility complex (MHC)
class II molecule. I-A (Todd et al., 1991). In a transgenic NOD mouse. the expression
of I-A0 transgenes (mouse HLA-DQ8 equivalent). which has i\sp57 or 1'1'056 instead
of the normal Ser57 or His56. respectively, prevents diabetes (Demuinc et al., 1995).
T cells from NOD mice proliferate to the I-A (X6-101 amino acid residues) and
GAD65 (509-524 amino acid residues) peptides, since this peptide of I-A is similar to
that peptide of GAD65 (Xu et al., 1999).
.10
1.2.3.2Insulin gene
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The insulin gene is present on chromosome IlpIS.S. VNTR (variable numbers of
tandem repeats) polymorphism at the 5' end of the insulin gene has been shown to be
associated with type I OM (Lucassen et al., 1993; Davies et al.. (994). A 4.1 kb
region, including the insulin (INS) gene, which contains ten candidate
polymorphisms, are associated with HLA-OR4+ individuals (Uudlien et al., 1995;
Uudlien et al., 1994). Insulin is the islet p cell-specific autoantigen expressed early in
the development of diabetes. A small population of cells in the thymus express insulin
in mice (Smith et al., 1997) and in humans (Pugliese et al., 19(7). ) In Caucasian
populations, INS VNTR class I alleles predispose to diabetes. In contrast. individuals
who have INS VNTR class III alleles and have higher levels of INS mRNA in the
thymus and lower levels in the pancreas are protected. The higher levels of INS
mRNA may indicate greater levels of expression and enhance tolerance to
preproinsulin in the thymus (Pugliese et al., 1997).
It has been suggested that the INS VNTR class I alleles are not equally associated
with type 10M. The AHI-l allele is associated with type I DM while the 698-VNTR
class I allele, which is identical in size to the AHI-I. is not associated with type 10M.
It is not known whether the class II VNTR alleles. such as 81 repeat elements, are
associated with type I OM or not. Furthermore, some of the class III VNTR alleles,
such as HUMTHO I allele Z-8, are strongly protective against type 10M, while the
other HUMTHOI allele is weakly protective against type I OM (Owerbach et al.,
1996).
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1.2.3.3 Association of other Polymorphisms
The IfN-y3 and 6 alleles and IL-P polymorphisms are associated "ith type I OM
(Awata et al., 1994). Also. mitochondial gene mutations are associated with type I
OM (Awata et al., 199J). Furthermore, CTLA-4 is present on chromosome 2q31-33
lind has also been linked to type 1 OM (Nistico et 411.. 1996). The CTLi\-4. which is
expressed on activated T cells, is thought to be a negative regulator ofl cell function.
The CTLA-4 exon I polymorphism (49A/G) confers genetic susceptibility to type
DM (Hayashi et al., 19(9).
lhe CDJ E locus may be associated with type I OM in female subjects. Also, the
CD4* A4/ A4 genotype is significantly increased in type I OM patients. On the other
hand. the C03*91 allele of the 8 subunit may protect against type I OM
(Ghabanbasani et al., 1994).
1.2.4 Autoantibody Associations
Although the autoimmune destruction of islet P cells is T cell mediated. circulating
autoantibodies can often be detected years before the diagnosis of type I OM and can
he used in the prediction of type 10M.
1.2.4.1 Islet Cell Autoantibody (lCA)
Islet cell autoantibodies (leA) were first demonstrated In- the indirect
immunot1uorescence test on frozen pancreatic sections (Bottazzo et al., 1974). The
ICAs have been divided into two types, non-restricted ICAs (NR-ICAs), which
recognize all islet cells (a. p. () and pp cells), and restricted ICAs (R-ICAs), which
'")
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recognize only islet I~cells. The NR-ICAs do not react with brain (i/\i). whereas the
R-ICAs react with brain GAD (Palmer et al., 1994: Dorta et al., 1<)l)4)1. lhc R-ICAs
arc not predictive (Dorta et al., 1994; Christie et al.. 19(4). or lcsx predictive. of
diabetes development than NR-[CAs (Palmer ct al., 1(94).
The availability of standard ICA+ sera has allowed the reporting of results as JDFU
(juvenile diabetes foundation unit) based on an end point titration. In R-[CA+ sera.
the GAAs are present in 89% of type I OM patients (petersen et al.. 1994). In
addition, the ICAs arc associated with anti-37 kD autoantibodies (Bonifacio et al..
19(5). insulin autoantibodies ([AA) (Verge et al.. 1(94) and <lnti-40 kl)
autoantibodies (anti-ICA512bdc/IA-2 autoantibodies) (Fig. 1.2) described below. The
risk of diabetes in family members with ICA 2::40.IDFU and IAAs is 77U/u within five
years while in those with ICA 2::40 JOFU only is 42% (Eisenbarth et al.. 1994). This
indicates that the IAAs are associated with other autoantibodies and/or genetic
susceptibility. The risk of diabetes in relatives with [AAs. GAAs and anti-IA-2
autoantibodies can be as high as 100% within five years (Verge et al., 1996), Higher
predictive value for type I OM among first degree relatives may he obtained if only
individuals with high titre [CAs or double or triple ICA/IAA. (iAA or IA-2
(insulinoma-associated antigen-2 autoantibodies) are considered (Hagopian et al..
1995; Verge et al., 1996). Furthermore, the [CAs are present in some SMS and
autoimmune polyendocrine syndrome (APS) patients (Bosi et al.. 19(1) (see below).
The [CAs are detected in 90% of newly diagnosed diabetic patients (Genovese et al.,
1(92). The ICA titres in first-degree relatives and co-twins are higher than in diabetic
children without a family history of type I DM (Bingley et al.. 1994: Marchal et al.,
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1995). This indicates that the leAs are tightly associated with genetic susceptibility
(Fig. 1.2). The risk or type I DM is 33% in ICA + relatives with 111..\-f)Q~57 Asp-
and is <5% in ICA+ individuals without a family history or type I I)i\·1 (l:isenbarth et
al..1994).
lhe abrupt-onset type I DM patients have high titres of ICAs which decrease after the
first year of type I DM. In contrast. the slow-onset type I DM patients have low titres
or ICAs which continue fix a long period after diagnosis (Urukumi et al .. 1995). This
suggests that the autoimmune islet ~-cell damage in abrupt-onset type I DM patients
is much higher than in slow-onset type I OM patients. This strong islet p-cell damage,
in abrupt-onset type I DM. may cause more production of ICAs against the islet ~-
cells. and loss of all islet ~-cells will decrease ICA titres. In contrast. in slow-onset
type I DM patients. the slow rate of islet ~-cell damage may cause production of
ICAs in lower amounts than abrupt-onset type I DM patients. In addition, the
remaining islet p-cells. in slow-onset type 1 OM patients. will continue to stimulate
ICA production for a long period after diagnosis. Furthermore. some ICAs have the
ability to fix complement (CF-ICA). which may kill the cells by tormation of the
membrane attack complex. or may simply represent high titre or autoantibodies
(Yamada et al., 1997: Bosi et al., 1994).
M(Yo of type I OM sera can stain mouse islets (which contain little or no GAD) and
therefore recognise other islet cell components in addition to (iAD. while 32% can
not stain mouse islets but can react with human islets following absorption of sera
with GAD. Thus. mouse islet are able to differentiate between two groups of non-
(lAD reactive ICA (Richter et al., 1993c). Some islet cell autoantigcns do not seem to
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he affected by proteolysis and may represent a monosialogangliosidc (lipid) migrating
between the GM2 and GM 1 standards (Dotta et al., 19(3) (discussed below),
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Figllre 1.2 Decision tree for predicting type 1 diabetes mellitus
ill individuals with a family history (FH) of disease
(Bingley et al., 1994; Genovese et al., 1(92);
(rPIR=First Phase Insulin Realease).
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1.2.4.2Proinsulin and Insulin Autoantibodies (fAA)
Proinsulin is a major autoantigen in type 10M. i\ proliferative T-cc!l response to
proinsulin is observed in 7.7% of recent-onset type 1 OM patients. 16.7% long-
standing type I OM patients and 38.5% of ICA+ first-degree relatives of type I OM
patients. In contrast. a proliferative T-cell response to insulin is observed in 23% of of
ICA+ first-degree relatives of type 1 OM patients (Dubios-Laf'orgue et al., 1999). The
IAAs can cross-react with proinsulin (Ootta et al., 1994; Verge 19(4). This is not
surprising since proinsulin and insulin have strong amino acid residue similarity to
each other. Although the presence of the IAAs can result from insulin therapy, IAAs
can also be detected years before the onset of treatment (Dernaine et al.. 1995; Awata
et al.. 19(4).
Although there is a small population of cells in the thymus that express insulin in
mice (Smith et al., 1997) and in humans (Pugliese et al., 19(7). insulin is the only islet
[\ cell-specific autoantigen found in diabetes, and it is expressed early in development.
The IAA fluid phase radioimmunoassay has been standardised (Palmer et al., 19(0).
Standardisation could not be achieved in solid phase assays [such as. enzyme-linked
immunosorbent assay (ELISA)], indicating that the IAA epitope is conformational
(Kuglin et al., 1990).
At onset of diabetes, 65% of subjects aged> 10 years have lAAs whereas 93% of
subjects aged ::;10 years have IAAs. This indicates that the occurrence of IAAs is
inversely related to age. Furthermore, the frequency of the IAAs is higher in males
than females (Zimmet et al.. 19(4).
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l ligh levels of IAAs arc associated with HLA-OR4 and some I)()J\ I alleles, such as
I>QA 1*0102. DQA I *()201 and DQAI *0301. In contrast. the IAAs titres are very low
in HLA-DR3+ subjects (Dorta et al., 1994).
In the non-obese diabetic (NOD) mouse, the peptide region of the insulin B chain (15-
23 amino acid residues). which is recognised by previously isolated pathogenic CD4+
Th I cells, is also recognised by highly pathogenic CD8+ TC cells (Wong et al.,
19(9). In addition, there is evidence that the insulin B chain peptide (9-23 amino acid
residues) and GAO-65 are not primary diabetogenic autoantigcns in the type 1 OM of
the Bio-Breeding (BB) rat (Bieg et al., 1999).
1.2.4.3 Autoantibodies to Tryptic Fragments of 64 kD and to IA-21IA-2{J
Autoantibodies to 64kDa autoantigens are detected as early as ICA hut persist in the
circulation longer after diagnosis (Christie et al., 1990a). The M kD is a combination
of autoantigens expressed by islet ~ cells that are cleaved by trypsin to 50 kD, 40 kO
and 37 kD proteolytic fragments. Ninety three percent of diabetic patients have
autoantibodies to the 50 kO fragment (81%) and to protein tyrosine phosphatase
(PTP)-like proteins (37 kD/40 kO fragment) (77%) (Christie et al.. I()90b). The anti-
50 kO correlate with the level of GAA, indicating that the 50 kD fragment is derived
from GA065 (Christie et al., 1993). Also, the 40 kD fragment is deri ved from lA-2 or
its fragment lCA-512bdc. The 37 kO fragment (ICA-related PTP) is derived from IA-
lp. which is an insulin granule component named phogrin. lA-2 and IA-2P both being
transmembrane proteins within the secretory granule membrane of neuroendocrine
cells (Solimena et al.. 1996: Wasmeier and Hutton 19(6). The PTP-I ike domain oflA-
2 has no phophatasc activity detected, while IA-21~ has weak phophutase activity
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detected (Cui et al.. I99(): Lu et al., 1994). In addition. IA-2 and 11\-2[\ have structural
similarities to tyrosine phosphatases, Autoantibodies to IA-2 and 1.'\-2P are detected
by irnmunoprecipitation and autoradiography (Christie et al., 1992. I()()~).
The anti-50 kD autoantibodies. which react with a 50 kD fragment 01 UAD. can be
detected in most type I DM patients. in SMS and in all ICI\+ :\PS patients with or
without diabetes (Hchmkc et al., 1995).
The anti-37 kD (anti-IA-2p/anti-phogrin) autoantibodies arc detected in acute-onset
diabetic patients. in 66.7% of SMS patients with diabetes and in ()()o/" or ICA+ APS
patients who have acute-onset diabetes. Also, the anti-37 kD autoantibodies are more
strongly associated with concordance for diabetes in identical twins than are GAAs
(Christie et al., 1994: Notkins et al., 1996). Furthermore. the anti-37 kO
autoantibodies are strongly associated with ICAs but not associated with GAAs
(Bonifacio et al.. 19(5). The anti-37 kO autoantibodies are better predictive markers
of type I OM onset than ICA or GAA in the general population (Ongagna and Levy-
Marchal. 19(5) and in pre-diabetic twins (Christie et al.. 19(2). The major antigenic
determinant of phogrin is localized within 640-922 amino acid residues (Kawasaki et
al.. 19(8).
The anti-40 kO autoantibodies (specific for ICA-512bdc/IA-2) arc associated with
ICA + patients (Notkins et al.. 1996; Bingley et al.. 19(3). The prevalence of anti-IA-2
AAs is higher in acute onset type 1 OM than in slowly progressive type I OM
(Yamada et al., 1(97). The anti-IA-2 AAs are present in 56% type I DM patients.
47°/i, APS II patients with type 10M. 14% SMS patients. 4(Y., ;\ PS II patients without
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type I DM (Morgenthaler et al.. 19(7). Also, the 11\-2 autoantibodies an: associated
with HLA-DR4 (Genovese et al., 19(6).
Figul'c 1.3 Epitopes ofType I DM Autoantibodies on IA-2.
minor 'YPl' I 111\1E majur I'Pl' t 1)\1 r
NX7 "n")
IA-2 consists of an intracellular cytoplasmic domain (604-979 aa). which is
recognized by autoantibodies, and a luminal ecto-domain (31-577 an). which is not
recognized by autoantibodies. The anti-La-Z AAs and anti-phogrin :\!\s recognize
di fferent epitopes in a cytoplasmic domain of [A-2 [56% of sera to juxtamembrane
(.1M) region (601-691 aa), 83% to PTP-like domain (692-979 aa) anti 3l)'X) of sera to
both these regions (.1M region and PTP-like domainj] (Lampasona et ;11.. 19(6). In
contrast, the anti-[A-2 AAs and anti-phogrin AAs recognize only the PTP-like
domain of phogrin (640-10 IS aa) (Kawasaki et al.. 19(8). The major antigenic
determinant of [A-2 IS localized within 762-887 aa. while the nunor antigenic
determinant of IA-2 IS localized within 601-762 aa (Fig. 1.3). which is highly
homologous between 11\-2 and phogrin. In addition. it has been suggL'sted that some
of the anti-IA-2 AAs recognize a conformational epitope(s) associated with the C-
terminal region of native IA-2 (949-979 aa) (Kawasaki et al., 1991{). Furthermore, the
PTP-like domain of phogrin shares 80% amino acid sequence identity to IA-2
(Lampasona et al., 1996: Kawasaki et al., 199R·). The .1M domain shows 50%
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homology between lA-2 and IA-2~. Whereas, the luminal ecto-doruains of both IA-2
and IA-2~ share less than 10% homology (Larnpasona et al., 19(5). IA-2 and IA-2~
probably share common epitopes but also show distinct epitopes: 5()-XO% of type 1
DM sera that react with IA-2 also recognize IA-2p. Alternatively. even 95% of type
I OM sera reacting with IA-2~ also recognize IA-2 (Notkins et al., 199X). In all anti-
IA-2 AAs/anti-phogrin AAs positive sera, the binding to phogrin is completely
blocked by preincubation with recombinant IA-2. while the binding to IA-2 is
partially blocked by preincubation with recombinant phogrin (Lampasona et al.,
1996; Kawasaki et al., 1(98). This suggests that the type 1 OM AAs may develop
predominantly to IA-2 rather than phogrin.
Human monoclonal antibodies (huAbs) have been produced from newly diagnosed
type 1 OM patients against IA-2. For example. huAb 76112 recoginzes 794-845 aa of
IA-2 and 741-1033 aa of IA-2~, huAb 96/3 recognizes 780-979 aa of IA-2 and 741-
1033 aa of IA-2~, huAb 96/4 recognizes 687-776 aa of IA-2, huAb 96/5 recognizes
X90-979 aa and huAb 103/5 recognizes 603-686 aa of IA-2. Interestingly, the huAb
96/3 inhibits the binding of 10 out of 14 of newly diagnosed type I DM sera to IA-2
(Kolm-Litty et al., 2000). Sera of type 1 OM patients respond to three peptides 831-
850 aa, 841-860 aa and 751-770 aa of IA-2 (Hawkes et al., 2000).
Proliferation of peripheral blood mononuclear cells (PBMCs) in response to IA-2 has
been observed (Ellis et al., 1998; Durinovic-Bello et al.. 19(6). T-cell lines have also
been generated to epitopes on IA-2 (Hawkes et al., 2000: Honeyman et al., 1998).
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1.2.4.4 Glutamic acid decarboxylase autoantibodies (GAA)
(iAD is present in the cytoplasm and microsecrctory vesicles lli' iskt f~ cells and
neurons secreting y-aminobutyric acid (GABA) (Daw et al.. 19%). (j/\I) catalyzes the
conversion of glutamate to GABA. GABA is a major inhibitory neurotransmitter of
the central nervous system. but its function in islet f\ cells remains tu he clarified.
There are two non-allelic isomers of GAD, GAD65 and (;/\1 )(17. (j;\D65 is the
smaller amphiphilic form and consists of 585 amino acid residues. which is encoded
on human chromosome 10. In contrast. GAD67 is the larger soluble hydrophilic form
and consists of 594 amino acid residues, which is encoded on human chromosome 2.
(iA065 and 67 are present in GAB A-secreting neurons and ill the cytosol of rat
pancreatic islet f~ cells. whereas only GAD65 is present in human islet f~ cells and
little GAD65 is present in mouse islet p cells (Ujihara et al .. 1()l)4). Furthermore,
(iAD65 and 67 are highly conserved. 97% identity exists between rat and human
(iAD67, while 9(-'(Yc, identity exists between rat and human (jAD()). In human,
(,AD65 and (-,7 share 76% identity and 87% similarity throughout 174-)X5 amino acid
residues. but they differ within the N-terminus. In the first 95 au. they share 22%
identity and -61 % similarity (Hahmke et al., 1995). Whereas ill the <>6-173 amino
acid residues. they share 49% identity.
(iAD autoantigen can be detected by different assays. such as radiul igand binding
assay for recombinant (jA065 (Falorni et al., 19(5). solid phase assays (ELISA or
immunoblotting) for GAA65 in SMS sera which are specific to linear cpitopes (Kim
et al.. 1994) and immunoprecipitation assay which is specific to conformational
cpitopes (Baekkeskox et al., 1(82).
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However. APS (diabetic or not diabetic). SMS and about I ()(Yc) or diabetes sera
recognise both isoforrns of GAD (GAD65 and GAD(7) (Tuomi et al.. I ')t)6).
1.2.4.4.1 Type I Diabetes Mellitus Associations with GAD
(,AD autoantibodies (GAAs) are present in 70-80% of newly diagnosed diabetic and
prediabetic patients (Christie et al., 1994).20% of nondiabetic idcnticul twins who are
at low risk of diabetes (Christie et al., 1994),80% ofrelatives ofdiabcuc patients who
themselves developed type I OM (Bingley et al.. 19(3) and S()(~;;) ICA + diabetic
patients (Morgenthaler et al., 1997).
(iAAs can also be associated with other autoantibodies such as <Inti-ONA/RNP
autoantibodies. rheumatoid factor (Petersen et al.. 19(4). anti-smooth muse le cells
autoantibodies and anti-parietal cell autoantibodies.
As discussed earlier. genetic and environmental factors and other autoantibodies may
contribute to GAAs associations. GAAs are significantly associated with HLA-DR3
phenotypes (Verge et al., 1996; Genovese et al., 1996; Hagopain et al.. 19(5) and not
associated with HLA-OR4 (Daw et al., 1(96). The PEVKEK sequence is identical
between P2-C protein of CVB4 and GAD65. The high similarity or the amino acid
sequences of GAD65/67 to the P2-C protein of CVB4, suggests that the immune
response against P2-(, protein of CVB4 may cross-react with GAl) Ilr islet p cells.
leading to more destruction of islet p cells and further release of GAD from islet p
cells. The frequency of GAAs is higher in females than males (Verge et al., 1994;
Verge et al., 1996: Yu et al., 1(94). Also, the frequency of (,Al\s is not associated
1 '
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vvith the age differences among children (Verge et al., 1(94). I ligh levels ofGAAs are
negatively associated with [;\:\s (Yu et al., 1994).
High levels of GAAs are detected in newly diagnosed type I [)rv[ patients. but the
(iAA levels decrease by 50(Ynwithin two years after diagnosis. By six years after
diagnosis. the GAA levels in type I DM and healthy individuals arc the same
(Kaufman et al., 19(2). While in SMS patients with long-standing tvpc [ DM, the
(iJ\J\s do not disappear (V clloso et al., [993).
rh: OAAs of type I DM sera, which are present at high titre. recognize
predominantly conformational epitopes on OAD65 fmiddle( M )-rcgiol1 cpitope (240-
435 amino acid residues: aa, type I DM El) and carboxyl Cj-terminal cpitope (451-
570 aa, type I DM El). as the major antigenic determinants (Fig. 1.4). and amino(N)-
terminal epitope, as a minor antigenic determinant] and rarely on (jJ\!)() 7 (Lampasona
et al., 1997; Daw et al.. 1995). The GAD-67 reactivity is thought to be mainly against
epitopes shared with liAD-65 (Hagopian et al., 1993). It has been suggested that the
humoral autoimmune response to OAD-65 in OAA+ offspring of diabetic parents is
initially against epitopes within the middle portion of GAD-65 (%-444 amino acid
residues). as a primary target. and spreads to epitopes in other regions 01· GAD-65 (1-
9). 96-444 and 445-585 amino acid residues) and GAD-67 (Bonifacio et al., 2000).
Also. the GAAs of a rare group of type I DM patients who have high titre of GAAs65
and protective allele IILA-DR2 can recognize a linear epitope in 421-442 aa (Kim et
al.. 1994). Furthermore. some ICAs can react with the middle (M) Ulll'-442 amino
acids) and carboxy (Cj-terminal region (443-585 amino acids) of (iAD()) or with the
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<Imino (N )-terminal region ( 1-195 amino acids) of both CiAD65 and ()7 (l Jj ihara et al.,
1994 ).
Conformational epitopcs of GAO-65. 245-450 and 450-585 amino acid residues. are
common targets of (iAAs in type I OM (50%), APS without diabetes (71 %). APS
with diabetes (90%) and SMS (100%). There are two dominant linear cpitopes: first,
7-124 amino acid residues which arc recognised by GAAs from pat kilts of type I
DM. SMS, APS without diabetes and APS with diabetes. Second. amino acid residues
5J5-SR5 which are recognised by GAAs from patients of APS without diabetes. APS
with diabetes and SMS (Sohnlein et al., 2000).
Complete suppression of pancreatic islet p cell GAD expression can block the
generation of diabetogenic T cells and protects islet grafts hom autoimmune injury in
NOD mice. Thus. islet p cell-specific GAD expression is required tor the
development of autoimmune diabetes in NOD mice (Yoon et al.. 19(9).
Some studies have detected lymphocyte-mediated immunity in type 1 DM patients
directed to the region of GA065 (247-279 amino acid residues) (Karlsson and
l.udvigsson 19(8) or (250-273 amino acid residues) (Ellis et al.. 1()l)(): Atkinson, et
al., 1(94). This indicates that these regions of GAD-65 (247-279 or ~5()-273 amino
acid residues). which includes the similar amino acid sequence of the 1'2-C protein of
('YB4 (PEYKEK), are involved in the development of type 10M.
More than 50% of recent-onset type 1 DM patients have T cell responses to GAD
(Atkinson et al.. 1992: Harrison et al., 1993). In addition. T cells of patients with type
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1 DM respond to other (;AD65 fragments. including 161-24:1 and 47.'-555 amino acid
residues (Lohmann et al.. 20(0). Also. other studies in humans and N()[) mice have
detected T cell reactivity to the C-terminus ofGAD65 (amino acids 5~4-541 and 521-
535) (Schloot, et al.. 1997; Patel et al., 1997). Furthermore. the T cells of type 1 DM
patients have been reported to recognise a peptide 379-390 amino acids out of a range
of different GAD65 peptidcs spanning the region of 379-450 amino acid residues
(Rharbaoui. et al.. 19(9).
Figure 1.4 Epitopes of Type 1 OM and SMS Autoantibodies on (i/\()()5.
, Iy.p.t: !...~M..~.I , ......I~J)l·11'\1 L~
240 451 475 571! 585
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1.2.4.4.2 SMS Associations with GAD
SMS results from an impairment of GABA-ergic inhibitory input to «-motor neurons
(Yu et al., 1994). This may be induced by reaction of GAAs with (;I\!) in GABA-
secreting neurons (Baekkeskov et al., 1990). GAAs are detectable in X9% of SMS
diabetic patients (Morgenthaler et al., 1(97).
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In 11100 dilution of SMS sera. the GAAs can react with full k'n~th (iAD. GAD
fragments, denatured (lAD and GAD peptides; but in III O.OO() dilution of SMS sera.
the GAAs react with full length GAD only. In contrast. in type I DM sera. the GAAs
cannot bind with GAD fragments, denatured GAD or (jA[) peptide» but they bind
with full length GAD (l Ijihara et al., 1994; Daw et al.. 1996: Duw et nl .. 19(5). This
suggests that the GAAs in lDDM sera recognize conformational cpitopcs on GAD65
since these conformational cpitopes are lost in GAD fragments.
In SMS sera. the GAAs recognize GAD65 and GAD67 by immuuoprccipitation assay
and recognize only GAD65 on western blots. In contrast. in type I I)M sera, the
(iAAs can recognize only GAD65 by immunoprecipitation assay but not on western
blots, and only 1O-20!YtI of type I OM sera recognize GAD67 (Kim et ul.. 1(94). This
suggests that the GAAs in SMS sera can recognize linear and conformational epitope
on GAD65 and only conformational epitope on GAD67. However. in both type 1 OM
and SMS sera. GAAs recognize GAD65 lacking the first 2~~ aa by the
immunoprecipitation assay. This suggests that the GAAs in type I Dr"1 and SMS sera
recognize conformational epitopes in the carboxy-terminal region or (iAD65 (Kim et
al., 1(94).
In SMS and APS I sera. the GAAs are present at high titre. In contrast. in type I OM
sera. the GAAs are present at lower titre (Bjork et al.. 19(4). The titre of GAAs in
SMS sera is 100-500 fold higher than GAAs in type I DM sera. The (iAAs in SMS
sera bind to GAD65 and 67 at titres 2:10,000, whereas the GAAs in type I OM sera
hind to GAD65 only at titres 1/100 (Daw et al., 19(6). This indicates that the affinity
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(If (JAAs of SMS sera is higher than those in type I DM sera and/or arc present at
higher concentrations in SMS sera. Also. as mentioned above. the (i;\As of SMS.
\\hich are present at high titre. are less dependent on the conformation of the GAD
and commonly target (i!\D67 as well as GAD65 (Larnpasona et al.. I ()<)7).
Preincubation of SMS sera with 188-442 aa/GAD65 can block the binding of
CiAAs67 with GAD67. whereas preincubation with CiAD67 cannot block the binding
or CiAAs65 with (i!\()65 (Daw et al., 1996). This indicates that the (i!\As in SMS
sera recognize a specific epitope in GAD67, which is highly homologous to 188-442
aa/GAD65. whereas other GAAs65 recognize epitopes which arc not present in GAD-
67. Furthermore. preincubation of SMS sera with 354-368 aa/( iA[)65 inhibits the
hinding of SMS sera with GAD65. In the 354-365 aa/(iAD65. there arc four amino
acid residues K-Kl-M which differ from E-NL-L of GAD67 (Li et al., 1994). This
suggests that these four amino acid residues (K-KI-M) may contribute the binding of
SMS sera with GAD65.
In SMS sera.GAAs recognize in GAD65 either an N-tcrminal epitope 1-8 aa (Kim et
ul., 19(4) and/or 1-95 aa (SMS E2) (Hagopain et al.. 1995; Bjork et al., 1994) as a
major antigenic determinant. a middle region epitope 39()-403 aa (Daw et al., 1996; Li
et al., 1(94). and a ("-terminal epitope 475-585 aa (SMS El) (Butler cl al.. 1993; Kim
et al.. 1(94) as a minor antigenic determinant (Fig. 1A). The SMS (iAAs recognize
SMS El (475-585 aa) (Hagopain et ai., 1995) and SMS E2 (1-95 aa) on western blots
(Kim et al., 19(4). This indicates that the GAAs in SMS sera recognize linear
cpitopcs in both N- and C-terminal regions of GAD. In human and rat (iAD. SMS El
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shares 97% identity and 100°,";) similarity (Butler et al., 199:1). Thus. till' human and rat
(iAD react equally with SMS sera.
lhe SMS sera may block the active site of GAD. which contains the pyridoxal 5-
phosphate (PLP) binding site. GAD67 is fully saturated with PLP hut GAD65 is
partially saturated with PLP. The middle region of GAD65 (390--W:I aa), which is
recognized by SMS sera. includes the PLP binding site. The intcrch.mgc. Leu-s-Pro
-HII. in 390-403 aa peptide inhibits the binding of SMS sera with this peptide. Also.
the preincubation of SMS sera with the PLP binding site of (JAD() 7 (399-413 aa
peptide) inhibits the binding of SMS sera with GAD65 PLP binding site (Li et al.,
19(4).
T cells derived from a non-diabetic SMS patient. recognise two pcpridcs of GAD65
(amino acids 331-350 and 341-360), as immunodominant epiiopcs. This region
(amino acids 331-3(0) is 100% identical in human, mouse and rat GA()65. Also, this
region of GAD65 (amino acids 339-352), which is recognised by the T cells of a non-
diabetic SMS patient. has no reactivity with T cells of newly diagnosed type 1 OM
patients. In addition. these T cells of a non-diabetic SMS patient rccouuised peptides
close to the N-terminal part of GAD65 (amino acids 61-90 and 191-22() and close to
the (,-terminus (amino acids 491-520) of GAD-65 (Schloot et al.. 1l)l)() l. In addition.
the T cells of SMS patients recognise two regions of GAD-65 (X1-171 and 313-403
amino acid residues). including regions previously reported to he inununodirninant
(Lohmann et al., 20(0).
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1.2.-1.4.3 APS Associations with GAD
(,/\;\s are present in X9% of APS II patients with type I DM and 21 (1/" Ilr APS patients
without type I DM (Morgenthaler et al., 1997). Also. in AI'S I sera. the GAAs
recognize UAD65 on western blots (Bjork et al., I()94). This suggests that the GAAs
in APS I recognize linear epitopes on GAD65. The (jAAs of AI'S. which are present
at high titre. are less dependent on the conformation of the (,AD and commonly target
(ii\[)67 as well as GAD65 (Lampasona et al., 19(7).
Using GAD65/67 chimeras. to maintain conformation-dependent epitopcs of GA065.
that the APS II human monoclonal antibodies (b35. b78 and b(6) target amino acids
270-359 (type I OM-E I) and 443-585 (type I DM-(2) and do not target the N-
terminal third of OAD65. Interestingly, b78 and b96 require both amino acid regions
:' 14-528 and 529-570. not only 514-528 alone (Powers et al., 1(99).
Furthermore. the GAAs of diabetic APS patients' sera recognise a linear epitope
within 7-124 aa ofGAD65. This region ofGAD65 (7-124 aa) is also recognised by
other patients' sera (type 10M. non-diabetic APS and SMS). but at a lower frequency
than diabetic APS as a dominant linear epitope (Sohnlein et al.. 20(0).
1.2.-1.4.4 Monoclonal Antibodies to GAD
Human monoclonal anti-islet cell antibodies (MICA) have been produced that react
with GAD. The MICA 4/6 and MICA 10 recognize epitopes in the middle region of
(,AD (245-450 aa). The MICA 2 epitope (506-531 aa) is very similar to MICA 1/3
epitope (450-570 aa). but the MICA 2 recognizes a linear epitope (on western blots)
in the Cvterrninal reuion of GAD whereas the M ICA I!J recounizc a conformational
~ ~
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cpitope in Cvterruinal region of GAD (Richter et al., 1993: Syren et al., 1(96). MICA
7 recognizes a similar epitope to MICA 1/3 and 2. In addition. Ml CA 8 and 9
recognize the Nstcnuinal region of GAD (Syren et al.. 19(6).
The mouse monoclonal antibody (GAD-6) recognizes an epitope on (iAD65. 475-585
aa (SMS El) (Hagopian et al., 1(95). The GAAs ol·IDDM. SMS and APS n (diabetic
and non-diabetic) sera recognize the region 0 f the (; AD-Cl cpi tope on GAD-65
(Davenport et al.. I()(J7). In addition, the extreme C-Ierminal sixteen amino acid
residues of GAD65 arc not involved in epitopes of GAAs of srvls and APS II sera and
the epitope of GAD-() (Davenport et al., 1997). Furthermore. (jA[)-() binds only to
(;AD65. not to GAD() 7 (Daw et al., 1995).
1.2.4.4.5 The Three-dimensional modeling ofGAD-65
GAD65-specific residues have been mapped for one linear and 13 conformational
epitopes recognised hy 16 human monoclonal antibodies (M I-I O. hn. b96, DPA.
DPB. OPC and OPO) derived from four type 1 OM patients and one ICA+ individual
with APS. The three-dimensional modeling of GAD65 predicts that all the epitopes
are within charged hydrophilic patches on the surface of the native molecule, and
together cover most of the surface of the middle and ('-terminal regions of GAD65
(Schwartz et al.. 19(9),
The sequence of the PLP-binding region (middle region) (M yers et al., 2000;
Schwartz. et al., 19(9) and C-terminal domain (Schwartz. cl al .. I ()99) of human
(iAD65 was threaded onto the PLP-binding domain of ornithine decarboxylase
( lORD) (ORO residues 161-425/GA065 residues 211-4()O) and the C-terminal
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domain of dialkylglycine decarboxylase (2DKB) (DKB residues 3~()-432/GAD65
residues 461-585). respectively. as templates for the model. In the ubscncc of proteins
of known structure with significant homology to the N-terminal domain of GAD65.
the secondary structure of this region was predicted using the algorithm by Chandonia
.md Karpulus 1999 (Fig. 1.5). The first 46 amino acid residues or the N-terminal
region of GAD65 may be buried in the folded molecule (Schwartz. Cl al.. 19(9).
lhe three-dimensional model of the middle region of a (iAD65 dim. .-r (~11-460 amino
acid residues) was built by using lORD template (Myers et al.. lOO(): Schwartz. et al..
19(9). The PLP-binding middle region consists of a seven-stranded p sheet
surrounded by seven a-helices. Two monomers and one monomer or GAD65 are
shown in the model of Schwartz et al. (1999) (Fig 1.6a) and in the model of Myers et
al. (2000) (Fig. 1.6b). respectively.
lhc three-dimensional model of the C-terminal region of a GAD65 dirner (461-585
ua) was built by using 2DKB template. It predicts an cd~~ fold composed of a four-
stranded p sheet and three amphipathic a-helices (Fig. 1.7). \vith localization of
hydrophobic residues toward the p-strands and residues involved in epitope
recognition on the charged face of these helices (Schwartz. et ul., 1991»).
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Figure 1.S Space-filling model of GAD65. The C-terminal domain (gray) and the
middle domain (white) are shown. Approximate locations of the amino acids required
for human monoclonal antibody recognition are coloured as follows: MICA8 and
MICA9 (green), DPC (pink), the C-terminal epitopes (blue, red, orange) and the
middle region epitopes (purple). Within the C-terminal epitopes, MICA 7 (blue) binds
across the face of two helices (helices Rand T) forming a blocking group with
MICA8 and MICA9 (green), as well as, MICA2, MICAS and b78 (orange, red) which
bind to an exposed helix (helix S). Within the middle domain, MICA!, MICA3 and
DPA bind the backside of helix R, as well as, MICA4, MICA6 and MICAIO which
bind to helix M. Two murine monoclonal antibodies (65-! and 65-2), which block
MICA 7, bind the bottom region of the dimer and span both the C-terminal and middle
domains. The N-terminal domain of GAD-65 is predicted to be located at the top of
this model (Schwartz et aI., 1999).
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Figure 1.6 Three-dimensional model of the middle region (PLP-binding region) of a
GAD-65 dimer. a, Two monomers of GAD65 are shown. PLP molecules are modeled
in red colour. Helix J contains E264 (purple) which is essential for MICAIO binding
and involved in MICA6 binding. K358 (purple) at the C-terminal end of helix M is
essential for the MICA4 epitope. R317 (purple) in helix L is essential for MICA4, b96
and MlO. P231 and S234 (Pink) are involved in the DPC epitope. W375 and E411
(white) differ between GAD65 and GAD67 (Schwartz et al., 1999). b, The PLP-
binding region of GAD-65 is shown highlighting the regions to which MICA3
binding peptides [residues 262-270, which constitutes the PEVKEK loop, is coloured
yellow, a-helixes (residues 285-296 and 215-334) are coloured red, and residues 373-
395 are coloured blue] (Myers et al., 2000).
a)
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Figure 1.7 Helix wheel projections and a three-dimentional model of the Csterminal
domain of a GAD-65 monomer. Helix wheel projection are viewed from the N-
terminal end of the 3 a-helices in the C-terminal region of GAD-65. Hydrophobic
amino acid residues are shown in black (Schwartz et aI., 1999).
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1.2.4.5 Other Autoantibodies
Carboxypeptidase-H (('PH) is a 52 kO glycoprotein. which is expressed by islet [)
cells and other neuroendocrine cells. In islet ~ cells. ('PH is present in secretory
granules to enhance the conversion of proinsulin to insulin. Anti-C 'PH autoantibodies
are present in 25% of ICA+ first-degree relatives (Dotta et a .. 19(4) and 30% of
prediabetic individuals (Eisenbarth et al., 1994).
JX kD autoantigen is present in insulin secretory granules of islet I~cells and other
neuroendocrine cells. It is recognised by newly diagnosed type I DM patients' sera
(Datta et a .. 1994). Anti-ICA69 are detected in 70% of newly diagnosed type I OM
patients. 25% of recent-onset type 1 OM (Roep et al., 1996), q°lt) of first-degree
relatives (Datta et a .. 1(94) and GAAs+ or anti-S? kD+ patients (Bonifacio et al..
19(5).
Anti-GM2-1 islet ganglioside autoantibodies are detected in 65% of ICA+ first-degree
relatives. Also. some leA can react with the GM2-1 ganglioside (Datta et a., 1994).
Islet cell surface autoantibodies (lCSAs) are weakly cytotoxic for islet [) cells. ICSA
have been detected using cultured rodent or human fetal islet cells and it is possible
that these specificities are distinct from K'A specificities. Also. the IgM insulin
receptor autoantibodies ({RAs) react with insulin receptor in newly diagnosed type
DM patients (Eisenbarth et al., 1994).
IgG and IgA anti-B-lacroglobulin autoantibodies (anti-B-l.G) are increased in type I
DM patients <3 years of age and in siblings. Among siblings. the levels of anti-p-
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lactoglobulin are the same either before or after the clinical onset of tYI1L'1 DM (Iorini
cl al., 1994).
Anti-DNA Topoisornerase type II (anti-TopII) autoantibodies are detected in type I
DM patients. The anti-Topll autoantibody epitopes are 1-47 aa. 2X(l-·P2 aa and ('-
terminal third of ONA Topll. There is evidence that the anti-Topl l autoantibodies
may crossreact with other islet p cells autoantigens, such as CiAD. insulin. CPH and
IISP65 (Chang et al.. 19(6).
Anti-steroid 21 hydroxylase (P450c21) autoantibodies are present ill type I OM
patients. 86% of those patients have HLADQB 1*0201 (Peterson er al.. 19(7). Anti-
pancreatic disialo-ganglioside G03 autoantibodies are present in nc\\ly diagnosed
type 1 OM patients but not in IAA and/or ICA+ relatives of type I [)M patients
(Tiberti et al., 1995).
To determine the extent of gluten associated autoimmunitv in type 10M.
autoantibodies to tissue transglutaminase C (tTGA). a major autoantigen in coeliac
disease. were measured in patients with new-onset type 10M. Interestingly. an
increased prevalence of coeliac disease in patients with type I DM is \\ ell established.
The prevalence of IgA to tTGA is about 8% and IgG to tTGA is about 32% in newly
diagnosed type 10M. This suggests that the high prevalence or autoimmunity to
ITGA may be due to an involvement of the gut in the pathogenesis or type I OM or to
release of tTGA from destroyed pancreatic beta cells (Lampasoua et al.. 1999; Lorini
cl al., 2000).
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Gastric parietal cell antibodies (PCA). which are a marker fix iron deficiency and
pernicious anaemia and atrophic gastritis (Baekkeskov et al., 1990: Riley et al., 1982).
are highly prevalent in type I DM. especially in patients with ICA t~3 years after
diagnosis. The PCA arc associated with GAD autoantibodies and/or HLA DR5
haplotype (De Block et al., 2000).
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1.3 Phage-displayed Random Peptide Library
1\ random peptide library reveals a large repertoire of peptides expressed as fusions
with a coat protein of bacteriophage, resulting in display of the fused proteins on the
surface of the virions. while the DNA encoding the fusions resides within the virions.
Some of the expressed peptides may bind to the selector molecule (such as antibody,
enzyme. cell surface receptor. etc.) and often display a common consensus amino acid
sequence. In some eases. this sequence (motif) shows similarity with a region of the
natural protein binding to the selector molecule (Parmley and Smith I !)XX).
Phage-displayed random peptide libraries (PPL) have been used in a number of
applications (Cortese et al., 1993), including epitope mapping (Scott and Smith 1990),
mapping protein-protein contacts (Hong and Boulanger 19(5). and identification of
peptide mimics of non-peptide ligands (Devlin et al., 19(0). Hioactivc peptides have
been identified either by panning against immobilised purified receptors (O'Neil et
al., 1(92) or against intact cells (Doorbar and Winter 19(4). Larger proteins [antibody
fragments (Barbas. S .. and Barbas, C., 1994) , hormones (Lowman et al., 1991),
protease inhibitors (Roberts et al., 1992), enzymes (Soumillion et al.. 19(4) and DNA
hinding proteins (Choo and Klug 1995)] have been displayed on phage. and variants
with altered affinity or specificity have been isolated from libraries of random
mutants.
The uses of combinatorial libraries include the definition of high affinity ligands both
for T cell and antibodies, the application of relevant peptides for lise as potential
preventative and therapeutic vaccines, the requirements for [,CR interactions with
peptide-Ml+C complexes in immunogenicity, and the establishment of new principles
(JO
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regarding the level of cross-reactivity in immunological recognition (Pinilla et al.,
19(9). The B cell cpitopes are classified as either discontinuous. which recognise only
native. folded structures. or continuous (Pinilla et al., 19(9).
Regarding T cell epitopes, MHC-peptide complex formation has been achieved by the
presence of anchor amino acids which mediate contact to the spcci ficity pockets of
MHC class [or class II molecules (Rammensee et al., 1(97). The recognition of this
ligand by the TCR requires contacts with polymorphic and nonpolymorphic residues
of the a-helical domains of the MHC molecule which flank the peptide-binding
groove (Madden et al., 1(95) and also requires specific amino acids or the peptide that
interact with the TCR (Kersh and Allen 1996). Class-l-restricted T cell clones show
higher antigen affinities and the class I binding groove accommodates shorter
peptides (8-10 amino acid residues) than class II (Rotzschke et ul.. 1990). Thus,
relatively less complex peptide libraries can be used to determine class-l-restricted
specificities. By contrast. Class-II-restricted T cell clones show lower antigen
affinities (Davis et al., 1998) and the class II binding groove accommodates longer
peptides (10-25 amino acid residues) (Pinilla et al., 19(9). Thus. more complex
peptide libraries can be used to determine class-Il-resricted specificities, resulting in
lower concentrations of individual peptides (complexity increases hy 20-fold with
each additional position) and T cell specific peptides with lower affinities.
Furthermore, the combinatorial library can be used to identify the number of different
peptide ligands that can associate with the appropriate MHC molecule and stimulate a
single CD4+ T cell clone (T cell degeneracy) (Pinilla et al.. 19(9).
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lhc range of applications of phage technology has been extended to include the
search for peptides binding to cell receptors (Cortese et al., 1(95). For example.
SrcSH3 domain is an intracellular receptor that has been used to select binding
peptides (Sparks et al.. 1994). Interleukins can also be displayed on phage and
preserve their capacity to interact with their receptors (Gram et al.. 19(3). Random
phage display peptide libraries and affinity selection methods were used to isolate
small peptides that bind to and activate the receptor for the cytok inc erythropoietin
(EPO) (Wrighton et al., 1996). This discovery may form the basis for the design of
small molecule mimetics of EPO.
Phagotopes are phage peptides selected for their ability to bind to antibody. as do anti-
idiotypes. Also. ph ago topes can induce antibodies (anti-anti-antibodies) that are
specific for the antigen recognised by the tirst antibody. which can he used as a
vaccine. For example. mimotopes (selected peptides) selected with an anti- human
immunodeficiency virus (anti-Hl V) gp120 monoclonal antibody can induce a specific
humoral immune response to gp 120 (Keller et al., 1993). This ind icates that it is
possible to develop vaccines based on mimotopes identified by their capacity to bind
to patients' antibodies. An example is provided by mimotopes selected with the serum
of HbsAg immunised individuals: these mimotopes were able to induce an antibody
response against HbsAg in experimental animals (Folgori et al., 19(4).
Fab antibody fragments have also been displayed on the surface of filamentous phage
MD (Barbas and Lerner 1991) by linking the heavy or light chain to a coat protein
and secreting the other chain into the bacterial periplasm where the two chains are
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associated (Better et ul., 19X8). With filamentous phage. it is also possible to mimic
the expression of soluble antibody from the plasma cell (Hoogcnboom et a!.. 1991).
1.3.1 T7 Phage Peptide Library
A constrained T7 phage peptide library C9C, (constrained 9-mers with cystine-cystine
loop) (rig. 1.8). was constructed by Dr Paddy Tighe (Division or Immunology,
University of Nottingham). T7 is a double stranded DNA phage with the capability of
lysing E.coli (strain BL 21). It expresses the inserted peptides as -+ I:' copies on the
surface coat protein encoded by gene X. The displayed peptide 9-lllers are expressed
at the C-terminus of gene X. between the EcoRI and Hindlll restriction sites.
Furthermore, it is easy to grow and its replication is very rapid in comparison to the
filamentous phage. Also. it is very robust and stable to harsh conditions that inactivate
other phage. It can display peptides and proteins do not need to he capable of export
through the periplasm and the cell membrane, as is necessary with filamentous phage
(Rosenberg et al., 19(7).
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Figure 1.8 Structure of the T7 Phage Paticle (Rosenberg et al., 1997).
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1.3.2 M13 Filamentous Phage Peptide Library
M13 is a single stranded DNA phage that infects specific strains of E.coli. There are
two types ofM13 filamentous phage peptide library in which the peptides are fused to
either the gene III or VIII proteins (Fig. 1.9). Both of them express their displayed
peptides at the amino terminus of the gene.
Figure 1.9 Structure of the M13 Filamentous Phage. Different Genes (ill, VI, Vll,
VIII and IX) are shown.
pG_ VIII (approx 2800 copies)
j \
pGeneVII and
pG_IX
(5 copies cl each)
I6.snm
viral ssDNA (1 copy, about
930nm
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1.3.2.1M13 Filamentous Phage Peptide Library Gene III
Two types of M 13 Iilamentous phage peptide library gene III (pili) "here used in the
present study: a library of unconstrained 12-mers (without cystine-cystine loops) and a
constrained library C7C (7-mers with cystine-cystine loopsj.Thcsc can infect E.coli
strain called ER 2537. They express the inserted peptides as 3-5 copies on the surface
coat protein encoded by gene III. The displayed peptide 12-mers an: expressed at the
N-terminus of pll l, between the KpnI and EagI restriction sites. The pili is responsible
for attachment of the phage to the bacterial F-pilus and infection (Marks et al., 1992).
1.3.2.2 M13 Filamentous Phage Peptide Library Gene VIII
Constrained M 13 filamentous phage peptide library gene VIII 5('4('4 ( l S-rners with
cystine-cystine loops) was used in the present study. It can infects E.Coli strain K91
Kan. It expresses the inserted peptides on a proportion of the 300 copies of the surface
coat protein encoded by gene VIII, vector f88-4. The displayed peptide 15-mers are
expressed at the N-terminus of gene VIII, between the HindIlI and Pstl restriction
sites. The pVIII is responsible for coating the douhle stranded DNA (Marks et al.,
1(92).
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1.4 Rationale and Aims of the Project
lhe aim of these studies was to determine the epitopes In (iAD()) of three
different mouse monoclonal antibodies: N-terminal monoclonal <Intibody within
4-17 amino acids (au). Cvterminal monoclonal antibody within .5 n-)X5 aa and
GAD-6 (Fig. 1.10): to determine the epitopes in IA-2 of two different mouse
monoclonal antibodies 7613 and 76F (Fig. 1.11): and to determine the cpitopes of
two different human monoclonal antibodies. b78 and b96.11. on (i!\D-65 (Fig.
1.10). Two different types of random peptide phage libraries were used: T7 and
M 13 libraries. The different libraries may yield complementary information which
helps in locating epitopes with more confidence. Previous studies showed that the
(iAD-6 epitope is present in the C-terminal region of GAD. but did 110t reveal
definitively the specific amino acid residues of the GAD-6 epitope. Also. previous
studies showed that the 7613 and 76F epitopes are present in the extracellular
domain of IA-2 and in the N-terminal region of cytoplasmic domain of IA-2.
respectively. but also did not reveal definitively the specific amino acid residues
of the 76B and 76F epitopes. In addition, previous studies showed that the b78
and b96.11 epitopes are present in 532-540 aa and 308-365aa. respectively. on
(iAD-65 (Schwartz et al.. 1999). but did not reveal definitively the specific amino
acid residues of the b78 and b96.11 epitopes. The determination or epitopes
recognized by these monoclonal antibodies might help LIS to understand the
antigenic nature of the GAD65 and IA-2 autoantigens.
Since epitope mapping is generally simpler with monoclonal antibodies than with
polyclonal antibodies. these studies should indicate how best to use the random
phage peptide libraries to determine the epitope specificities of patients' serum
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autoantibodies. Thus. a further aim of these studies was to determine the
immunodominant epitopes (public epitopes) in GAD65 or SMS patients' serum
autoanti bodies.
Figure l.tO Epitopes of Mouse (N- and Cvterminus and GA[)-6) and Human (b96.ll
and b78) Monoclonal Antibodies on GAD65.
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An aim of these studies was also to investigate the influence oj" particular features
of the random peptide libraries on their usefulness for epitopc mapping. The
variable features included the importance of using peptides with a cysteine-
cysteine loop (constrained library) or linear peptides, and the importance of using
different libraries with different features [peptide copies. expression. infection.
peptide numbers of amino acids per peptide (7, 9. 12 or IS-mel'S) and coat protein
on which peptide expressed (gene pl ll, pVIII or pX)] in cpitope recognition.
CHAPTER TWO
GENERAL MATERIALS AND METHODS
General Materials and Methods
2 General Materials and Methods
2.1 T7 (e9C or linear 9-mers) Phage Peptide Libraries
2.1.1 General Preparations
In this section. standard procedures are described which were employed 111 the
protocols described in detail in the following sections.
2.1.1.1 Ecoli BL 21 in LB Agar Plate
LB agar Petri dishes were inoculated with E.coli BL 21 strain (Novagen. US) using a
sterile wire loop. and incubated at 37°C overnight.
2.1.1.2 Ecoli BL 21 Overnight Culture
A single colony of E.coli BL 21 was removed from an LB agar plate using a sterile
wire loop. added to IOmls of LB broth in a conical Bask and incubated on a shaker at
37°C overnight.
2.1.1.3 Mid-log Phase Ecoli BL 21 Culture
0.5ml of E.coli BL 21 overnight culture was added to 20-30111lsof LB broth and then
incubated on a shaker at 37°C for 2-3 hours until the optical density at 600 nm
(OD600)=0.6-0.8 as determined by spectrophotometry.
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2. 1. 1.4 Serial Dilution of Non-amplified Eluate
Ten microlitres of the non-amplified eluate (described in section 2.1.2) were serially
diluted by adding 990~t1 LB broth and then mixed. giving a JO-~ dilution. Then. 100~t1
of 10-2 diluted eluate were added to 900J-li LB broth and then mixed giving a 10-3
dilution. Then. 100~t1 of 10-3 diluted eluate were added to 900~t1 LB broth and then
mixed. giving a 10-4 dilution; and so on.
2. 1. 1.5 Plating the Diluted Non-amplified Eluate
One hundred microlitres of a dilution of non-amplified eluate were added to I00~t1 of
mid-log phase E.coli BL 21 culture and then mixed with 3mls of top ugarose (0.7%
agarose and 0.1 % MgCh·6H20 in LB broth), which were pre-warmed to 45°C, in a
Pijuo tube. The mixture was poured on to an LB agar Petri dish and incubated at 37°C
for 3 hours.
2.1.1.6 Lysate-treated Membrane
One hundred microlitres of T7 wild-type phage were added to 20mls of mid-log phase
E.coli BL 21 culture in a conical flask and incubated on a shaker at ~7°C for 45
minutes to induce lysis of the E.coli by the phage (termed the lysate). then centrifuged
at 4°C and 1,500 g for 20 minutes. Then, the pellet was collected and resuspended in
2mls of TBS. The lysate was poured on a nitro-cellulose membrane and incubated for
~ominutes at room temperature. Then, the lysate-treated membrane was washed with
0.1 % TBS-T for 15 minutes then with TBS for 5 minutes and then blocked with 5%
BSA/TBS and incubated on a rotator for one hour at room temperature.
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2. 1. 1. 7 Loading of peR Product and Gel Electrophoresis
Five microlitres of peR product or 0.5~d of 100 base pair (bp) standard DNA ladder
were added to 2~Llof loading buffer [0.25% bromophenol blue. 0.2.51% xylene cyanol
FF. 15% Ficol (type 400. Pharmacia) in water]. The agarose ge1121Yc. agurose in Tris-
borate/EDTA (TBE) butter (90mM Tris, 90mM borate and 2mM UHA pH 8.3)
with cthidium bromide O.2~Ll/IllI] was placed in the gel electrophoresis tank,
immersed with TBE and loaded with the samples. The gel was run at X()volts for 45
minutes, observed under an (ultra-violet) UV transilluminator and photographed.
2.1.1.8 5x Buffers Band C
Buffer B was prepared by mixing 300mM Tris HCl pH 8.5. 75mM (NlbhS04 and
IOmM MgCh. While buffer C was prepared by mixing 300mM Tris HCI pH 8.5,
75mM (NH4)2S04 and 12.5mM MgCh.
2.1.2 Bio-panning of Antibody with T7 (C9C or Linear g-mers) Phage Peptide
Libraries
One millilitre (1111) of diluted mouse monoclonal antibody (ntAb), [10
micrograms/millilitre, (1Oug/mll] in 0.05M sodium carbonate/sodium bicarbonate
buffer pH 9.6 (coating buffer). was coated onto a Nunc immune-tube at .foe overnight
on a rotator. The tube was washed 5 times with 25 millimolar (25mM) Tris-buffered
saline (l50mM NaCl) pH 7.4 (TSS) containing 0.1% Tween-20 (0.1 'Yr. TBS-T); each
time the tube was incubated at room temperature for 3 minutes with the TBS- T. The
tube was then blocked with 5% bovine serum albumin (BSA) in TRS (5% RSA/TBS)
(blocking solution) at room temperature for one hour on a rotator. Ten microlitres of
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the T7 phage library IlxlOlo plaque forming units (pfu)1I0pll ill 11111 of blocking
solution. was added to the ntAb-coated tube and incubated at 4°(' lor .20 minutes on a
rotator.
The tube was then washed ten times in 0.1% TBS-T to remove unbound phage and
11111of a mid-log phase E.coli BL 21 culture 00600=0.6-0.8 was added and incubated
on a rotator at room temperature for 5 minutes. This suspension or Lcoli infected
with the phage which had bound to the mAb was termed the non-amplified eluate.
Ten microlitres of the non-amplified eluate were taken for dilution and plating (as
described in sections 2.1.1.4 and 2.1.1.5, respectively) to be confident that the specific
phage had been eluted. Thus, the phage formed lysis plaques on the plate and the
number of plaques of each round were compared with the number or plaques of the
previous rounds as an indication of the specificity of the biopanning. The remainder
of the eluate was added to 20-30mls of the mid-log phase E.coli HI. 21 culture in a
conical flask and incubated on a shaker at 37°C for 1-3 hour(s) for amplification, thus
1()("J11ingthe amplified eluate.
Following amplification. the T7 phage lysed the E.coli BL 21 causing dotted strands
of DNA to become visible. 250111 of chloroform were then added and mixed to
complete lysis of the E.coli BL 21 and release of the phage. lhc enriched phage
(amplified eluate) were centrifuged at 4°C and 9.500 g (}I' I() minutes. The
supernatant containing the phage was transferred to a fresh tube and subjected to a
second cycle of affinity selection following the procedure described above. Thus, the
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enriched phage of the preceding round of biopanning were used II.H· the next round.
Four rounds were carried out in this way for the biopanning of the '1"7phage library.
2.1.3 Detection of Antibody-specific T7 (C9C or Linear 9-mers) Phage Peptide
Clones by Immuno-blotting Assay
The phage of the final round (fourth round) of biopanning were plated out (as
described in section 2.1.1.5) to obtain 100-200 plaques per Petri dish. A millipore
nitro-cellulose membrane (0.45~LM pore size and 82mm area) (Millipore, UK) was
placed onto the plate and incubated for 30 minutes at roOI11 temperature. The
membrane was then blocked with 5% BSA/TBS and incubated on a rotator for one
hour at room temperature. Ten millilitres of diluted mouse monoclonal antibody,
(IOug/ml, diluted in 2.5% BSA ITBS-T) was added to the membrane and incubated
on a rotator for 2 hours at room temperature. The membrane was washed with 0.1 %
TBS- T for 15 minutes and then with TBS for 5 minutes.
Sheep anti-mouse IgG (whole molecule) antibody was depleted of reactivity against
T7 phage and E.coli prior to addition to the membrane in order to reduce the non-
specific background staining. This was achieved as follows: 10mis or diluted sheep
anti-mouse IgO (whole molecule) alkaline phosphatase conjugate (Sigma) (diluted
I: I000 in 2.5% BSA/TBS- T) was adsorbed with lysate-treated membrane (prepared
as described in section 2.1.1.6) for 30 minutes at room temperature on a rotator. It was
then added to the membrane that had the selected phage clones and antibody bound,
and incubated at room temperature for one hour. The membrane was washed as above
and BCIPINBT (5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium)
substrate (Sigma) in de-ionised water with 5mM lcvamisolc \\as added to the
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membrane and incubated for 30 minutes at room temperature. Following the
appearance of the blue spots, the membrane was washed with TBS, then with water
and dried.
Antibody-specific phage clones, which developed as blue spots on the membrane,
were selected from the original plate using a wire-loop and each of them mixed with
Iml of mid-log phase E.coli BL 2 t culture and iucubated on a shaker at 37°e for 3
hours for amplification (amplified eluate). Following amplification and lysis of E.coli
by the T7 phage, 25~tI of chloroform were added to each clone to complete lysis. The
amplified eluates were centrifuged at 4°C and 9.500 g for I() minutes. The
supernatants containing the phage were transferred to fresh tubes and used for
polymerase chain reaction (peR), sequencing and enzyme-linked immunosorbent
assay (ELISA).
2.1.4 PCR and Sequencing of Antibody-specific T7 (C9C or Linear s-rners)
Phage Inserts
O.S~t1of each clone of specific phage was added to 2S~t1of peR mixture [Sul of 5x
buffer B or e (described in section 2.L1.8), 0.2S~t1of I% tween, ().5~t1of t OmM
dNTPs (deoxynucleoside triphosphates), 0.5~1 of 20~lM T7 A primer (5' -AeA ACG
TTA TCG occ TGT Te-3'_), 0.5~Llof20~M T7 B primer (S'-TAC CCrG AGG TTe
ACC GAT AG-3'), I~LiofO.SU/~1 ofampliTaq or Hotstar Taq DNA polymerase and
17.S~d of sterile de-ionised water], The samples were transferred to a Hybaid
Omnigene peR machine, which was preheated to 75°(', and run on a peR reaction
program [(94°(', t 5 minutes)x t; (94°e, 50 seconds: 50°(" I minute; rrc. 1
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rninutcjx j S: (72°e. 5 minutes)x I]. One aliquot was left with no phage to be used as
a negative control.
Five microlitres of peR product were used for loading and gel electrophoresis (as
desribed in section 2.1.1.7) to confirm the appearance of the band of the PCR product
at 150 base pair (bp) length after the PCR reaction.
To prepare the sample (or the sequencing reaction. O.5~d of Exonuclease I (I Ol.l/pl)
and lul of shrimp alkaline phosphatase (SAP) (IlJ1~d) were added to 5~t1 of PCR
product. which showed a bright band at l50bp length. and run on the enzyme
treatment program (37°C, 15 minutes; 80°C 15 minutes) in the Omnigene PCR
machine. One microlitre of enzyme treated PCR product was then added to 4~t1
BigDye Terminator. which is labelled with the following dRhodaminc acceptor dyes:
dR6G to give green colour for terminator A, dROX to give red colour for terminator
C. dR II Q to give blue colour for terminator G and dTAMRA to give black colour for
terminator T (Perkin-Elmer Applied Biosystems). O.15~d of IO~lM '1'7 sequencing
primer (5' -TTA AGe TGC GTG ACT TGG C-3 ') and 5~t1of sterile de-ionised water
and run on a sequencing reaction program [(96°C_ 30 seconds: 50°('. 15 seconds:
60°('.4 minutes)x25: (28°C. I minute)x 1].
Ten microlitres of sequencing reaction product was purified by adding I24111
sequence cleaning mixture (ethanol: water: 3M sodium acetate pll 4.6-5.2. in a
dilution 25:5: I). The samples were centrifuged at 4°e and 2':21.000 g for 15 minutes.
The supernatant was removed and the pellet cleaned by adding 3()O~t1or 7Q% ethanol
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sheep anti-mouse IgG (whole molecule) alkaline phosphatase conjugate (diluted
I :1000 in 1% BSA/TBS-T) (Sigma) was added to all wells (IOOpl/well) and shaken
at room temperature tor one hour. Wells were washed 3 times in TBS-T and
substrate [1ug/rnl p-nitrophenyl-phosphate (pNPP) substrate (Sigma) III
diethanolamine buffer. 25mM MgCh. 15mM NaN;. pll 9.8] was added to all wells
( IOO~lllwell) and incubated at room temperature. Plates were read at optical density
(OD) 405 nm after 60 minutes at room temperature and overnight at 37°C on a
microtitre plate reader (Molecular Devices). The mean OD of the antigen-coated
wells was corrected by subtracting the mean OD of the equivalent blank wells.
2.1.5.2 ELISA with Maleic Anhydride Activated Polystyrene Plates
Ihe detection of specific T7 phage peptides was confirmed by using maleic anhydride
activated polystyrene (MAAP) 96-well plates (Pierce and Warriner. UK). The
selected phage. T7 wild-type (negative control) (diluted 1:20 111 0.2N
carbonate/bicarbonate buffer pH 9.7) was coated onto wells (I OOpl/well) of the
MAAP plate and incubated for one hour at room temperature on a shaker. Wells were
washed 3 times with washing buffer (0.1 % BSA and 0.05% TBS- T). and blocked with
blocking buffer (3°1t) BSA and 0.05% TBS- T) at room temperature for one hour.
Blank wells, which were not coated with phage. were also blocked with blocking
buffer. as above. Following 3 washes. mouse monoclonal antibody (I ug/ml in
washing buffer) or a negative control antibody (I ~lg/ml in washing buffer) was
applied (lOOpl/well) in duplicate to antigen-coated and blank wells and shaken at
room temperature for two hours. Following 3 washes. sheep anti-mouse IgO (whole
molecule) alkaline phosphatase conjugate (diluted I: 1000 in washing buffer) was
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added to all wells (IOOpl/\vell) and shaken at room temperature 1'01' one hour. Wells
were washed .1 times ill TBS-T and pNPP substrate was added to all wells
(IOO~t1/well) and incubated at room temperature for one hour. Plates were read alter
(lO minutes at OD 405 nm on a microtitre plate reader (Molecular Devices). The mean
OD of the antigen-coated wells was corrected by subtracting the mean OD of the
equivalent blank wells.
2.1.6 Construction of T7 Linear 9-mers Phage Peptide Library
2.1.6. 1 Preparation of Double-stranded DNA from Degenerate
Oligonucleotides
The random peptides of the T7 library were encoded by a double stranded DNA insert
assembled from synthetic degenerate oligonucleotides and cloned into gene X of the
vector (T7select415-1) (Bioscience, Cambridge, UK). Oligonucleotide sequences
were as follows: (9Iin3'), 5' -GAT CAC CGA AGC TTC AAU AGC-J' (15 nmol)
(2Ibp) and (9Iin). 5' -GeT GCT TAT eTA GGA ATT CC (NNK)., lei" GGC TCT
TGA AGC TTC GGT GAT C-3' (10.3 nmol) (72bp) (Cruachem. Paisley. Scotland).
The oligonucleotides were annealed to produce double-stranded DNA and extended
by combining the following components: 40J,l1 of buffer C. S~t1of 51llM dNTPs, 2pl
of 1% tween, 4~L1of upper primer (9Iin3'), 4J,l1of lower primer (9Iin), 2~d of O.5U/~d
Taq DNA polymerase and 140J,l1 sterile de-ionized water; followed by running the
following program: 94°(', 10 minutes; 57°C, 2 minutes: 72°C. 20 minutes; into the
Omnigene PCR machine.
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The DNA was extracted by adding an equal volume (2()()~tI) of 50:50
phenol:chloroform to the peR product, mixed and centrifuged at 4°(, and 21.000 g for
30 seconds. The supernatant (DNA) was transferred to a fresh microccntrifuge tube
and precipitated by adding 2.5 volume of 100% ethanol and 0.1 volume of 3M Na-
acetate pH 5, incubated at -20°C for 10 minutes, centrifuged at 4°(, and 21.000 g for
20 minutes and cleaned by adding 0.5ml of 70% ethanol and centri fugcd at 4°C and
21.000 g for 5 minutes. The supernatant was discarded, while the pellet (DNA) was
suspended in 20~t1 or lOx OPA (One Phor All) (Pharrnacia, UK) and mixed with
160pl of sterile de-ionized water. Then, the suspended DNA was transferred to 4 fresh
microcentrifuge tubes as follows: 20~tl without digestion. 20~t1 digested by adding 2pl
of EcoRl, 20pl digested by adding 2pl of HindIII or 120~t1 digested by adding both
6.5~t1 of EcoRI and 6.5~t1 of HindIII and incubated at 37°(' overnight.
The whole amount of undigested and digested DNA (EcoRI. HindIII and
EcoRI+HindIII) or 0.5~tI of 10bp standard DNA ladder were added to loading buffer
and loaded into a 20'X) polyacrylamide gel in TBE. The gel was run at lOW and 10mA
for 3 hours. The DNA was visualized by ethidium bromide staining under UV and
photographed. The band of the DNA insert, which was digested with EcoRI+HindIIL
was visualized at 45bp; and excised and crushed into a tine paste. The gel was
suspended in 3ml of 0.5M ammonium acetate. incubated on a shaker at 37°C
overnight and centrifuged at 4°C and 1,500 g for I minute. The supernatant was
filtered using mobitec syntered plastic disc to remove residual polyacrylamide
fragments of the gel. The supernatant was treated with l-butanol extractions [by
adding an equal volume of I-butanol, mixing and centrifugating at 40(' and 21,000 g
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for 30 seconds, then the upper phase was removed while the aqueous (lower) phase
was retained for the next extraction]. The I-butanol extractions were repeated to
reduce the volume to 0.5ml containing the DNA insert.
The DNA insert was extracted by adding an equal volume (0.5ml) of 50:50
phenol.chloroform, mixed and centrifuged at 4°C and 21,000 g for JO seconds. The
supernatant (DNA) was transferred to a fresh microcentrifuge tube and precipitated by
adding 2.5 volume of 100% ethanol and 0.1 volume of 3M Nu-acetate pH 5.2,
incubated at -20°C for 10 minutes, centrifuged at 4°C and 21.000 g for 20 minutes
and cleaned by adding 0.5ml of 70% ethanol and centrifuged at 4°(, and 21,000 g for
5 minutes. The supernatant was discarded, while the pellet (DNA) was air dried and
re-suspended in 20-30~d of de-ionized water. The insert was aliquoted and stored at
-70°C.
2. 1.6.2 Preparation of Linearized Vector DNA
The vector (T7 wild type phage) (50ml) had been amplified in E.Coli BL21 strain.
The vector was treated with DNAase! (Iug/rnl) and RNAaseA (I OO~lg/ml) and
incubated for 15 minutes at room temperature. Then. 2M ZnCI (20~t1/ml) was added
to the treated vector and incubated for 5 minutes at 37°C. Alter centrifugation at 4°C
and 9,500 g for 1 minute, the pellet was suspended in TES buffer (0.1M Tris-HCI, pH
8; 0.1M EDTA and 0.3% SDS) (500~I/ml) and incubated for 15 minutes at 60°C.
Then, 3M potassium acetate pH 5.2 (60~I/ml) was added, mixed and incubated on ice
for 10-15 minutes. After centrifugation at 4°C and 13.000 g for I minute, the
supernatant was collected. An equal volume of isopropanol was added, mixed and
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incubated on ice for 5 minutes. After centrifugation at 4°C and 13.000 g for 1 minute,
the pellet was cleaned by adding 70% ethanol and centrifuged at 4°(, and 13,000 g for
5 minutes. The supernatant was discarded, while the pellet (DNA) was air dried and
re-suspended in TE (I OmM Tris-HCI, pH:8; ImM EDTA) buffer (20-1 ()O~Ll/ml).
The suspended DNA vector was extracted by adding an equal volume (600~Ll) of
50:50 phenol.chloroform, mixed and centrifuged at 4°(, and 21.000 g for 30 seconds.
The supernatant (DNA) was transferred to a fresh centrifuge tube and precipitated by
adding 2.5 volume of 100% ethanol and 0.1 volume of 3M Nu-acetate pH 5,
incubated at -20°C for 10 minutes, centrifuged at 4°C and 21.000 g I()("20 minutes
and cleaned by adding 0.5ml of 70% ethanol and centrifuged at 4°(, and 21.000 g for
5 minutes. The supernatant was discarded, while the pellet (DNA) was suspended in
II O~Llof lOx OPA and mixed with 890).11of sterile de-ionized water. The suspended
DNA (lml) was transferred to a fresh microcentrifuge tube and digested by adding
both 50).11of EcoRI and 50~Liof HindIII and incubated at 37°C overnight. The DNA
vector was then de-phosphory lated by adding 1O~Llof shrimp alkal ine phosphatase (1-
3U/~lg of DNA) and incubated at 37°C for 30 minutes.
The DNA vector was extracted by adding an equal volume (1.11 O~tl) of 50:50
phenol:chloroform, mixed and centrifuged at 4°e and 21,000 g for :;0 seconds. The
supernatant (DNA) was transferred to a fresh centrifuge tube and precipitated by
adding 2.5 volume of 100% ethanol and 0.1 volume of 3M Nu-acetate pH 5.2,
incubated at -200e for 10 minutes, centrifuged at 4°C and 2l.000 g !()J" 20 minutes
and cleaned by adding 0.5ml of 70% ethanol and centrifuged at 4°(, and 21,000 g for
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5 minutes. The supernatant was discarded, while the pellet (DNA) was air dried and
re-suspended in IOO~tIof de-ionized water.
2. 1.6.3 Ligation of the vector and insert DNA
The ligation reactions were set up by assembling the following components:
O.04pmol vector, O.12pmol insert, O.51l1of lOx ligase buffer, O.Spl or IOmM ATP,
O.5~tlof 100mM OTT and l ul of0.4-0.6 Weiss units o1'T4 DNA ligase. Then, 5~tl of
ligation reaction were mixed gently by pipetting up and down and then incubated 3-
16 hours at 16°C. The 5~Llof ligation reaction was then added to 25pl of T7Select
packaging extract (Bioscience, Cambridge, UK) and incubated at room temperature
for 2 hours. The reaction was stopped by adding 270~L1LB medium.
One microlitre of the non-amplified eluate was taken for dilution and plating (as
described in sections 2.1.1.4 and 2.1.1.5, respectively). giving Ix I()III pfu/rnl. The
bulk of the phage were added to 200-400mls of the mid-log phase E.coli BL 21
culture and incubated on a shaker at 37°C for 1-3 hour(s). Following the lysis, lml of
chloroform was added and mixed to complete lysis the E.coli BL 21 and release of
the phage. The amplified phage were centrifuged at 4°(, and 9,500 g 1<)("10 minutes.
The supernatant containing the phage was transferred to a fresh tube. which was
termed the T7 (linear 9-mers) phage peptide library.
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2.2. M13 pili (C7C or Linear 12-mers) Filamentous Phage Peptide
Libraries
2.2.1 General Preparations
In this section, standard procedures are described which were employed In the
protocols described in detail in the following sections.
2.2. 1. 1 Minimal Plate
Five hundred millilitres of 2X M9 salts, 500ml of 3% agar. 20ml of 20fYc, glucose, 2ml
of 1M MgS04• O.lml of 1M CaCh, Iml of lOmg/ml thiamine were sterilized
separately, combined together at temperature <70°C and poured onto Petri dishes.
2.2.1.2 E.eoli ER 2537 in Minimal Plate
A minimal Petri dish was inoculated with E.coli ER 2537 strain (New England
Biolabs, UK) using a sterile wire loop, and incubated at 37°C overnight.
2.2.1.3 E.eoli ER 2537 Overnight Culture
A single colony of E.coli ER 2537 was removed from a minimal plate using a sterile
wire loop. added to IOmls of LB broth in a conical flask and incubated on a shaker at
] 7°C overnight.
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2.2.1.4 Mid-log Phase E.coli ER 2537 Culture
0.2ml of E.coli ER 2537 overnight culture was added to 20mls of LB broth and then
incubated on a shaker at 37°C for 3 hours until the OO('oo=O.S as determined by
spectrophotometry.
2.2.1.5 Early-log Phase E.coli ER 2537 Culture
0.2ml of E.coli ER 2537 overnight culture was added to 20mls of LB broth and then
incubated on a shaker at 37°C for 15 minutes until the 00(,00=0.05 as determined by
spectrophotometry.
2.2.1.6 Serial Dilution of Non-amplified Eluate
One microlitre of the non-amplified eluate (described in section 2.2.2) was serially
diluted by adding 99~ll LB broth and then mixed. giving a 10-2 dilution. Then, 10~1 of
10-2 diluted eluate were added to 90~1 LB broth and then mixed. giving a 10-3
dilution. Then, 1OO~tl of 10-3 diluted eluate were added to 90~ll LB broth and then
mixed, giving a 10-4 dilution; and so on.
2.2. 1. 7 Plating the Diluted Non-amplified Eluate
Ten microlitres of a dilution of non-amplified eluate were added to 200~Llof a mid-
log phase E.coli ER 2537 culture and then mixed and incubated at room temperature
for 1-5 minute(s) (to allow the M13 pIlI phage to infect the E.coli ER 2537) and then
mixed with 3mls of top agarose (0.7% agarose and 0.1% MgCh·61-bO in LB broth),
which were pre-warmed to 45°C. in a Pijuo tube. The mixture was poured onto a LB
agar Petri dish and incubated at 37°C overnight.
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2.2.1.8 Concentration and Purification of Amplified Eluate from Bio-panning
The amplified phage were centrifuged at 4°C and 9,500 g for 1() minutes. The
supernatant containing the phage was transferred to a fresh tube and re-centrifuged.
One sixth volume of PEGfNaCI [20% (w/v) polyethylene glycol in 2.5M NaCl] was
added to the supernatant to precipitate the phage, and incubated at 4°(, overnight. The
precipitated phage were centrifuged at 4°C and 9.500 g tor 15 minutes. The
supernatant was removed and the pellet suspended in 1ml TBS. The suspension was
transferred to a microcentrifuge tube and centrifuged at 4°C and 9,50() g lor 5 minutes
to pellet residual cells. The supernatant was transferred to a fresh microcentrifue tube,
and re-precipitated with 1/6 volume of PEGfNaCI and incubated on ice for 15-60
minutes. The precipitated phage were centrifuged at 4°C and 9,500 g for 10 minutes.
The supernatant was removed and the pellet was re-suspended in 200~L1of TBS.
0.02% NaN3. The suspension was centrifuged at 4°C and 9,500 g for one minute to
pellet any remaining insoluble matter. The supernatant (the amplified eluate) was
transferred to a fresh microcentrifuge tube.
2.2.1.9 Lysate-treated Membrane
One hundred microlitres of M 13 pIlI wild-type (M 13K07) phage were added to 20mls
of early-log phase E.coli ER 2537 culture (00600=0.05) in a conical flask and
incubated on a shaker at 37°C for 4.5 hours to infect the E.coli by the phage (termed
the lysate), then centrifuged at 4°C and 1,500 g for 20 minutes. Then. the pellet was
collected and resuspended in 2mls ofTBS. The lysate was poured on a nitro-cellulose
membrane and incubated for 30 minutes at room temperature. Then, the lysate-treated
membrane was washed with 0.1% TBS- T for 15 minutes then with TnS tor 5 minutes
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and then blocked with 5% BSA/TBS and incubated on a rotator for one hour at room
temperature.
2.2.1.10 Lysis of E.coli ER 2537 Overnight Culture by Sonication
Forty millilitres of E.coli ER 2537 overnight culture (described in section 2.2.1.3)
were centrifuged at 4°C and 1,500 g for 20 minutes. The pellet was collected and
suspended in 4mls of TBS, in ice to avoid secretion of E.coli enzymes which may
cause proteolysis of human serum antibodies. Then. the suspension was sonicated for
5 minutes at level lOin ice to lyse the bacteria. The lysate was fi Itcrcd using a filter
(pore size=G.Zp.M) and stored at -20°e.
2.2.2 Bio-panning of Antibody with M13 pili (C7C or Linear 12-mers) Phage
Peptide Library
Mouse monoclonal antibody (lO~g/ml), in O.OSM sodium carbonate/sodium
bicarbonate buffer pH 9.6 (coating buffer), was coated onto a Nunc immune-tube at
4°C overnight on a rotator. The tube was washed 5 times with 50mM Tris-buffered
saline (l50mM NaCl) pH 7.5 (TBS) containing 0.1 (Yo Tween-20 (0.1 (~, TBS-T); each
time the tube was incubated at room temperature for 3 minutes with TBS-T. The tube
was then blocked with 0.5% BSA in TBS containing 0.02% NaN, (blocking
solution) at room temperature for one hour on a rotator. Following 6 washes, IOul of
the MI3 pIll phage library rz-to'' pfu/IOul) (New England Biolabs, UK) in l ml of
0.1 % TBS·T were added and incubated at 4°C for 30 minutes on a rotator. The tube
was washed IQ times and 1ml of elution buffer (0.1 % BSA in 0.2M glvcine-HCl pH
2.2) was added and incubated ar room temperature for 10 minutes on a rotator. This
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non-amplified eluate was removed and neutralized with ISOpl of neutralizing buffer
( IM Tris-Hel buffer pH 9.1 ).
One microlitre of the non-amplified eluate was taken for dilution and plating (as
described in sections 2.2.1.6 and 2.2.1.7, respectively). While the rest of the eluate
was added to 20mls of the early-log phase E.coli ER 2537 culture (01)()00=0.05) and
incubated on a shaker at 37°e for 4.5 hours for amplification.
The amplified eluate. which was concentrated and purified (as described in section
2.2.1.8), was subjected to a second cycle of affinity selection following the same
procedure described above. Thus, the enriched phage of the preceding round of
biopanning were used for the next round. Three rounds were carried out in this way
for the biopanning of the M13 pIlI phage library.
2.2.3 Detection of Antibody-specific M13 pili (C7C or Linear 12-mers) Phage
Peptide Clones by Immuno-blotting Assay
This was performed as described in section 2.1.2 for the T7 phage library. The phage
of the final round (third round) of biopanning were plated (as described in section
2.2.1. 7) to obtain 100-200 plaques per Petri dish. A millipore nitro-cellulose
membrane (O.2IlM pore size) was placed onto the plate and incubated for 30 minutes
at room temperature. The membrane was then blocked with SCY!) BSA/TBS. Ten
millilitres of diluted mouse or human monoclonal antibody. (1Oug/ml. diluted in 2.5%
BSA ITBS- T) was added to the membrane and incubated on a rotator for 2 hours at
room temperature. The membrane was washed with 0.1% TBS- T. Ten millilitres of
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diluted sheep anti-mouse IgG (whole molecule) alkaline phosphatase conjugate
(diluted I: I000 in 2.51% BSA/TBS-T) was blocked with lysate-treated membrane then
added to the membrane that had the selected phage clones and antibody bound, and
incubated for one hour at room temperature. The membrane was washed. as above,
and BCIPINBT substrate in de-ionised water with 5mM levamisolc was added to the
membrane. Following the appearance of the blue spots, the membrane was washed
and dried.
Antibody-specific phage clones, which developed as blue spots on the membrane,
were selected and each of them mixed with Iml of early-log phase Lcoli ER 2537
culture and incubated on a shaker at 37°C for 4.5-5 hours for amplification (amplified
eluate). The amplified eluates were centrifuged at 4°C and 9.500 g lor 30 seconds.
The supernatants containing the phage were transferred to fresh tubes and used for
purification, sequencing and ELISA.
2.2.4 Purification and Sequencing of Antibody-specific M13 pIlI (C7C or
Linear 12-mers) Phage Inserts
Five hundred microlitres of phage clones were precipitated hy adding 200JlI of
PEGlNaCI. mixed and incubated at room temperature for 1() minutes. The
precipitated phage were centrifuged at 4°C and 9,500 g fix 10 minutes. The
supernatant was removed and the pellet suspended in IOOJlIof Iodide buffer (I OmM
Tris-HCl pH 7.5, ImM EDTA and 4M Nal) and 250~d of 1001Yt. ethanol, and
incubated at room temperature for to minutes to precipitate single-stranded phage
DNA. The precipitated phage DNA was centrifuged at 4°C and 9.500 g for 10
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minutes. The supernatant was removed and the pellet washed by adding 350f.!1of
70% ethanol and dried briefly under vacuum. Then. the pellet were re-suspended in
30~d ofTE buffer (Tris-HCI pH 8 and ImM EDTA). as purified phage.
To perform the sequencing, 4.4f.!1of the purified product was added to 4pl BigOye
Terminator and 1.6~t1of 1pM/~d of -96 gIll sequencing primer (5' -('CC TCA TAG
TTA GCG TAA CG-J·. 1pmol/ul) and run on the sequencing reaction program. Ten
microlitres of sequencing reaction product was purified. dried and prepared for cycle
sequencing, as described in section 2.1.4 for T7 phage library.
2.2.5 Detection of Antibody-specific M13 pili (C7C or Linear 12-mers) Phage
Peptide Clones by Capture ELISA
Rabbit anti-fd IgG (Sigma) (diluted 1:100 in coating buffer) was coated onto wells
( 100~tl/we211)of maxisorp ELISA plates on a shaker. The plates were incubated at
4°C overnight. Wells were washed 3 times (200lll/well) in 0.1% TBS-T. and blocked
with 3% BSA/TBS (120~tl/well) at room temperature for one hour. The selected
phage, unselected phage or helper M13 phage as a negative control (diluted 1:20 in
1% BSA/TBS- T) were applied (I OOllllwell) to test wells. while 1% BS/\/TBS- Twas
applied to blank wells. and shaken at room temperature for 2 hours. following 3
washes. the mouse or human monoclonal antibody or a negative control antibody,
(Iug/rnl in 1% BSA/TBS- T) was applied (1OOf.!l/well)in duplicate to antigen-coated
and blank wells and shaken at room temperature for 2 hours. Following 3 washes.
sheep anti-mouse lg'G (whole molecule) or goat anti-human IgG (Fe specific)
alkaline phosphatase conjugate (diluted 1:1000 in 1% BSA/TBS-T) "vas added to all
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2.3 M13 pVIII (5C4C4) Phage Peptide Library
2.3.1 General Preparations
In this section, standard procedures are described which were employed 111 the
protocols described in detail in the following sections.
2.3.1.1 Minimal/Kanamycin Plate
Five hundred millilitres of2X M9 salts, 500ml of 3(% agar, 20ml of 2()(YcIglucose, 2ml
of 1M MgS04, 0.1 ml of IM CaCh, 1ml of lOmg/ml thiamine were sterilized
separately, combined together with 100J..lg/ml of kanamycin at temperature <70°C and
poured onto Petri dishes.
2.3.1.2 E.coli K91BluKan in Minimal/Kanamycin Plate
A minimal/kanamycin Petri dish was inoculated with E.coli K91 B1uKan strain
(Kanamycin-resistant work-horse strain) (New England Biolabs. UK) using a sterile
wire loop and incubated at 37°C overnight.
2.3.1.3 E.coli K91BluKan Overnight Culture
A single colony of E.coli K91BluKan was removed from a minmal/kanamycin plate
using a sterile wire loop, added to 10mls of LB broth with 1Ouug/rnl of kanamycin in
a conical flask and incubated on a shaker at 37°C overnight.
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2.3.1.4 Late-log Phase E.coli K91BluKan Culture
Forty micolitres of E.coli K91BluKan overnight culture was added to -lmls of terrific
broth and then incubated on a shaker at 37°e for 3-4 hours until the OD('()o=2as
determined by spectrophotometry, followed by re-incubation 011 a gentle (slow)
shaker at 37°e for 5 minutes to allow sheared F pili to regenerate.
2.3. 1.5 Amplified E. coli K91BluKan culture
Two millilitres of the late-log phase E.coli K91 BluKan culture was added to 20mls of
LB broth/0.2~Lg/ml of tetracycline. followed by addition of 40~tI of 10mg/ml
tetracycline
2.3.1.6 Serial Dilution of Non-amplified Eluate
One microlitre of the non-amplified eluate (described in section 2.3.2) was serially
diluted by adding 99~LlLB broth/n.zug/ml of tetracycline and then mixed, giving a
10-2 dilution. Then, IO~Llof 10-2 diluted eluate were added to 90~LlLB broth/0.2~Lg/ml
of tetracycline and then mixed. giving a 10-3 dilution. Then. I0()~t1of 10-3 diluted
eluate were added to 90~d LB brothlO.2~g/ml of tetracycline and then mixed, giving a
10-4dilution; and so on.
2.3.1.7 Plating the Diluted Non-amplified Eluate
Ten microlitres of a dilution of non-amplified eluate were added to 90~tl of a late-log
phase E.coli K91BluKan culture, mixed and incubated at room temperature for 5
minutes (to allow the M13 pVIII phage to infect the E.coli ER 2537). and then mixed
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with 500~d of LB broth/G.Zug/ml of tetracycline and incubated on a shaker vigorously
at 37°C for 35 minutes. Two hundred microlitres hom that mixture were poured onto
LB agar Petri dishes containing 40~g/ml of tetracycline and IOOpg/ml of kanamycin
and incubated at 37°C overnight. The number of phage was corrected by
multiplication by 3, because 1/3 volume (200~1) of the mixture (I O+l)()+500=600~ll)
were poured onto the Petri dishes.
2.3.1.8 Lysate-treated Membrane
One hundred microlitres of M 13 pIlI wild-type (M 13K07) phage were added to 2mls
of the late-log phase E.coli K91 BluKan culture (OD(100=2) in a conical tlask and then
incubated on a slow shaker at 37°C for 15 minutes. Then. 20mls of LB
hroth/0.2~lg/ml of tetracycline were added and incubated on a shaker vigorously at
J 7°C for 35 minutes. This was followed by addition of 40~tI or l Omg/rnl of
tetracycline and incubation on a shaker vigorously at 37°(, overnight to allow
infection of the E.coli by the phage (termed the lysate). The lysate was centrifuged at
4°(, and 1,500 g for 20 minutes. The pellet was collected and resuspended in 2mls of
TBS. The lysate was poured on a nitro-cellulose membrane and incubated for 30
minutes at room temperature. Then, the lysate-treated membrane was washed with
0.1 % TBS- T for 15 minutes then with TBS for 5 minutes and finally blocked with 5%
I3SA/TBS and incubated on a rotator for one hour at room temperature.
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2.3.2 Bio-panning of Antibody with M13 pV1I1Phage Peptide Library
Mouse monoclonal antibody (I Oug/rnl), in O.05M sodium carbonate/sodium
bicarbonate buffer pl-l 9.6 (coating buffer), was coated onto a Nunc immune-tube at
4°C overnight on a rotator. The tube was washed 5 times with 50mM Tris-buffered
saline (150mM NaCI) pH 7.5 (TBS) containing 0.1% Tween-20 (O.I(Yr,TBS-T); each
lime the tube was incubated at room temperature for 3 minutes with the TBS- T. The
tube was then blocked with 0.5% BSA in TBS containing 0.02% NaNJ (blocking
solution) at room temperature for one hour on a rotator. Followi ng 6 washes, IO~l of
the MI3 pVIII (5C4C4) phage library (lxl013 pfu/IOul), which was kindly provided
by Dr George Smith (Missouri, USA), in lrnl of 0.1% TBS-T were added and
incubated at 4°C for 30 minutes on a rotator. The tube was washed 10 limes and 1ml
of elution buffer (0.1 % BSA in 0.2M glycine-HCl pH 2.2) was added and incubated at
room temperature for 10 minutes on a rotator. The non-amplified eluate was removed
and neutralised with l50~1l of neutral ising buffer (1M Tris-HCl buffer pH 9.1).
One microlitre of the non-amplified eluate was serially diluted and plated (as
described in sections 2.3.1.6 and 2.3.1.7). While the rest of the phage were added to
2m Is of the late-log phase E.coli K91 BluKan culture (OD()oo=2) in a conical tlask and
then incubated on a slow shaker at 37°C for 15 minutes. Then. 20m Is of LB
brothlO.2~g/ml of tetracycline were added and incubated on a shaker vigorously at
}7°C for 35 minutes, followed by addition of 40~Ll of l Omg/ml or tetracycline and
then incubated on a shaker vigorously at 37°C overnight.
The amplified phage were concentrated and purified (as described in section 2.2.1.8).
The amplified eluate was subjected to a second cycle of affinity selection following
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the same procedure. Thus. the enriched phage of the preceding round of biopanning
were used for the next round. Four or five rounds were carried out in this way for the
hiopanning of the M 13 pVIII (5C4C4) phage peptide library.
2.3.3 Detection of Antibody-specific M13 pVlll (5C4C4) Phage Peptide Clones
by lmmuno-blotting Assay
The phage of the last round (fourth or fifth round) of biopanning were plated out (as
described in section 2.3.1.7) to obtain 50-100 plaques per Petri dish. Some phage
clones were selected by using a wire-loop and each of them was mixed with 0.5ml of
amplified E.coli K91BluKan culture and incubated on a shaker at 370(, overnight for
amplification. The amplified phage of each clone were centrifuged at 40(, and 9.500 g
for 30 seconds. The supernatant was transferred to a fresh tube and subjected to
imuno-blotting, PCR. sequencing and ELISA.
The immuno-blotting was performed as described in section 2.1.2 for the T7 phage
library. The amplified clones were placed onto a millipore nitro-cellulose membrane
using sterile tips on a multi-channel pipette and incubated for 5 minutes at room
temperature to dry. The membrane was then blocked with SCYt) BSA/TBS. Ten
millilitres of diluted mouse monoclonal antibody. (I Oug/rnl, diluted in 2.5% BSA
ITBS- T) were added to the membrane and incubated on a rotator for .2 hours at room
temperature. The membrane was washed with 0.1% TBS-T. Ten millilitres of diluted
sheep anti-mouse IgG (whole molecule) alkaline phosphatase conjugate (diluted
1:1000 in 2.5% BSA/TBS- T) were adsorbed with lysate-treated membrane then added
to the membrane that had the selected phage clones and antibody bound, and
incubated for one hour at room temperature. The membrane was washed. as above,
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and BCIPINBT substrate in de-ionised water with 5mM levamisole was added to the
membrane. Following the appearance of the blue spots, the membrane was washed
and dried.
2.3.4 PCR and Sequencing of Antibody-specific M13 pV1I1 (5C4C4) Phage
Inserts
The PCR and sequencing of Ml3 pVIII (5C4C4) phage inserts were performed as
described in section 2.1.4 for T7 phage library. 0.5~d of each clone of specific phage
was added to 25J..lI of PCR mixture [5J..lIof 5x buffer B or C. ().2S~L1of I% tween,
O.5~L1of lOmM ofdNTPs, O.5~Liof20J..lM M13 gene VIII primer (forward) (5'-GTA
AAA CGA CGG CCA GT-3'), O.5J..lIof20J..lM of Ml3 gene VIII primer (reverse)
(S'-GGA AAC AGe TAT GAe CAT G-3'), l~Ll ofO.5U/~L1 ofampliTaq or Hotstar
Taq DNA polymerase and 17.5J..lI of sterile de-ionised water]. The samples were
transferred to a Hybaid Omnigene PCR machine, which was preheated to 75°C, and
run on a Pf'R reaction program [(94°C, 15 minutes)xl; (94°C, 45 seconds; 55°C, 45
seconds; 72°C, 1 minute)x25; (72°C, 10 minutes)x 1]. One aliquot was left with no
phage to be used as a negative control.
Five microlitres of PCR product were used for loading and gel electrophoresis to
confirm the appearance of the band of the PCR product at 150 bp length after the
peR reaction.
Finally, 0.5J..ll of Exonuclease I (lOU/J..ll) and l ul of SAP (IU/~t1) were added to 5J..lI
of peR product and run on the enzyme treatment program. One microlitre of enzyme
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treated PCR product was then added to 4~t1BigDye Terminator. O. 15~L1of 1O~lM
MI3 gene VIII sequencing primer (S'-TTC TTA ATG GAA ACT TCe TC-3') and
5~t1of sterile de-ionised water and run on a sequencing reaction program. Ten
microlitres of sequencing reaction product was purified, dried and prepared for cycle
sequencing, as described in section 2.1.4 for the T7 phage library.
2.3.5 Detection of Antibody-specific M13 pV1I1(5C4C4) Phage Peptide Clones
by Capture ELISA
This was performed as described in section 2.2.5 for MI3 pIlI phage library. Rabbit
anti-to IgO (diluted I: I00 in coating buffer) was coated onto wells of maxisorp
ELISA plates and then incubated at 4°C overnight. Wells were washed 3 times in
0.1% TBS- T, and blocked with 3% BSA/TBS. The selected phage, unselected phage
or helper M13 phage as a negative control (diluted 1:20 in 1% BSA/TBS-T) was
applied (lOO,..il/well) to test wells, while 1% BSA/TBS- T was applied to blank wells,
and shaken at room temperature for 2 hours. Following 3 washes, the mouse
monoclonal antibody or a negative control antibody, (I ug/ml in 1'X, BSA/TBS-T) was
applied to antigen-coated and blank wells and shaken at room temperature for 2 hours.
Following 3 washes, sheep anti-mouse IgG (whole molecule) IgO alkaline
phosphatase conjugate (diluted 1:1000 in 1% BSA/TBS- T) was added to all wells and
shaken at room temperature for one hour. Wells were washed 3 times and pNPP
substrate was added to all wells and incubated at room temperature for one hour.
Plates were read after 60 minutes at OD 405 nm on a microtitre plate reader. The
mean OD of the antigen-coated wells was corrected by subtracting the mean OD of
the equivalent blank wells.
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MOUSE MONOCLONAL ANTIBODIES
Mouse Monoclonal antibodies
3 Mouse Monoclonal Antibodies
3.1 N-terminal and C-terminal Specific Mouse Monoclonal Antibodies
3.1.1 Introduction
Amino-terminal specific mouse monoclonal antibody (N-terminal Mu/vb), GC 3208
(clone I I), is a mouse IgG I monoclonal antibody. This N-term inaI MoAb reacts
weakly with GAD65 on blots, and also reacts with native GAD65.
A non-obese diabetic mouse was immunized with complete Freund's adjuvant at day
6 and a single dose of pancreatic islet p-cell toxin streptozotocin at day 3 before the
fusion was performed. to trigger an immune response against the animals own GAD
released from the damaged islet p cells. Lymphoctes from the spleen of the
immunized mouse were fused with mouse myeloma cells. The fusion mixture was
seeded in 96-well culture plate containing mouse peritoneal cells prepared from a
BALB/c mouse one day before the fusion (Ziegler et al.. 19(4).
Epitope mapping has shown that the N-terminal MoAb recognizes a linear epitope at
the N-terminus of rat GAD-65. Full abolition of N-terminal Mo/vb activity, as
determined by Western blotting on whole rat brain lysate. has been achieved using the
N-terminal peptide [rat/human GAD-65 (4-17) amino acid (aa) residues]. The MoAb
was purchased from Affiniti Research Products (ARP). UK. Interestingly, non-
diabetic SMS serum (DH) can inhibit the binding of the N-terminal monoclonal
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antibody. in a competition ELISA (data not shown). This indicates that OAAs of
some SMS sera recognize epitopes within the extreme N-terminus ofCiAD-65.
Carboxy-terminal mouse monoclonal antibody (C-terminal MnAb), GC 3108 (clone
I II). is a mouse IgO 1 monoclonal antibody (Ziegler et al.. 19(6). This C-terminal
MoAb reacts strongly on blots, but may not react with native GAD65.
BALB/c mouse was immunized with full-length human recombinant OAD-65
(obtained from a baculovirus expression system), which was emulsified in incomplete
Freund's adjuvant, intraperitoneally (i.p) and subcutaneously (s.c) at day 0 and also
after 2 months. Three days before the fusion experiment, the mouse was immunized
with OAD-65, which was dissolved in saline only. as one s.c and i.p injection.
Lymphoctes from the spleen of the immunized mouse were fused with mouse
myeloma cell line SP2/0 (Ziegler et al., 1996).
Full abolition of C-terminal MoAb activity, as determined by Western blotting on
whole rat brain lysate, has been achieved using the C-terminal peptide [rat/human
GAD-65 (572-585) aa residues]. The MoAb was purchased from Aftiniti Research
Products (APR), UK.
The N-terminal and C-terminal MoAb, whose epitopic regions on GAD-65 were
already closely defined (4-17 and 572-585 aa on GAD65. respectively), were
screened with different phage peptide libraries to act as controls for the screening of
other monoclonal antibodies (GAD-6, 76B, 76F and b96.11) for which the specific
amino acid residues of their epitopes were less closely defined. Thus. it was hoped
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that screening these two mouse MoAbs (N-terminal and Cvterminal MoAbs) with
different types of phage peptide libraries CMl3 plll, M13 pVIII and/or '1'7 pX) might
help to indicate the usefulness of these different libraries for screening other mouse or
human MoAbs to determine their epitopes on GAD65 or on other proteints).
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3.1.2 Results
3. 1.2. 1 M13 pili (linear 12-mers) Phage Peptide Library
3.1.2.1.1 Sequences of Phagotopes Isolated by Bio-panning of M 13 pili Phage Peptide
Library (linear 12-mers) and lmmuno-blotting Assay with N-tenninal or C-
terminal Specific Mouse Monoclonal Antibodies.
M13 pIlI phage library (linear 12-mers) was screened by 3 rounds or imrnunopanning
against N-terminal or C-terminal MoAb as described in section 2.2.2. The number of
plaques obtained in each round during plating increased consecutively. indicating that
the biopanning rounds were successful (Table 3.1).
The specific plaques of the third round were selected by blotting assay as described
in section 2.2.3. Sheep anti-mouse (whole molecule) alkaline phosphatase conjugate
was used to detect the binding of the N-terminal or C-terminal MoAb to the phage
clones. About 20% or 30% of these plaques (clones) showed high affinity, i.e.
showed blue spots on the nitrocellulose membranes, to the N-terminal or C-terminal
MoAb, respectively.
Thirteen and fifteen clones specific to the N-terminal or (,-terminal MoAb,
respectively, were sequenced successfully as described III section 2.2.4. All
sequences have been aligned with the relevant portions of GAD-()) (Fig. 3.1 and
3.2).
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Eight out of these 13 clones (10,13,18,22,25,26,28 and 30). which were specific to the
N-terminal MoAb, showed a motif of proline followed by glycine followed by 3
amino acids followed by tryptophan followed by serine. Also. 4/1J clones (1,24,27
and 29) showed a motif of proline followed by 4 amino acids followed by tryptophan
followed by serine followed by phenylalanine. Furthermore. 1113clones (21) showed
a motif of proline followed by glycine followed by serine. Thus. the main motif of N-
terminal mouse monoclonal antibody is P-G-X-X-X-W-S-F, corresponding to amino
acid residues 4-11 ofGAD-65 (P-G-S-G-F-W-S-F) (Fig. 3.1).
The 15 clones which were specific to the C-terminal MuAb. which were sequenced
successfully, showed a motif of Phenylalanine (11/ 15 clones) or tryptophan (1115
clones) followed by leucine (14115 clones) or valine (IllS clones) followed by
isoleucine (11/15 clones) followed by an amino acid followed by glutamate (14/15
clones) followed by valine (11115 clones), isoleucine (1/15 clones) or leucine (IllS
clones) followed by aspartate (14/15 clones) followed by an amino acid followed by
leucine (12115 clones). Thus, the main motif of C-terminal MoAb is F-L-I-X-E-
I1VIL-D-X-L, corresponding to amino acid residues 573-581 of GAD-65 (F-L-I-E-E-
I-E-R-L), which showed conservative substitutions. Isoleucine, valine and leucine
have aliphatic side chains and thus are similar residues. Aspartate and glutamate have
acidic side chains and thus are similar residues (Fig. 3.2).
103
Mouse Monoclonal antibodies
3.1.2.1.2 Testing of N-terminal or C-terminal Specitic Mouse Monoclonal Antibody-
specific Phagotopes of M 13 pIlI Phage Peptide Library (linear 12-mers) by
Capture ELI SA
Sequenced phagotopes of MI3 pIlI (linear 12-mers) phage library were selected for
investigation of their binding to N-terminal or C-terminal MoAb by capture ELISA as
described in section 2.2.5. Mouse IgO 1 kappa myeloma protein was used as a
negative control antibody (Sigma) (1 ug/ml in I (y<, BSA/TBS- T). Sheep anti-mouse
(whole molecule) alkaline phosphatase conjugate was used to detect the binding of the
N-terminal or C-terminal MoAb or negative control antibody (mouse IgU 1 kappa) to
the phage clones. Wild-type MI3K07 phage was used as a negative control phage.
Significant binding with the N-terminal or C-terminal MoAb, respectively. was shown
by 12 out of 13 clones (not clone number 1) selected with the N-terminal MnAb, and
16 out of 18 clones (not clone numbers 1 and 12) selected with the (,-terminal MnAb.
compared to the negative controls (mouse IgO 1 kappa and M 13K07 phage) (Fig. 3.3
and 3.4, respectively).
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Table 3.1 Number of Plaques Obtained in Each Round of Biopanning with Different
Phage Peptide Libraries
Phage Peptide ;\10. nf Plaques No. of Plaques ;\In. of l'laqucs I\u. uf 1'lallUl'S No. of Plaques
Antlbody Library per 1111ill the per rnl ill the per 1111in the per 1111ill the per 1111in the
Firsl Round Second Round Third Rnund Fnurlh I{uulld Fifth round
"N-terminal
-T7 rX linear 2x1O' 3xI0" 7xlO -"---:j:lO'
MoA" 9-mcrs.
-MI3 rill 2x1O' 3xI0" 6x IO'
linear 12-lllers.
-M13 rV11I 6x1O' 2x10~ -tx 10" 7, I(I"
5('4('4.
t -tcrminal
-MI3 rill _Ix 10' I xlO' 2x I()"
MoA" linear 12-mcrs.
(iAD-6 MoAh
-T7 rX ('9(' 7x 10' hIO" 2x 10' (hiO
-T7 rX linear 4x 10' 5xIO" I xlO' 2.10'
9-l11ers.
-MI3 rill -tx 10' 3xIO" 3x 10')
linear 12-l11crs.
-MI3 rill _Ix t 0' !x10" ~x I()"
('7('
2x 10'
-M 13 pV1I1 lx 10' 4xlO' ~dO' :' 10"
5('4('4.
76B MoAb -T7 pX (''Ie. 3xlO" 3x10" -hIO"
2,1(1"
-MI3 rill I xlO' !x10" 6x 10'
linear 12-lllcrs.
76F MoAh -T7 pX (,'1C'. 2xIO" 2xlO" I x")" I x 10"
.MI3 rill 5x10' I xiO' 5< I0"
linear 12-mcrs.
h96.11 huA" .M 13 rill 1x10' 5xI0" -tx 10'
linear 12-lllcl's.
SMS patient -MI) pili
_lxlO' (.10) 2xlO' (PT) 5< 10' (1)11) • I x 10" (Ill) KxIO' (PM)
sera. linear 12-lllcrs.
* Indicates that the eluate of only the third round ofbiopanning with SMS sera was amplified.
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Figure3.1 Sequences of Peptides Selected from the Filamentous MI:\ pilI (linear 12-
mers) Phage Peptide Library by Binding to N-terminal Specific Mouse Monoclonal
Antibody ..
GAD-65 (4-11 ) P G S G F W S F
10. 13, 18, 22, 25, 26. 28. 30 0 l~R J N lI~~lD21 L CSTVHC C S T1.24.27,29 S F P L L
Figure 3.2 Sequences of Peptides Selected from the Filamentous M I~ pili (linear 12-
rners) Phage Peptide Library by Binding to C-terminal Specific Mouse Monoclonal
Antibody.
GAD-65 (572-585) D F L E E E I~ L G
4,5,7,10,13,14. IS, 16. 18 G F L W E V J) I L S P
8,9 IG .iuu I) l J, l~
2 S F L Q T
f I J) N M G RI I
3 WO I T Y f t- ') I~ L W T
II G F L K W E V J) T M R P
17 A T H N P Q N E ~ ~ S I
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Figure 3.3 Capture ELISA: Binding of N-tenninal Specific Mouse Monoclonal
Antibody to M13 pill (linear 12-mers) Phage Clones Bound to ELISA Maxisorp
Plates via Rabbit anti-Id IgG.
1.6
1.4 .00 of N-term MoAb
1.2 DOD of IgG1 k
c 1E
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"
,,<::I "n;, ,,'0 '),." '),.'),. ~ {:> '),.co i' '),.'0 ~ n;,<::1 <S-n;,~
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Clone
Figure 3.4 Capture ELISA: Binding of C-tenninal Specific Mouse Monoclonal
Antibody to M13 pIlI (linear 12-mers) Phage Clones Bound to ELISA Maxisorp
Plates via Rabbit anti-fd IgG.
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3.1.2.2 T7 (linear 9-mers) Phage Peptide Library
J .1.2.2.1 Sequences of Phagotopes Isolated by Bio-panning 01''1'7 Phage Peptide Library
(linear 9-lllers) 'and Immuno-blotting Assay with Nucnninal Specific Mouse
Monoclonal Antibody
T7 phage library (linear 9-mers) was screened by 4 rounds of immunopunning against
N-terminal MoAb as described in section 2.1.2. The number of plaques obtained in
each round during plating increased consecutively. indicating that the biopanning
rounds were successful (Table 3.1).
The specific plaques from the fourth round of immunopanning the T7 phage library
(linear 9-mers) with the N-terminal MoAb were selected by blotting assay as
described in section 2.1.3. About 70% of these plaques (clones) showed high affinity
to the N-terminal MoAb. giving blue spots on the nitrocellulose membranes,
Twenty clones specific to the N-terminal MoAb were sequenced successfully (Fig.
3.5). Stop codons were found in all the clones at the end of the inserted portions. All
sequences have been aligned with the relevant portions of GAD-65. Fourteen out of
these 20 clones (1-14) showed a motif of proline followed by 2 amino acids followed
by either glycine (5/14) or alanine (9/14). Thus. the main motif of the N-terminal
MoAb is P-X-X-G. corresponding to amino acid residues 4-7 of GAD-()) (P-G-S-G).
which overlaps with P-G-S-G-F-W-S-F motif(4-11 amino acid residues). However.
this motif showed conservative substitutions. Glycine and alanine haw aliphatic side
chains and thus are similar residues. Also, three out of these 20 clones (15-17)
showed a motif of glycine followed by serine corresponding to amino acid residues
5-6 of GAD-65 (G-S). In addition, two out of these 20 clones (I X and 19) showed a
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motif of threonine followed by valine or isoleucine corresponding to amino acid
residues 6-7 of GAD-65 (S-G), which showed conservative substitutions. Glycine.
valine and isoleucine have aliphatic side chains and thus are similar residues. Also,
serine and threonine have aliphatic hydroxyl side chains and thus are similar residues
(Fig.3.5).
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Figure 3.5 Sequences of Peptides Selected from the T7 (linear 9-mers) Phage Peptide
Library by Binding to N-terminal Specific Mouse Monoclonal Antibody.
GAD-65 (4-7) P G S G
1-8 G S R N P T F A *
9-11 I J t J h *T S S K
I I I I I I
12,13 IR S N R Ir f f *
14 R K S S P T F A *
15-17 r R G S M K N A *
18 Q S R R S T V A *
I I I I
19 I K C f T I r f *I
20 I K S rTF M E *
I I ()
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3.1.2.3 M13 pV11I(5C4C4) Phage Peptide Library
3.1.2.3.1 Sequences or Phagotopes Isolated by Bio-panning of MI3 pV111 Phage Peptide
Library (5(,4C4) and Immuno-blotting Assay with N-terminal Specific Mouse
Monoclonal Antibody
M13 pVIII phage library was screened by 4 rounds of immunopanning against N-
terminal MoAb as described in section 2.3.2. The number of plaques obtained in each
round during plating increased consecutively, indicating that the hiopanning rounds
were successful (Table 3.1).
The plaques specific for N-terminal MoAb from the fourth round or M13 pVIII
phage screening were selected by blotting assay as described in section 2.3.3. About
40% of these plaques (clones) showed high affinity to the N-terminal MnAb. giving
blue spots on the nitrocellulose membranes.
Fourteen clones of M 13 pVIII phage library were sequenced successfully (Fig. 3.6).
All the clones showed a motif of serine followed by threonine followed by either
proline (12/14) or valine (2114). Thus, the motif obtained was S-T-P. which does not
correspond to amino acid residues 4-17 of GAD-65 and does not overlap with the
previous motifofthe N-terminal MoAb, i.e. P-G-S-G-F-W-S-F (4-10 amino acids).
3.1.2.3.2 Testing of N-tenninal Specific Mouse Monoclonal Antibody-specific Phagotopes
of M 13 pVIII Phage Peptide Library (5C4C4) by Capture ELISA
Sequenced phagotopes of MI3 pVIII phage library were selected for investigation of
their binding to the N-terminal mouse monoclonal antibody by capture ELISA as
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described in section 2.3.5. Mouse IgO 1 kappa myeloma protein was used as the
negative control antibody (Iug/rnl in ]% BSA/TBS-T). All the fourteen clones
showed strong binding with the N-terminal mouse monoclonal antibody, compared to
the negative controls (mouse IgO] kappa and WT phage) (Fig. 3.7).
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Figure 3.6 Sequences of Peptides Selected from the Filamentous M 13 pV1I1 (5C4C4)
Phage Peptide Library by Binding to N-terminal Specific Mouse Monoclonal
Antibody.
A N T C S T P LeW N E A
, , , ,
2 ( T N R P C IIIM C M G S y
J A S H D S C S T P M C S T P R
~ T T R E I C ~t ~F C T T N V
:; A M N P y C ~ ~ ~ L C G MI Q
() 'A D N P F C l + V H C S T T A
, , ,
7 ( N S P M C ,s Ir N c M y G T
N,9 A N Q K Q C S T P S C H N Y S
10 T N R D R C ~ ~ ~ T C N G Q s
II A P P M A C Is ~ V H C G M T
12 lA T K T C Is ~ p V C N N WV
, , I IIJ ( D S V A C ,S r f N C p Q T G
I~ A S E M K C S T P F C G S L S
Figure 3.7 Capture ELISA: Binding of N-terminal Specific Mouse Monoclonal
Antibody to M13 pVIII (5C4C4) Phage Clones Bound to ELISA Maxisorp Plates via
Rabbit anti-fd IgG.
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3.1.3 Discussion
Thirteen clones, which were obtained from the third round of successful biopanning
of the M13 pIlI (linear 12-mers) phage library and were positively immunostained in
the blotting assay (high affinity) with the N-terminal MoAb, showed a motif of P-G-
X-X-X-W-S-F (Fig. 3.1). This corresponds to amino acid residues 4-11 ofGAD-65
(P-G-S-G-F-W-S-F), as the epitopic determinant of the N-terminal MoAb.
All these 13 clones specific to the N-terminal MoAb obtained from the M 13 pIlI
(linear 12-mers) phage library were screened in ELISA. Twelve of these clones
showed significant binding with the N-terminal MoAb (Fig. 3.3).
Twenty clones, which were obtained from the fourth round of successful biopanning
of the T7 linear 9-mers phage library and were positively immunostained in the
blotting assay (high affinity) with the N-terminal MoAb, showed a motif of P-X-X-G,
corresponding to amino acid residues 4-7 of GAD-65 (P-G-S-G), which overlaps with
P-G-S-G-F-W-S-F motif (4-10 amino acid residues). However, this motif showed
conservative substitutions. Glycine and alanine have aliphatic side chains and thus are
similar residues. Also, three out of these 20 clones (15-17) showed a motif of glycine
followed by serine corresponding to amino acid residues 5-6 of GAD-65 (G-S). In
addition, two out of these 20 clones (18 and 19) showed a motif of threonine followed
by valine or isoleucine corresponding to amino acid residues 6-7 of GAD-65 (S-G),
which showed conservative substitutions. Glycine, valine and isoleucine have
aliphatic side chains and thus are similar residues. Also, serine and threonine have
aliphatic hydroxyl side chains and thus are similar residues. Only one clone did not
show a significant motif (Fig. 3.5)
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Stop codons were present in T7 phage peptide library (linear 9-mers). at the C-
terminal region of the insert. It is possible that the full length of the insert expressed in
some clones, but the MoAb only binds when the insert is present at the extreme C-
terminus of the surface coat protein. Another possibility is that the insert within the
surface coat protein is unstable and not expressed. except at the extreme C-terminus.
Fourteen clones, which were obtained from the fourth round of successful biopanning
of the M13 pVIII (5C4C4) phage library. and were positively immunostained in the
blotting assay (high affinity) with the N-terminal MoAb, showed a motif of S-T-P
(Fig. 3.6). This does not correspond to amino acid residues 4-17 of GAD-65 and does
not overlap with the motif of the N-terminal MoAb. i.e. P-O-S-Ci-F-W-S-F (4-10
amino acid residues).
Sequenced phagotopes of M13 pVIII phage library were selected for investigation of
their binding to the N-terminal MoAb by capture ELISA. All the 14 clones showed
strong binding with the N-terminal MaAb, compared to the negative controls (mouse
(gOI kappa and WT phage) (Fig. 3.7).
Thus. the overall motif of the N-terminal MoAb screened with these three
different phage peptide libraries (M13 pVIII. Ml3 pill and T7 pX) is P-G-S-G-X-
W-S-F. corresponding to amino acid residues 4-11 of GAO-65 (P-O-S-G-F-W-S-
F). This indicates that the epitope, which is recognized by the N-terminal MoAb,
is probably not a helix in GAO-65 due to the recognition of most of the amino
acid residues of the region. Also, this indicates that the phenylalanine. which is in
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the middle of that epitope and not present in the phage peptides recognized by the
N-terminal MoAb, may be buried in the GAO-65 structure.
The sequences of the peptides selected by using the T7 pX (linear 9-mcrs) and M13
pIlI (linear 12-mers) phage peptide libraries showed some similarity possibly due to
similarity in expressing linear displayed peptides (non-constrained). although they
expressed their displayed peptides at the C-terminus of gene X and N-terminus of
gene III, respectively. The differences in the sequences of the peptides selected by
using the MI3 pVIII (5C4C4) and T7 pX (linear 9-mers) phage peptide libraries,
may be due to the differences in their capability to express their displayed peptides
either at the N-terminus of gene VIII and at the C-terminus of gene X. respectively,
and/or due to the exposed peptides being constrained (cystinc-4-cystine loop,
conformational epitope) and non-constrained (linear epitope), respectively. although
they express a similar number of copies of inserted peptides on the phage surface.
This highlights how different peptide libraries screened with the same antibody can
give very different results, which mayor may not correspond to the cpitope in the
protein to which the antibody is specific.
Interestingly, SMS serum (OH) can inhibit the binding of the N-tcrminal MnAb, in a
competition ELISA (data not shown). This indicates that GAAs of some SMS sera
recognize epitopes within the extreme N-terminus of GAD-65. This consistent with
other studies on the epitope specificities of anti-GAD antibodies in SMS patients at
the N-terminal region of GAD-65 (Bjork et al., 1994; Hagopain et al.. 1995; Kim et
al., 1994). Also, 3 out of 30 sera (i.e. 10%) from type 1 OM patients specifically
displaced the binding of the N-terminal MoAb from GAD-65 (Ziegler et al., 1994).
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In addition, anti-GAD antibodies of a type 1 OM patient's serum an: directed against
residues 5-9 aa of GAD-65 (Rharbaoui et al., 1998). which overlaps with the
predicted overall epitope of the N-terminal MoAb (4-11 aa). Therefore, the N-
terminal region carries a continuous antigenic determinant recognized by the sera
from type 1 OM patients as well as the sera from the SMS patients.
Fifteen clones, which were obtained from the third round of successful biopanning
of the M13 pIlI (linear 12-mers) phage library and were positively inuuunostained in
the blotting assay (high affinity) with the C-terminal MoAb, showed" motif of F-L-
I-X-E-IN/L-O-X-L (Fig. 3.2), corresponding to 573-581 aa of GAJ)-(J) (F-L-I-E-E-
l-E-R-L), as the epitopic determinant of the C-terminal MoAb.
All these 15 clones specific to the C-terminal MoAb obtained from the M 13 pIlI
(linear 12-mers) phage library were screened in ELISA. All of these 15 clones show
significant binding with the C-terminal MoAb, comparing to all negative controls
(mouse IgGl kappa and M13K07) (Fig. 3.4).
The motif of the C-terminal MoAb, 573-581 aa, spans most ofn-helix T (568-582 aa)
in the three-dimensional model of the C-terminal region of GAD-65 (Schwartz et al.,
1999) (Fig. 3.8). The C-terminal MoAb could clearly not interact simultaneously with
all these amino acid residues as an a-helical structure, suggesting that the helix must
he denatured for the MoAb to bind. Indeed, other studies in our luhorutory indicate
that the C-terminal MoAb binds only to denatured. and not native. (iAD. It may be
relevant that the C-tenninal MoAb was derived from a mouse injected with GAD
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emulsified in incomplete Freund's adjuvant, which will have a denaturing effect on
the antigen.
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Figure 3.8 The Three-dimensional Model of the C-terminal Region of GAD-65
shows that the motif of the C-terminal Specific Monoclonal Antibody, 573-581, spans
most of a-helix T (Schwartz et aI., 1999).
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3.2 GAD-6
3.2.1 Introduction
GAD-6. a murine IgG2a monoclonal antibody, was purchased from Roche, UK.
GAD-6 reacts with GAO-65 on Western blots, as well as reacting with native GAD-
65. This indicates that GAD-6 can recognize a linear epitope on GAD-65.
BALB/c mice were immunized with purified rat brain GAD emulsified in complete
Frendss adjuvant and boosted one month later with the same protein emulsified in
incomplete Freund's adjuvant. Lymphocytes from the spleen of the immunized mice
were fused with NS-1 myeloma cells to create the GAD-6 hybridorna clone. GAO-6
was produced in ascites and purified by ammonium sulfate precipitation and anion-
exchange chromatography (Chang and Gottlieb 1988).
GAD-6 recognizes a specific epitope on GAD65 but not on GAD67. within amino
acid residues (aa) 475-585 (SMS El) (Butler et al., 1993). The GAAs of type I OM,
SMS and APS II (diabetic and non-diabetic) sera recognize the region of the GAO-6
epitope on GAO-65. In addition, the extreme C-terminal sixteen amino acid residues
of GAD65 do not form the epitopes of GAD65-specific GAAs of SMS and APS II
sera. nor the epitope ofGAO-6 since these 16 aa are identical with GAD67.
Other work from this laboratory has indicated that lCA+ non-diabetic APS II patients'
sera vary in the proportion of GAAs that inhibit GAO-6 binding to CiAO. There are
no significant differences in levels of GAAs which inhibit GAD-6 binding to GAD
between diabetic APS II patients with abrupt onset and slow onset type 1 OM
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(Davenport et al., 19(8). In addition, site-directed mutagenesis 01" the amino acid
residue at position 550 of GAD65 does not inhibit the binding of (iAD-6 to GAD65
(Davenport et al.. 1(98). indicating that this amino acid residue is not involved in the
GAD-6 epitope. Furthermore, GAD67 and GAD65 diner particularly in the 515-527
amino acid residue region (Daw and Powers, 1995), indicating that this region might
be recognized by GAD-6 which recognizes an epitope on GA[)65 only. Also, this
region might be recognized by GAAs of type I DM sera which recognize epitopes
mainly on GAD65.
The different phage peptide libraries (T7 pX linear 9-mers. M 13 pili linear l2-mers
and MI3 pVIII 5C4C4) which had been screened with the N-tcrminal and C-terminal
MoAb were also screened with GAD-6. In addition. two other libraries er? pX C9C
and M 13 pIlI C7C) were screened with GAD-6.
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3.2.2 Results
3.2.2. 1 T7 (GgG or linear s-mers) Phage Peptide Libraries
3.2.2.1.1 Sequences of Phagotopes Isolated by Bio-panning of T7 Phage Peptide Libraries
(C9C or linear 9-lllcrs) and lrnmuno-blotting Assay with GAD-Cl
'1'7 phage library, either C9C or linear 9-mers. was screened by 4 rounds of
immunopanning against GAD-6 as described in section 2.1.2. The number of plaques
obtained in each round during plating increased consecutively. indicating that the
biopanning rounds were successful (Table 3.1).
The plaques specific to GAD-6 from the fourth round of screening the T7 phage
library, either C9C or linear 9-mers, were selected by immuno-blouing assay as
described in section 2.1.3. About 12% of these plaques (clones) showed high affinity
to GAD-6, giving blue spots on the nitrocellulose membranes.
Sixteen clones of T7 (C9C) phage library and 7 clones of T7 (linear 9-mers) phage
library were sequenced successfully. Stop codons were found in all clones. either in
the middle of the inserted portions (in 7 out of the 16 clones of the '1'7 C9C phage
library), or at the end of the inserted portions (in 9/16 clones of the '1'7 C9C phage
library and in all the 7 clones ofT7 linear 9-mers phage library) (Fig. ~.(».
All sequences have been aligned with the relevant portions of GAD-()). indicating
sequence homologies in terms of identical residues and conservative substitutions
(i.e. amino acids with biochemically similar side chains) (rig. J.9). In T7 (C9C)
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phage library, 13116 clones (2,4,5,6,7,8,9,1 0, 11,16.18,20 and 21) showed a motif of
either arginine (81l3) or lysine (5/13) followed by either leucine (4/13), alanine
(3/13) or isoleucine (1113) followed by an amino acid followed by lysine. Thus, the
most significant motif for GAD-6 is R(or K)-L(A.l or X)-X-K. Thus. 4 out of these
13 clones (6,8,11 and 16) showed a motif of R-L-X-K. showing strong homology
with amino acid residues 525-528 of GAD-65. Arginine and lysine both have basic
side chains and thus are similar residues. Leucine, alanine and isoleucine have
aliphatic side chains and thus are similar residues. Also. 2 clones (I and 3) showed a
motif of methionine followed by two amino acids followed by alanine. Thus, the
second group of sequences showed another motif which is M-X-X-!\. This shows
homology to amino acid residues 523-526 (M-X-X-L) of GAD-65 which overlaps
with the R-L-X-K sequence (525-528 aa) (Fig. 3.9).
Amongst the clones selected from the T7 (linear 9-mers) phage library. 217 clones (l
and 2) showed a motif of arginine followed by 2 amino acids followed by lysine.
Thus, the most significant motif ofGAD-6 is R-X-X-K. showing homology to amino
acid residues 525-528 of GAD-65. Also, 417 clones (3.4.5 and 6) showed a motif of
leucine followed by an amino acid followed by lysine (L-X-K). This shows
homology to amino acid residues 526-528 of GAD-65 which overlaps with the R-L-
X-K motif(525-528 aa), Clone 7 did not show a significant motiftFig. 3.9).
I
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Figure 3.9 Sequences of Peptides Selected from the T7 Phage Peptide Libraries by
binding to GAD-6.
GAO-67 (532-537) R E K L H R
M S k L s kGAO-65 (523-528)
T7 (C9C) phage library:
Group I
2
II
10
20
21
9
18 CEVTLK
CRELT*A
clT
cJ J{Lp~.
J J ~ c I *
~L I
tKTGYtll*
IVRR
Q J P L R T
R Y K *
c k *4,5,7
16
1,2
T7 (linear 9-mers) phage library:
QI
J,4,5
7
D L P K *
I~N •
T7 (C9C) phage library:
Croup II
I
13
J
* Indicates stop codon.
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~.2.2.1.2 Testing of liAD-6-specific Phagotopes of T7 (C9(') Phage Peptide Library by
Direct and Capture ELISA
Sequenced phagotopes of T7 (C9C) phage library were selected fix investigation of
their binding to GAD-6 by direct ELISA. Six out of the 22 clones were screened in
[LlSA by using maxisorp plates as described in section 2.1.5.1. Five out of these 6
clones (1,2,3,4 and 6) showed binding with GAD-6. compared to the negative
controls [mouse anti-KLH IgG2a (l ug/ml in 1% BSA/TBS-T) (Sigma). wild-type
(WT) phage or unselected (US) phage] (Fig. 3.10).
All the 22 clones were screened in ELISA using maleic anhydride activated
polystyrene plates as described section 2.1.5.2. All of these 22 clones showed
binding with the GAD-6, compared to the mouse IgG2a kappa (negative control).
However, only about eleven out of these 22 clones (I. 3-10. 12 and 15) showed
hinding with the GAD-6 that was higher than the binding of GAD-() to WT phage
(Fig. 3.11).
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Figure 3.10 Direct binding of GAD-6 to T7 (C9(,) phage clones coated on ELISA
maxisorp plates.
0.6
0 0.5
• OOof GAD-6
iii o ODof anti-KLH gG2a
.0
::l 0.4u
S
1: 0.3
Cl
c 0.2ID
>
0
0 10 ID0 0.1 0 ID0 0 0 00
2 3 4 5 6 WT US
clones
Figure 3.11 Direct binding of GAD-6 to T7 (C9C) phage clones coated on ELISA
maleic anhydride activated polystyrene plates.
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3.2.2.2 M13 pili (linear 12-mers or C7C) Phage Peptide Libraries
3.2.2.2.1 Sequences or Phagotopes Isolated by Bio-panning or M I:; pili Phage Peptide
Library (linear 12-lllers or C7C) and Immuno-blotting Assay with (iAD-6
M 13 pIlI phage libraries, linear 12-mers and C7C. were screened by 3 rounds of
immunopanning against GAD-6 as described in section 2.2.2. The number of plaques
obtained in each round during plating increased consecutively. indicating that the
biopanning rounds are successful (Table 3.1).
The plaques from the third round of M13 pIlI phage library screenings were selected
by immune-blotting assay as described in section 2.2.3. Sheep anti-mouse (whole
molecule) alkaline phosphatase conjugate was used to detect the binding of the
GAO-6 to the specific clones. No plaques showed high affinity to the (iAO-6 (i.e.
only very weak blue spots were seen on the nitrocellulose membranes). The clones
which were sequenced and compared with one another did not show a clear motif
and it was impossihle to align them (data not shown).
3.2.2.2.2 Testing of GA D-6-specific Phagotopes of M 13 pili Phage Peptide l.ibrary (linear
12-mers or C7C) by Capture ELISA
Sequenced phagotopes of M 13 pIlI (either linear 12-mers or C7C) phage libraries
were selected for investigation of their binding to GAD-Cl by capture ELISA as
described in section 2.2.5 using mouse IgG2a kappa myeloma protein (I ug/ml in 1%
BSA/TBS-T) as a negative control, and sheep anti-mouse (whole molecule) alkaline
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phosphatase conjugate. None of the clones showed binding with GAD-6. compared to
the negative controls (mouse IgG2a kappa or WT phage) (data not shown).
3.2.2.3 M13 pV11I (5C4C4) Phage Peptide Library
3.2.2.3.1 Sequences of Phagotopes Isolated by Bio-panning of M 13 pV111 Phage Peptide
Library (5C4C4) and Immune-blotting Assay with GAD-6
M13 pVII[ phage library was screened by 5 rounds of immunopanning against GAD-
6 as described in section 2.3.2. The number of plaques obtained in each round during
plating increased consecutively, indicating that the biopanning rounds were successful
(Table 3.1).
The specific plaques from the fifth round of M 13 pVIII phage library screening were
selected by immuno-blotting assay as described in section 2.3.3. About 90% of these
plaques (clones) showed high affinity for GAD-6, showing blue spots on the
nitrocellulose membranes.
Ninteen clones of M 13 pVIII phage library were sequenced successfully (Fig. 3.12).
Interestingly, all sequences were identical to each other. This suggests that the M13
pVIII phage library has only one peptide specific to GAD-6.
All the clones showed a motif of methionine followed by two amino acids (cysteine
and tryptophan) followed by alanine. This is consistent with a motif for GAD-6 of M-
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X-X-A, corresponding to amino acid residues 523-526 (M-X-X-L) of( iAD-65 which
overlaps with the R-L-X-K motif (525-528 aa).
1.2.2.3.2 Testing of GAD-6-specific Phagotopes of M tl pV1I1 Phage Peptide Library by
Capture ELISA
Sequenced phagotopes of M 13 PVIII phage library were selected for investigation of
their binding to GAD-6 by capture ELISA as described in section 2.3.5. All the
ninteen clones showed strong binding with GAD-6. compared to the negative controls
fmouse anti-KLH IgG2a (I ug/rnl in 1% BSA/TBS-T). wild-type (WT) phage or
unselected (US) phage] (Fig. 3.(3).
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Figure 3.12 Sequences of peptides selected from the filamentous M I':; pVIII (5C4C4)
phage library by binding to GAD-6.
GAD-67 (532-537)
GAD-65 (523-528)
19 clones ARRWDCDGHMCWAQ
Figure 3.13 Capture ELISA: binding ofGAD-6 to MI3 pVIII (5('4('4) phage clones
bound to ELISA maxisorp plates via rabbit anti-to IgG.
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3.2.3 Discussion
Sixteen and seven clones, which were obtained from the fourth round of successful
hiopanning of the T7 phage libraries (C9C and linear 9-mers. respectively) and
which positively immunostained in the immuno-blotting assay with GAD-6
(therefore showing high affinity), were successfully sequenced. The sequences were
aligned with the relevant portions of GAD-65, showing sequence homologies in
terms of identical residues and conservative substitutions (i.e. amino acids with
biochemically similar side chains). Thirteen out of the sixteen clones selected from
the T7 (C9C) phage library and 217 clones selected from the T7 (linear 9-mers)
phage library expressed the motif RlK-LlA/I-X-K or R-X-X-K (Fig. 3.9),
respectively, possibly corresponding to 525-528 aa of GAD-65 (R-L-S-K) as an
important epitopic determinant of GAD-6. Interestingly. 4 out of these 13 clones,
which were selected from the T7 (C9C) phage library. contained the motif R-L-X-K.
Arginine and lysine both have basic side chains and are thus similar residues.
Leucine, alanine and isoleucine have aliphatic side chains and arc similar residues.
The two amino acid residues on the ends of the motif (arginine and lysine) are highly
conserved. suggesting that they are important in the paratope-epitope interaction
between GAD-6 and GAD-65.
Another motif of GAD-6 obtained from 3 other clones. which were selected from the
T7 (C9C) phage library, was M-X-X-A, possibly corresponding to 523-526 aa (M-S-
R-L) of GAD-65. The presence of methionine and leucine thus appears to be
important in the paratope-epitope interaction between GAD-6 and GAD-6S.
131
Mouse Monoclonal antibodies
Five out of 6 clones. obtained from the T7 (C9C) phage library. showed binding with
GAD-6 in ELISA using maxisorp plates, compared to the 'negative controls (mouse
anti-KLH IgG2a, wild-type (WT) phage and unselected (LJS) phage) (Fig. 3.10).
Also, 22 clones were screened in ELISA by using maleic anhydride activated
polystyrene plates. All of 22 clones showed binding with GAD-6. compared to the
mouse IgG2a kappa (negative control). But only about 11 out of these 22 clones
showed binding with GAD-6, compared to both mouse 19G2a kappa lind WT phage
(negative controls) (Fig. 3.11).
Stop codons are present in T7 phage peptide libraries, both constrained (C9C) or
unconstrained (linear 9-mers), at the C-terrninal region of the insert. It is possible that
the full length of the insert can be expressed, but the MoAb only binds when the insert
is present at the extreme C-terminus of the surface coat protein. Another possibility is
that the insert within the surface coat protein is unstable and not expressed, except at
the extreme C-terminus, as mentioned previously with N-terminal and C-terminal
MoAb.
Other work from this laboratory has indicated that GAD-6 can recognize the motif
M-X-X-L (523-526 aa of GAD-65) by aligning 7117 clones. which were selected
from a linear I5-mers M13 filamentous phage library (Davenport. 1995), Also, other
work from this laboratory includes mutation studies in which M-S (523-524 aa) was
changed to R-E. This did not significantly affect GAD-6 binding. but may not have
affected the conformational epitope R-X-X-K and the binding of GAD-6 to the
native GAD-65 (Trigwell et al., unpublished observations).
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GAD-6 does not bind to GAD-67: it is therefore significant that the equivalent
residues of M-S-R-L-S-K, the possible motif of GAD-6 corresponding to 523-528 aa
of GAD-65, are R-E-K-L-H-R in GAD-67, which shows 5 amino acid substitutions
that may disrupt the GAD-6 epitope. Also, the equivalent residues of R-X-X-K,
corresponding to 525-528 aa of GAD-65 indicated by clones selected from the T7
phage libraries, are K-X-X-R in GAD-67; i.e. the opposite orientation of the motif R-
X-X-K in GAD-65. This may prevent the binding of GAD-6 to GAD-67 or other
changes to neighbouring amino acids may affect the binding of GAD-() (see below).
Sixteen clones, obtained from the third round of biopanning of the M 13 pIlI (linear
12-mers or C7C) phage libraries were weakly immunostained in the blotting assay
with GAD-6 and were successfully sequenced. None of the clones. which were
sequenced and compared with one another, showed a clear motif. Also, it was
impossible to align them (data not shown). None of these clones. which were
screened in ELISA, showed binding with GAD-6. compared to the negative controls
(mouse IgG2a kappa and WT phage) (data not shown). The reason for this may be
that peptides which specifically bind with GAD-6 are not present in this type of
library (M13 pIlI phage library, either linear or constrained). On the other hand, the
reason for this may be that the avidity is too low due to low copy number of peptides
(3-5 copies) expressed by the MI3 phage library on the surface coat protein encoded
by gene III.
Ninteen clones, obtained from the fifth round of successful biopanning of the M 13
pVIII (5C4C4) phage library, were immunostained in the immuno-blotting assay with
GAD-6, and were successfully sequenced (Fig. 3.12). Interestingly. all the sequences
I, ".1.)
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were identical to each other, i.e. they showed only one peptide. This indicates that the
MI3 pVlII phage library may contain only one peptide specific to CiJ\D-6 under the
conditions employed. All the clones showed a motif of methionine followed by two
amino acids followed by alanine. Thus, the other motif of OAD-6 is M-X-X-A,
possibly corresponding to amino acid residues 523-526 (M-S-R-L) or (iAO-65 which
overlaps with R-L-X-K motif (525-528 aa). It may be relevant that both the M 13
pVlII (5C4C4) and T7 (C9C) libraries gave the M-X-X-A motif in sequences
containing two cysteines and which could therefore form di-sulphide bridges.
Whereas the sequences of the T7 (linear 9-mers) gave the R-X-X-K motif. It is
noteworthy that the C-C bridge in the constrained libraries (M13 pVIl1 and T7) would
bring methionine and alanine close together, since these two amino acids are present
within the C-C bridge in MI3 pVIII (5C4C4) and in only the three constrained clones
(L 3 and 13) of the T7 (C9C) phage library. Interestingly, the M 13 pVIII (5C4C4)
phage peptide library gave a motif for the N-terminal MoAb that did not correspond
to its epitope in OAO-65, whereas this M13 pVIII (5C4C4) phage peptide library did
work with GAO-6 by giving both the specific motif and epitope consistent with the
sequences of OAO-65.
Sequenced phagotopes of the M13 pVIII phage library were selected for investigation
of their binding to OAO-6 by capture ELISA. All the ninteen clones showed strong
binding with the GAO-6, compared to the negative controls [mouse <1nti-KLH IgG2a,
wild-type (WT) phage or unselected (US) phage] (Fig. 3.13).
Differences in the sequences of the peptides selected using these two different
libraries (i.e. MI3 pVIII filamentous phage library and T7 phage library) may be
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partly due to the differences in their capability to express their displayed peptide
either at the N-terminus of gene VIII protein of M I ~ Iilamcntous plw~e or at the ('-
terminus of gene X protein of T7 phage. although they express similar numbers or
copies of inserted pcptides (300 or 415 copies. respectively) Oil the surface coat
protein employed by the gene. Two different sequences were selected by these two
different libraries which are recognized by GAD-6. indicating that the GAD-6
cpitope may possess conformational. as well as linear. characteristics. The effects of
conformation on cpitopes of GAD-65 has been shown by the observation that
replacement of Asn247Ser and Leu574Pro can inhibit the binding of human
monoclonal antibodies (II hum MoAbs) to GAD-65. although the positions of these
2 amino acid residues (Asn247 and Leu574) are not involved in the cpitopes of some
of these human monoclonal antibodies. For example. the replacement of Leu574Pro
can inhibit the binding of some C-terminal-directed antibodies. such ,IS MICA I and
MICA 3 (Tree et al.. 2000). In addition, the replacement of Val5~2l.ys can inhibit
the binding of MICA 5 to GAD-65, although this amino acid residue (VaI532) does
not form part of epitope of MICA 5 (Glu517, Glu520. Ser524 and Ser527) (Schwartz
et al., 1999).
Analysis of C-terminal deletion mutants showed that the removal of 41 aa at the C-
terminus of GAD65 (545-585 aa deletion mutant) abolished the binding of MICA-2
(human monoclonal antibody) and GAD-6 (Richter et al., 199~). Mapping of the
MICA-2 epitope within GAD-65 using an epitope cDNA library revealed that
MICA-2 recognizes an epitope between 506-531 aa of GAD65 (Richter et al.. 1996).
which includes the GAD-6 epitope proposed here. It has been suggested that the
removal of 41 aa at the C-terminus of GAD65 (545-585 aa deletion mutant l may lead
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to conformational changes of GAD-65 which abolishes the binding or MlCA-2. This
could also apply to the epitope of GAD-6.
There is other evidence for immunogenicity of this region of GAD-Cl5 which may
include the GAD-6 epitope (523-528 aa). In NOD mice, injection of GAD-65 peptide
524-543 aa activates diabetogenic T cells (Zekzer et al., 1998). Furthermore, T-cells
in type I OM patients can react with 379-585 aa ofGAD-65 (Rharbaoui et al., 1999).
A three-dimensional model of the C-terminal region of a GAD65 dimer (461-585
amino acid residues) was built by using the C-terminal domain or dialkylglycine
decarboxylase (2DKB) as a template. It predicts an alp fold composed of a four-
stranded P sheet and three amphipathic a-helices [helix R (467-486 aa), helix S (521-
540 aa) and helix T (568-582 aa)] with localization of hydrophobic residues toward
the p-strands and residues involved in epitope recognition on the charged face of
these helices (Schwartz et al., 1999). The proposed motif of GAD-6 (523-528 aa) is
present at the N-terminal end of u-helix S (521-540 aa) in this three-dimensional
model of the C-terminal region of a GAD-65 (Fig. 3.14).
In a-helix S, M523 and L526 are on the hydrophobic side while R525 and K528 are
on the hydrophilic side. The M--L and R--K are facing each other and in similar
positions on successive turns of a-helix S (Fig. 3.14). GAD-6 may recognize M-RL-
K in linear (denatured GAD-65), but might only recognize R--K in native GAD-65
since these residues (R--K) are on the exposed hydrophilic face of the Cl-helix S. It is
possible that the immunization of the BALB/c mouse. to produce OAD-6, with
purified rat brain GAD emulsified in oil (Freund's adjuvant) as a hydrophobic
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solution may have partially denatured GAD and may have exposed its hydrophobic
amino acid residues.
Interestingly, others have mapped the epitope of b78 human monoclonal antibody to
532-540 aa of GAO-65 (Schwartz et al., 1999), which is very close to the proposed
GAO-6 epitope (523-528 aa). In addition, the footprint pattern of CiAD-6 protected
trypsinized fragments of GAO-65 is similar to that given by h7X (Tremble et al.,
1(97). Thus, I investigated the cross-inhibition of binding to UAD-65 between GAD-
6 and b78, as described in section 4.1.2.
There are other regions which could fit with our motifs, but each of these has its
problems. Thus, KARMM at 534-538 aa would be MMRAK in reverse, but then
presumably the 'chirality' of the side chains would be wrong. Also. R536L mutant
bound to GAD-6 in the Schwartz study (legend to figure 3.14). Further, there is
MWRAK at 458-462 aa. but this is outside the region 475-572 to which the Butler
study mapped GAO-6.
One way to determine whether the phage peptides which were selected by
immunopanning with GAO-6 were acting as true mimotopes of GAD-65 epitopes,
would be to immunize mice with the GAD-6 reactive clones. Immunizing with
mimotope peptides presented on filamentous phage has been shown to raise peptide-
specific antibodies which may also bind to the native antigen (Meola et al., 1995).
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Figure 3.14 The Three-dimensional Model of the C-terminal Region of GAD-65
shows that the motifs of GAD-6, 523-528 or 458-461, which are present at the N-
terminal end of a-helix T or at the C-terminal end of a-helix Q (Schwartz et al.,
1999).
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3.3 768 and 76F Mouse Monoclonal Antibodies
3.3.1 Introduction
The prevalence of anti-IA-2 AAs is higher in acute onset type 1 DM than in slowly
progressive type I OM (Yamada et al., 1997). The anti-IA-2 AAs are present in 56%
type I OM patients, 47% APS II patients with type 10M, 4(X, APS II patients
without type 1 OM and 14% SMS patients (Morgenthaler et al.. 1()97). A major
antigenic determinant of IA-2 is localized to 762-887 aa, while a minor antigenic
determinant of IA-2 is localized to 601-762 aa (Kawasaki et al., I99R).
76B (lgG; isotype unknown) and 76F (IgG2b), are two mouse monoclonal antibodies
which recognize epitopes in the extracellular domain of IA-2 (37R-'577 aa) and N-
terminal region of the cytoplasmic domain of IA-2 (605-6R2 aa). respectively.
Hybridoma supernatants containing the MoAbs were kindly supplied by Dr Ezio
Bonifacio, Milan. Interestingly, huAb 103/5 recognizes 603-686 aa of IA-2 (Kolm-
Litty et al., 2000) which is similar to the region recognized by 76F MoAb.
Since the different phage peptide libraries (T7, MI3 pIlI and M13 pVIII) were
working well with purified mouse MoAbs to GAD-65 (N-terminal and C-terminal
MoAbs and GAD-6), I screened the 768 and 76F hybridoma culture supernatants
containing mouse MoAb with some of these phage peptide libraries.
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3.3.2 Materials and Methods
3.3.2.1 Screening of 768 or 76F Mouse Monoclonal Antibody with T7
(GgG) Phage Peptide Library
3.3.2.1.1 Bio-panning of 768 or 76F Mouse Monoclonal Antibody with 1"7 (C9C) Phage
Peptide Library
Hybridoma culture supernatant was exposed to solid-phase anti-mouse IgG to
selectively capture the IgG mouse monoclonal antibodies. The input phage might be
recognized by anti-mouse IgG antibody as well as mouse MoAb. Thus. the input
phage were depleted from anti-mouse IgG Ab-specifc phage (negative selection) by
exposing the input phage to three tubes coated with anti-mouse IgG only. Then, the
depleted phage were exposed to mouse MoAb. which was captured by anti-mouse
IgG Ab (Fig. 3.(5).
Figure 3.15 Schematic Representation of Negative Selection of Specific Phage
Peptides by using Goat anti-mouse IgO Antibodies.
Goat anti-mouse Supernatant of cloned cells ( 768 or 76F l\1oAbs)
~ I Elution or lnfection
I I ~ Specific p • • • •
rJtJ~~
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Goat anti-mouse IgG (Fe specitic) (Sigma) (20~lg/ml) in coating butter. was coated
onto three Nunc immune-tubes. Ten ug/ml of the goat anti-mouse IgG in coating
buffer, was also coated onto another Nunc immuno-tube. Following overnight
incubation at 4°C on a rotator, all the Nunc immuno-tubes were washed 5 times in
0.1 % TBS-T and blocked with 5% BSAITBS for one hour at room temperature on a
rotator. Ten microlitres of the T7 phage library (1 x 1010 pfull O~LI).as input phage, in
11111 of blocking solution, were added to one of the Nunc immune-tubes (first tube),
which had been coated with the goat anti-mouse IgG (20~lg/ml). and incubated at 4°C
for 30 minutes on a rotator. These pre-absorbed T7 phage were transferred from the
tirst Nunc immuno-tube to another Nunc immuno-tube (second tube). which had also
been coated with the goat anti-mouse IgG (20J.lg/mi). and also incubated at 4°C for 30
minutes on a rotator. The pre-absorbed T7 phage were then transferred from the
second Nunc immuno-tube to another Nunc immuno-tubc (third tube), which had
been coated with the goat anti-mouse IgO (20Jlg/ml), and incubated at 4°C for 30
minutes on a rotator. Hybridoma culture supernatant containing 76B or 76F mouse
monoclonal antibody. was added to the fourth Nunc immune-tube. which had been
coated with the goat anti-mouse IgO (lOJ.lg/ml), and incubated 011 a rotator for two
hours at 4°C. Following 5 washes of the fourth Nunc imrnuno-tube. the pre-absorbed
T7 phage were transferred from the third Nunc immuno-tube to the fourth Nunc
immune-tube (test Nunc-imrnuno tube) and incubated at 4°(, for ~() minutes on a
rotator. Following 5 washes of the test Nunc immuno-tube, 1ml of a log-phase BL 21
culture was added and incubated at room temperature for 5 minutes on a rotator. The
following steps including eluate amplification, plating and puri tication were
performed precisely as described in section 2.1.2.
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3.3.2.1.2 Detection of 76B or 76F Mouse Monoclonal Antibody-specific 1'7 (C9C) Phage
Peptide Clones by Immune-blotting Assay
This was performed as described in section 2.1.3. The specificity of the assay
involving binding of the 76B or 76F MoAbs with plaques on the membrane, was
confirmed by investigating the binding of the goat anti-mouse (gei ( IOug/ml in 2.5%
BSA/TBS- T), which had been pre-absorbed with lysate-treated membrane, with
plaques on duplicate membrane, followed by washing and adding mouse monoclonal
anti-goat (gO clone GT-34 alkaline phospatase conjugate (Sigma) (diluted 1:1000 in
2.5% BSA/TBS-T). After washing, the BCIPINBT substrate was added. Also, the
specificity of the assay was further confirmed by investigating the binding of the
sheep anti-mouse IgO alkaline phosphatase conjugate, which had been pre-absorbed
with lysate-treated membrane, with plaques on another duplicate membrane. This was
to exclude the false positive detection of plaques which showed binding with goat
anti-mouse IgO and/or sheep anti-mouse IgO (Fig. 3.16).
Figure 3.16 Schematic Representation of Immuno-blotting Assay to Exclude the
False Positive Binding of Ligands with non-specific Phage Peptides.
Nitro-cellulose membrane
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3.3.2.1.3 PCR and Sequencing of 76B or 76F Mouse Monoclonal Antibody-specific T7
(C9C) Phage Insert
This was performed as described in section 2.1.4.
3.3.2.1.4 Detection of 76B or 76F Mouse Monoclonal Antibody-specific T7 (C9C) Phage
Peptide Clones by Capture ELISA
This was performed as described in section 2.1.5.2. Mouse IgG2a kappa or IgG2b
kappa myeloma proteins (Sigma) were used as negative controls for 76B and 76F.
respectively (I ug/ml in washing buffer).
3.3.2.2 Screening of 768 or 76F Mouse Monoclonal Antibody with M13 pili
(linear 12-mers) Phage Peptide Library
3.3.2.2.1 Bio-panning of 76B or 76F Mouse Monoclonal Antibody with M 13 pili (linear
12-mers) Phage Peptide Library
Goat anti-mouse IgG (Fe specific) (Sigma) (20f,lg/ml) in coating buffer. was coated
onto three Nunc immuno-tubes. Ten ug/ml of the goat anti-mouse IgG in coating
buffer, was also coated onto another Nunc immuno-tube. Following overnight
incubation at 4°C on a rotator, all the Nunc immuno-tubes were washed 5 times in
0.1% TBS-T and blocked with 0.5% BSA containing 0.02% NaN1 in TBS (blocking
solution) for one hour at room temperature on a rotator. Following 6 washes, ten
microlitres of the M 13 (linear 12-mers) phage library (1xl 0 II pfu/I Oul), as input
phage in Iml of blocking solution, were added to one of the Nunc immuno-tubes (first
tube). which had been coated with the goat anti-mouse IgG (20~Lg/ml).and incubated
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at 4°C for 30 minutes on a rotator. These pre-absorbed M 13 phage were transferred
from the first Nunc immune-tube to another Nunc immune-tube (second tube). which
had also been coated with the goat anti-mouse IgG (20~lg/ml). and also incubated at
4°C for 30 minutes on a rotator. The negative and positive selections lor the next
tubes were performed precisely as described in section 3.3.2.1.1. Following 10 washes
of the fourth (test) Nunc immuno-tube, 1rnl of elution buffer was added and incubated
on a rotator for 10 minutes. The non-amplified eluate was removed and neutralized
with ISO~1 of neutralizing buffer (Fig. 3.15). The following steps including eluate
amplification. plating and purification were performed as described in section 2.2.2.
3.3.2.2.2 Detection of 76B or 76F Mouse Monoclonal Antibody-specific M 13 pili (linear
12-mers) Phage Peptide Clones by Immuno-blotting Assay
This was performed precisely as described in section 2.2.3 by using sheep anti-mouse
(whole molecule) alkaline phosphatase conjugate to detect the binding or the 76B and
76F MoAb to the specific clones. The specificity of the assay was confirmed using the
controls described in section 3.3.2.1.2 (Fig. 3.16).
3.3.2.2.3 Purification and Sequencing of768 or 76F Mouse Monoclonal Antibody-specific
M 13 pilI (linear 12-mers) Phage Insert
This was performed as described in section 2.2.4.
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3.3.2.2.4 Detection of 76B or 76F Mouse Monoclonal Antibody-specific M 13 pili (linear
12-mers) Phage Peptide Clones by Capture ELISA
This was performed as described in section 2.2.5. The phage were bound to the plate
via rabbit anti-fa IgG. Mouse IgG2a kappa myeloma protein was used as a negative
control for 76B and IgG2b kappa myeloma protein (Sigma) was used as a negative
control for both 76B and 76F (I ug/ml in 1% BSA/TBS- T). Sheep anti-mouse (whole
molecule) alkaline phosphatase conjugate was used to detect the binding of the 768
and 76F MoAb or their negative control antibodies (mouse IgG2a or IgJi2b kappa) to
the specific clones.
The specificity of the assay involving binding of the 76B or 76F with the phage. was
confirmed by investigating the binding of the goat anti-mouse IgG (2~Lg/ml in 1%
BSA/TBS-T) with the phage, followed by adding mouse anti-goat IgG alkaline
phospatase conjugate (diluted I :1000 in 1% BSA/TBS-T) and the pNPP substrate was
added. This was to exclude the false positive detection of clones which showed
binding with goat anti-mouse IgG (Fig. 3.17). A similar control investigated whether
the sheep anti-mouse conjugate bound to any of the selected phage (Fig. 3.17). Also,
the specificity of the assay was further confirmed by examining the binding of the
76B MoAb with 76F-selected phage, and by binding of the 76F MoAb with 768-
selected phage. This was to exclude the non-specific binding of the 7M3 and 76F with
76F-selected and 76B-selected phage, respectively.
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Figure 3.17 Schematic Representation of Capture ELISA to Exclude the False
Positive Binding of Ligands with non-specific Phage Peptides.
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mouse lIu'Ahs
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3.3.3 Results
3.3.3.1 T7 (e9C) Phage Peptide Library
3.3.3.1.1 Sequences of Phagotopes Isolated by Bio-panning of T7 Phage Peptide Library
(C9C) and lmmuno-blotting Assay with 7613 or 76f Mouse Monoclonal
Antibody
T7 phage library (C9C) was screened by 4 rounds of immunopanning against 768 or
76F mouse monoclonal antibodies (McAb) as described in section 3.3.2.1.1. The
number of plaques obtained in each round during plating increased consecutively,
indicating that the biopanning rounds were successful (Table 3.1 ).
The specific plaques from the fourth round of screening the T7 phage library (C9C)
with 768 or 76F MoAb were selected by immuno-blotting assay as described in
section 3.3.2.1.2. About 6% and 15% of these plaques (clones) showed high affinity,
giving blue spots on the nitrocellulose membranes, to the 76B or 76F MoAb
respectively. No plaques detected by the 768 MoAb showed high affinity to goat
anti-mouse IgG. However, about 2% of 76F plaques showed high affinity to goat
anti-mouse IgG.
Seventeen clones and nine clones, which were specitic to the 76B or 76F MnAb.
respectively, were sequenced successfully. Stop codons were found in all clones
either in the middle of the inserted portions in 15117 or 7/9 clones or at the end of the
inserted portions in 2/17 or 2/9 clones of the 768 or 76F mouse MnAb. respectively.
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All the sequences were aligned with one another and with the relevant portions of IA-
2. Nine out of the 17 clones-specific to the 768 MoAb (1.2.8.9.1 1.12.14.15 and 18)
showed a motif of lysine followed by proline followed by an amino acid followed by
serine. Thus, the main motif of the 768 MoAb is K-P-X-S. corresponding to amino
acid residues 479-482 of IA-2 (K-P-L-S); this precise sequence was given by 2 clones
(8 and 15). Furthermore. one clone (5) showed a motif of lysine followed by proline
which overlaps with the previous motif. In addition, two clones (12 and 7) showed a
motif of glutamine followed by lysine (not clone 7) followed by proline, giving a
motif (Q-K-P) (478-480 aa of IA-2), which overlaps with the previous motif. Thus.
the overall motif of the 768 MoAb from the sequences of these clones obtained from
the screening the T7 (C9C) phage library with 768 MoAb. is Q-K-P-L-S.
corresponding to 478-482 aa of IA-2. The other 6 clones (3. 4. 6. 10. IJ and 16) did
not show any significant motif (Fig. 3.18).
Three out of the 9 clones-specific to the 76F MoAb (3,5 and 7) showed a motif of
phenylalanine (3,7) or tryptophan (5) followed by an amino acid followed by histidine
followed by glutamine (7) or asparagine (3,5). Thus, the main motif of the 76F MoAb
is F/W-X-H-QIN, corresponding to amino acid residues 626-629 of 1/\-2 (F-E- Y-Q),
which showed conservative substitutions. Phenylalanine and tryptophan have
aromatic side chains and are thus similar residues. Tyrosine and histidine have amide
side chains and are thus similar residues. Also. glutamine and asparagine have
aromatic side chains and are thus similar residues. Furthermore. :2 clones (13.22)
showed a motif of tyrosine followed by glutamine which overlaps with the previous
motif. In addition. 3 clones (2. 8 and 12) showed a motif of histidine followed by
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asparagine (H-N). corresponding to 628-629 aa of IA-2 (Y -Q). which showed
conservative substitutions and also overlaps with previous motif. Clone 4 did not
show a significant motif (Fig. 3.19).
3.3.3.1.2 Testing of 768 or 76F Mouse Monoclonal Antibody-specific Phagotopes of T7
Phage Peptide Library (C9C) by ELISA
Sequenced phagotopcs of T7 (C9C) phage library were selected for investigation of
their binding to the 76B or 76F MoAb by ELISA as described in section 3.3.2.1.4.
Six clones specific to 76B and six specific to the 76F MoAb were screened in ELISA
by using MAAP plates. All of these 76B-specific clones showed a significant binding
with the 76B MoAb. compared to both negative controls [mouse IgG2a kappa (Fig ..
3.20a) and WT phage. as indicated by the ratio of OD for binding of 76B to its
specific clones divided by OD for binding of IgG2a to the 76B-spccilic clones (Fig.
3.20b)]. In contrast, all of the 76F-specific clones showed a significant binding with
the 76F MnAb. compared to the negative control antibody (mouse IgG2b kappa)
only (Fig. 3.21a), whereas, only some of the clones (particularly clone 4) showed
binding with the 76F Mo Ab, compared to both negative controls (mouse IgG2b
kappa and WT phage, as indicated by the ratio of OD for binding of 76B to its
specific clones divided by OD for binding oflgG2a to the 76B-specitic clones) (Fig.
3.21b).
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Figure 3.18 Sequences of Peptides Selected from T7 (C9C) Phage Peptide Library by
Binding to 768 Mouse Monoclonal Antibody.
IA-2 (478-483) Q K P L S L
III C
IK I
P IIL V *
11,15 eNS V K P L S *
s c ~ Ip F Q K *
1,2, II C P K T k ~ M S k *
9,14 c ui.u.
12 I I I I Ic G Q fKIPMSR*
7 C Q P P A M K R *
() C T N ~MK K *
J, -', 13, 16 C S P M G K S K *
10 C ~ ~ T M IK R *
Figure 3.19 Sequences of Peptides Selected from T7 (C9C) Phage Peptide Library by
Binding to 76F Mouse Monoclonal Antibody.
IA-2 (626-631 ) F E Y Q D L
13,22 C G H N A Y Q D K *
7 C K P K K Ir E tH
J
C Ir p r r f I*
5 C NWS H N E A *
2, 12 C K DJ ~ IN R *
8 C ~6~ ~~IR*
"
C G F K Q *
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Figure 3.20 a) Direct Binding of 76B Mouse Monoclonal Antibody to T7 (C9C)
Phage Clones Coated ELISA Maleic Anhydride Activated Polystyrene Plates. b)
Ratio of OD for Binding of 76B to its Specific Clones divided by OD for Binding of
IgG2a to the 76B-specific Clones.
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Figure 3.21 a) Direct Binding of 76F Mouse Monoclonal Antibody to T7 (C9C)
Phage Clones Coated ELlSA Maleic Anhydride Activated Polystyrene Plates, b)
Ratio of OD for Binding of 76F to its Specific Clones divided by ()I) for Binding of
IgG2b to the 76F-specitic Clones.
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3.3.3.2 M13 pili (linear 12-mers) Phage Peptide Library
3.3.3.2.1 Sequences of Phagotopes Isolated by Bio-panning of M 13 pili Phage Peptide
Library (linear 12-mers) and Immune-blotting Assay with 76B or 76F Mouse
Monoclonal Antibody.
M13 pIlI phage library (linear l2-mers) was screened by 3 rounds of immunopanning
against 76B or 76F MoAb as described in section 3.3.2.2.1. The number of plaques
obtained in each round increased consecutively, indicating that the hiopanning rounds
were successful (Table 3.1).
The specific plaques from the third round ofM13 pIlI phage library (linear l2-mers)
immuno-panning with 76B or 76F MoAb were selected by immuno-blotting assay as
described in section 3.3.2.2.2. About 30% and 15% of these plaques (clones) showed
high affinity, giving blue spots on the nitrocellulose membranes. to the 76B or 76F
McAb, respectively. About 3% of the 76B plaques showed high affinity to goat anti-
mouse IgG. Also, about 3% of the 76F plaques showed high affinity to goat anti-
mouse IgG.
Eleven and sixteen clones specific to the 76B or 76F MoAb. respectively, were
sequenced successfully. All sequences were aligned with the relevant portions of IA-
2. The 11 clones specific to the 76B MoAb showed a motif of aspartic acid followed
by an amino acid followed by lysine followed by proline followed by leucine
followed by serine. Thus, the main motif of the 76B MoAb is D-X-K-P-L-S,
corresponding to amino acid residues 477-482 of lA-2 (D-Q-K-P-L-S). which was
exactly represented in one clone (11) (Fig. 3.22). Furthermore. this motif overlaps
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with the previous motif, which was obtained by using T7 (C9C) phage library (see
above).
The 16 clones specific to the 76F MoAb showed a motif of phenylalanine 8/16
(3.4.10.11,12,13,16.20). tryptophan 7/16 (5,6,8.9.14.15.19) or tyrosine 1/16 (7)
followed by an amino acid followed by tyrosine 15116 or tryptophan 1116 (7)
followed by glutamine 15/16 or an amino acid 1116 (II). Thus. the main motif of the
76F MoAb is F/W/Y-X-Y/W-Q, corresponding to amino acid residues {126-629 of IA-
2 (F-E- Y-Q) (Fig. 3.23), which showed conservative substitutions. Phenylalanine,
tyrosine and tryptophan have aromatic side chains and arc thus similar residues.
Furthermore. this motif is similar to the motif that was obtained by using T7 (C9C)
phage library (see above).
3.3.3.2.2 Testing of 768 or 76F Mouse Monoclonal Antibody-specific Phagotopes of M 13
pIlI Phage Peptide Library (linear 12-mers) by ELISA
Sequenced phagotopes of Ml3 pIlI (linear 12-mers) phage library were selected for
investigation of their binding to 76B or 76F MoAb by capture ELlSA as described in
section 3.3.2.2.4. All the II or 20 clones, which were specific to 7(lB or 76F Mo Ab,
showed a significant binding with the 76B or 76F McAb. respectively. compared to
all negative controls [mouse IgG2a kappa (negative control for 76B MnAb). mouse
IgG2b kappa and helper MI3 (M13K07) phage] (Fig. 3.24 or 3.25. respectively).
Also, these II or 20 clones, which were specific to 76B or 76F mouse monoclonal
antibody, respectively. showed negligible cross-reactivity with goat anti-mouse IgG.
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In addition, five randomly selected clones specific to 768 MoAb showed negligible
cross-reactivity with 76F MoAb, compared to the negative control (WT phage), in
capture ELISA as described in section 3.3.2.2.4 (Table 3.2). Conversely, five
randomly selected clones specific to 76F MoAb showed negligible cross-reactivity
with 76B MnAb, compared to the negative control (WT phage) (Table 3.2).
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Figure 3.22 Sequences of Peptides Selected from M 13 plll (linear 12-mers) Phage
Peptide Library by Binding to 76B Mouse Monoclonal Antibody.
IA-2 (477-484) TDQKPLSL
DOL K P L S Q A G R S
4 H Q T
I
N I
2
J
"
A L
I D T 0 S K P L S R Y K
YQT~~wk~L~L
HM+~Qk~l!l
TM~SHHHYAA
w R P 0 A K P L S L
9
10
IJ
14 V H
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Figure 3.23 Sequences of Peptides Selected from M 13 pIll (linear 12-mers) Phage
Peptide Library by Binding to 76F Mouse Monoclonal Antibody.
IA-2 (623-631) DTTFEYQDL
3
10
4 S N I I
7
9
II
12,13
14
15
16
19
20
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Figure 3.24 Capture ELISA: Binding of 76B Mouse Monoclonal Antibody to M 13
pilI (linear 12-mers) Phage Clones Bound to ELISA Maxisorp Plates via Rabbit anti-
l·cIIgG.
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Figure 3.25 Capture ELISA: Binding of 76F Mouse Monoclonal Antibody to M 13
plll (linear 12-mers) Phage Clones Bound to ELISA Maxisorp Plates via Rabbit anti-
fd IgG.
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Table 3.2 Capture ELISA: Binding of 76F Mouse Monoclonal Antibody to M13 pIlI
(linear 12-mers) Phage Clones Specific to 76B Mouse Monoclonal Antibody Bound
to ELISA Maxisorp Plates via Rabbit anti-fd JgO, compared to Wild-type Phage
(WT) and Negative Control Antibodies (Mouse Ig02b and IgCi2a kappa). Also.
Binding of76B Mouse Monoclonal Antibody to Ml3 pili (linear 12-mcrs) Phage
Clones Specific to 76F Mouse Monoclonal Antibody Bound to ELISA Maxisorp
Plates via Rabbit anti-to IgO. compared to Wild-type Phage (WT) and Negative
Control Antibody (Mouse IgG2b kappa).
76B- 00176B 00176F 001 001 761"- 001761" O[}176B 001
Specific Binding Binding Ig2bk IgG2ak Specific Binding Binding IgG2bk
Clones Binding Binding Clones Binding
2.952 0.657 0.303 0.296 4 2.589 OT,<) 0.333
J 2.905 0.646 0.335 0.322 9 2.813 o 745 0.277
4 2.918 0.587 0.370 0.313 15 2.559 1.()90 0.580
8 2.930 0.629 0.365 0.316 17 2.560 O.<J71 0.418
9 2.925 0.614 0.359 0.318 18 2.716 O.X<)7 0.327
WT 0.941 0.918 0.871 0.824 WT 0.918 0.941 0.871
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3.3.4 Discussion
Seventeen clones. which were obtained from the fourth round of successful
biopanning rounds of T7 (C9C) phage library and were positively immunostained in
the blotting assay (high affinity) with the 768 MoAb. were successfully sequenced.
Nine out of these 17 clones showed a motif of K-P-X-S (Fig. 3.18). corresponding to
479-482 aa of IA-2 (K-P-L-S), as the epitopic determinant of the 768 MoAb.
Interestingly, 2 out of these 9 clones showed the precise moti f of K-P-L-S. Six of the
clones were screened in ELISA by using maleic anhydride activated polystyrene
plates. All of these 6 clones showed binding with the 768 MoAb. compared to both
negative controls [mouse IgG2a kappa (Fig. 3.20a) and WT phage: by looking at the
ratio of OD for binding of 768 to its specific clones divided by ()[) for binding of
IgG2a to the 768-specific clones (Fig. 3.20b)].
Stop codons are present in T7 (C9C) phage peptide library at the ('-lerminal region of
the insert. It is possible that the full length of the insert is expressed. but the MoAb
only binds when the insert is present at the extreme C-terminus of the surface coat
protein. Another possibility is that the full insert within the surface coat protein is
unstable and not expressed, except at the extreme C-terminus. as mentioned
previously with N-terminal and C-terminal MoAb and GAD-6.
Eleven clones, which were obtained from the third round of successful biopanning
of the M13 pIlI (linear 12-mers) phage library and were positively immunostained in
the blotting assay (high affinity) with the 768 MoAb, were successfully sequenced.
All of these II clones showed a motifofD-X-K-P-L-S (Fig. 3.22). corresponding to
477-482 aa of IA-2 (D-Q-K-P-L-S), as an important epitopic determinant of the 768
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MoAb. Interesingly. lout of these 9 clones (clone II) showed the precise motifofT-
D-Q-K-P-L-S, corresponding to 476-482 aa of IA-2.
All these 11 768-specitic clones obtained from the M13 plIl (linear 12-mcrs) phage
library, which showed negligible cross-reactivity with 76F MoAb. negative control
antibodies (mouse IgG2b and Ig02a kappa) (Table 3.2) and goat anti-mouse IgO
(data not shown), were screened in ELISA. All of these 11 clones showed significant
binding with the 7613 MoAb, compared to all negative control antibodies (mouse
IgG2a and IgG2b kappa) and helper M13 (WT phage) (Fig. 3.24).
The sequences of 768-specific clones obtained from both libraries IT7 (C9C)and
M13 pIlI (linear 12-mers)] showed homologies amongst themselves and with the
originallA-2 sequence. Thus, the main motif of 768 is O-X-K-P-L-S. corresponding
to 477-482 aa of IA-2 (D-Q-K-P-L-S).
Nine clones, which were obtained from the fourth round of successful biopanning of
the T7 phage library and were positively immunostained in the blotting assay (high
affinity) with 76F MoAb, were successfully sequenced. Eight out of these 9 clones
showed a motif of Y/H-QIN (Fig. 3.19), corresponding to 628-629 aa of IA-2 (Y-Q).
as part of the epitopic determinant of the 76F MnAb. Tyrosine and histidine both
have aromatic side chains and are thus similar residues. Also. glutamine and
asparagine both have amide side chains and are thus similar residues. lnteresingly, 1
out of these 8 clones (clone 7) showed a motif of F-E-H-Q. corresponding to 626-629
aa of IA-2 (F-E- Y-Q). which shows a conservative substitution. One clone did not
show a clear motif of IA-2.
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Six clones obtained from the T7 (C9C) phage library. were screened in ELISA by
using maleic anhydride activated polystyrene plates. All of these () clones showed
hinding with 76F MoAb, compared to the negative control antibody (mouse IgG2b
kappa) only (Fig. 3.2la), whereas, only certain of the clones (particularly clone 4)
showed binding with the 76F MoAb, compared to hoth negative controls (mouse
IgG2b kappa and WT phage, as indicated by the ratio ofOl) for binding of 76B to its
specific clones divided by OD for bindin,g of IgG2a to the 76B-speci lie clones) (Fig.
3.21b). This may be due to a high level of non-specific reactivity with the wild-type
phage.
Sixteen clones, which were obtained from the third round of successful biopanning
of the M 13 pIlI (linear 12-mers) phage library and were positively inununostained in
the blotting assay (high affinity) with 76F MoAb. were successfully sequenced.
Fifteen out of these 16 clones showed a motif of F/W/Y-X-Y/W-O (Fig. 3.23),
corresponding to 626-629 aa of IA-2 (F-E- Y-Q). as an important epitopic
determinant of 76F MoAb. Phenylalanine, tryptophan and tyrosine have aromatic
side chains and are thus similar residues. Interestingly. one out of these 15 clones,
clone 9 showed a motif of W-E-Y-Q.
Twenty 76F-specitic clones obtained from M13 pIlI (linear 12-mers) phage library.
which showed negligible cross-reactivity with both 76B MoAb. negative control
antibody (mouse IgG2b kappa) (Table 3.2) and goat anti-mouse IgG (data not
shown), were screened in ELISA. All of these 20 clones showed significant binding
162
Mouse Monoclonal antibodies
with the 76F. compared to all negative control antibody (mouse [g(i2b kappa) and
helper M [3 phage (WT phage) (Fig. 3.25).
The sequences of 76F-specific clones obtained from both libraries 11'7 (C9C) and
M13 pIlI (linear 12-mers)] show homologies amongst themselves and with the
original IA-2 sequence. Thus, the main motif of 76F is F-X-Y-Q. corresponding to
626-629 aa ofIA-2 (F-E- Y-Q).
Since 76F MoAb may recognize 626-629 aa of IA-2 and huAb 103/5 recognizes 603-
686 aa of IA-2 (Kolm-Litty et al., 2000) which is similar to the region recognized by
76F MoAb, both 76F MoAb and huAb 103/5 may recognize the same region on IA-
2. i.e. 626-629 aa. In addition, 621-630 aa oflA-2 (epitope .1M2) is one of the major
epitopes recognized by sera from over 50% of patients with type I [)M (Bearzatto et
al., 2001), which overlaps with the predicted epitope of 76F MoAb 011 11\-2 (626-629
aa). This is also supported by a recent report identifying an epitope within IA-2 623-
631 aa recognized by type I OM patients' sera (Notkins et al., 19(7). which also
overlaps with the predicted epitope of 76F MoAb. HLA-DR4 containing haplotypes
are always found in relatives and type 1 DM patients with IA-2 .1M2 specific
antibodies. Also. HLA-DR3 and DR13 are associated with [1\-2 .1M2 specific
antibody positive relatives. It has been suggested that 13cell receptor binding to the
.1M2 autoantibody epitopes preferentially generates T cell epitopcs which can bind to
HLA class 1I molecules expressed in DR3/4, DR4/4. DR4/13 or DR I14 B cells and
results in T cell help for 1M2 specific B cells (Bearzatto et al., 200 I). Also. this
region of IA-2 (626-629 aa), which may be recognized by 76F MoAh, is present
within the minor antigenic determinant of IA-2 which is localized to 601-762 aa
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(Kawasaki et al., 1(98). Thus, it will be worthwhile to investigate competition
between 76F MoAb and anti-IA-2 sera of type I OM patients.
Since these different phage peptide libraries (T7 and M 13 pili) were working well
with hybridoma culture supernatant mouse monoclonal antibodies (76B and 76F), it
encouraged me to screen these phage peptide libraries with A-cell line culture
supernatant human monoclonal antibodies followed by screening these phage libraries
with human polyc1onal antibodies (patients' sera), as described in chapter 4.
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HUMAN ANTIBODIES
Human Antibody
4 Human Antibodies
4.1 Human Monoclonal Antibodies
4.1.1 b96.11 Human Monoclonal Antibody
4.1.1.1 Introduction
Venous blood was obtained from a nondiabetic APS-II patient, who had been treated
with radioiodine for Graves' disease complicated by ophthalmopathy and pretibial
myxoedema. He was positive for multiple autoantibodies. including thyroid
stimulating hormone (TSH) receptor, thyroid peroxidase, gastric parietal cells and
lt.A, and he was strongly positive for GAD-65 and GAD-67 autoantibodies.
Peripheral blood lymphocytes (mononuclear cells) were isolated and immortalized
with Epstein-Barr virus (EBV). The mononuclear cells were infected by overnight
culture with infectious EBV supernatant from the 8-95 marmoset cell line, and the
IgG-secreting B cells were isolated by magnetic separation on beads coated with
anti-human IgG. These IgG-secreting B cells were plated in complete medium and
screened for antibodies to GAD-65, cloned and expanded (Tremble et al., 1997).
b96.11 is an IgG I human monoclonal antibody (huAb) derived Irorn the above
patient (Tremble et al., 1997). Culture supernatant of the EBV -trunstormed B-cell
line producing the b96.11 human monoclonal antibody, which recognizes amino acid
residues between 308-365 on GAD-65 but not on GAD-67 (Schwartz et al., 1999),
was kindly supplied by Dr J Paul Banga (Department of Medicine, King's College
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School of Medicine. London, UK). It is noteworthy that the bl)() line huAb
recognizes amino acid residues between 514-570 on GAO-65 (Powers et al.. 1999)
and thus is different from the epitope of b96.11 clone huAb described here. The
reason for this is not clear but may relate to the isolation of a cell clone with a
different specificity to the original cell line.
Since M 13 pili (linear 12-mers) was working well with hyhridoma culture
supernatant mouse monoclonal antibodies (76B and 76F: section .Ll). Ihis library was
screened with culture supernatant of the EBV-transformed [3 cell line producing
b96.ll.
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4.1.1.2 Results
4.1.1.2.1 Sequences of Phagotopes Isolated by Bio-panning of M 1J pili Phage Peptide
Library (linear 12-mers) and Immune-blotting Assay with b96.11 Human
Monoclonal Antibody.
Negative selection was performed as described in section 3.3.1.1.1 (Fig. 4.1). Then,
M 13 plll phage library (linear 12-mers) was screened hv 3 rounds of
immunobiopanning against b96.11 huAb as described in section 1.~.1. Goat anti-
human IgG (Fe specific) (Sigma) was used to capture h96.11 hu/vb. The number of
plaques obtained in each round during plating increased consecutively. indicating
that the biopanning rounds were successful (Table 3.1).
Figure 4.1 Schematic Representation of Negative Selection or Specific Phage
Peptides by using Goat anti-human IgG Antibodies.
Goat anti-human Supernatant of cloned cells (b96.11 huAhsl
phage
~ I
Elution or Infection
Specific ph• • •
I .t- L
~
The specific plaques from the third round ofMl3 pill phage library (linear 12-mers)
screening with the b96.11 huAb were selected by immuno-blotting assay as
described in section 2'.2.3. About 12% of these showed high affinity. giving moderate
hlue spots on the nitrocellulose membrane, to b96.11 huAh. Goat anti-human (Fe
specific) alkaline phosphatase conjugate (Sigma) was used to detect h96.ll huAb.
Also, the specificity of the assay was confirmed by investigating the binding of the
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goat anti-human IgG with plaques on duplicate membrane. which \V,IS detected by
mouse monoclonal anti-goat [gG clone OT-34 alkaline phosphatase conjugate
(Sigma) as described in section 3.3.2.2.2. Also. the specificity 01' the assay was
further confirmed by investigating the binding of the goat anti-human IgO alkaline
phophatase conjugate with plaques on another duplicate membrane. This was to
exclude the false positive detection of plaques which showed binding with either
conjugated and/or unconjugated goat anti-human IgCi (Fig. 4.2). About 10% of these
plaques (clones) showed high affinity to goat anti-human IgG. giving pale blue spots
on the nitrocellulose membranes.
Figure 4.2 Schematic Representation of Immune-blotting Assay to Exclude the False
Positive Binding of Ligands with non-specific Phage Pepticles.
Goat anti-lnunau
coujuaatc
Mouse anti-goal "'on,iugah'
Coal auri-luunan
Seven clones specific to b96.ll huAb were sequenced successfully. These clones
showed a motif of isoleucine (317 clones) or valine (117 clones) followed by serine
(317 clones) or threonine (417 clones) followed by alanine (117 clones). glycine (117
clones) or leucine (117 clones) followed by threonine (317 clones) 01' serine (417
clones) followed by alanine (217 clones) or leucine (217 clones). Thus. the main motif
o lthe b96.ll huAb is V/I-S/T-A/G/L-T/S-A/L. This is similar to amino acid residues
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332-336 of GAD-65 (V -S-A- T-A). with conservative substitutions (Fig. 4.3a).
Threonine and serine have aliphatic hydroxyl side chains and thus are similar
residues. Also. alanine. glycine, leucine, valine and isoleucine haw aliphatic side
chains and thus are similar residues. However, these 7 clones can also he aligned to
show another motif of serine (417 clones) followed by threonine (217 clones) or
serine (517 clones) followed by glycine (117 clones). alanine (117 clones). leucine
(317 clones) or isoleucine (217 clones). Thus, the other motif of the h%.11 huAb is S-
T/S-G/A/LII. This is similar to amino acid residues 338-340 of (i/\I)-(l5 (T-T-V),
with conservative substitutions (Fig. 4.3b). Since the other motif of hl)().11 huAb is
very close to the previous motif: the overall motif of b96.11 hu Ab may require amino
acid residues 332-340 of GAD-65.
4.1.1.2.2 Testing of b96.11 Human Monoclonal Antibody-spec: lie Phauotopes of M 13
pili Phage Peptide Library (linear 12-mers) by Capture ELI Si\
Sequenced phagotopes of MI3 pIlI (linear 12-mers) phage library were selected for
investigation of their binding to the b96.11 huAb by capture ELISA as described in
section 2.2.5. Goat anti-human IgO alkaline phosphatase conjugate was used to detect
b96.ll huAb. All the 7 clones. which were screened in ELISA. did not show binding
with the b96.11 hu/vb, compared with the negative controls (b 7X huAb and WT
phage) (data not shown). In particular, high optical density readings of binding of
b96.11 huAb and the negative control antibody (b78 huAb) were given with WT
phage as well as the selected phage clones. Thus. because of this high background
reactivity with WT phage. it was not possible to demonstrate specific binding to the
specific phage.
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Figure 4.3 Sequences of Peptides Selected from M1J pili (linear 12-mers) Phage
Peptide Library by Binding to b96.11 Human Monoclonal Antibody.
a)
CAD-65 (332-336) V SAT A
7 K N Y I S H • SAT P T
6 u.u. PAPTI'P
I I I
I.J K L F S S
S • IF Ii W
J
.t. :; G L Y T S S L RFWPI'
2 T L P N Y L NM ~ G ~
h)
(;AD-65 (338-340) T T V
2 T L H P N Y L NM T G T
I I I I7 K N Y I S H II ,i ITfT
J6 V T L T P L P A P r I' I'1,3 F S S ~ I. Is F S A W
4,5 G !t ~IS ~ IL IR IF W P P
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4.1.1.3 Discussion
Seven clones, which were obtained from the third round of successful hiopanning of
the M 13 pIlI (linear l2-mers) phage library and were moderately immunostained in
the blotting assay with the b96.ll huAb, showed a motif of llV -T/S-/\/( i/L- TIS-AIL
(Fig. 4.3a), which might correspond to 332-336 aa of UAD-6S (V -S-!\- T-A), and
another motif of S-T/S-GI A/LII (Fig. 4.3b), which might correspond to 338-340 aa of
OAD-65 (T -T -V) as important epitopic determinants of the b96.1 I hu/vb. Thus, the
overall motif of b96.11 might correspond to 332-340 aa of GAD-6S. which is within
the region of GA065 (308-365 aa) to which binding of b96.11 hu.vb is abolished
when replaced by the UAO-67 sequence (Schwartz et al., 1999).
All these seven b96. I l-specific clones obtained from the M 13 pill (I iIleal' 12-mers)
phage library were screened in ELISA but b96.II huAb gave high optical density
readings with both selected phage and the negative control (WT phage). In addition,
negative control antibody (b78 huAb) also bound to the phage selected with b96.11
and bound to the WT phage in this assay. The reason for this non-speci lie reactivity is
unclear.
The three-dimensional model of the middle region of a GAD6S dimer (211-460
amino acid residues) was built by using ornithine decarboxylase (I ORO) as a
template. The PLP-binding middle region consists of a seven-stranded [3 sheet
surrounded by seven a-helices (Schwartz et al., 1999). In Schwartz' s model, amino
acid residues 332-340 aa. are present within a P strand between Cl-helix L (313-324
aa) and a-helix M (348-356 aa) (Fig. 4.4), which is also present in the same region of
Myers's model (Myers et al., 2000).
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Figure 4.4 The Three-dimensional Model of the Middle Region of GAD-65 shows
that the motif of b96.11 Human Monoclonal Antibody, 332-340, which is present
within a ~ strand between a-helix L and a-helix M (Schwartz et al., 1999).
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4.1.2 b78 Human Monoclonal Antibody
4.1.2.1 Introduction
The b7R huAb was derived from the same patient as b96.11 huAb (see above section
4.1.1.1) (Tremble et al., 1997). Supernatant of the cultured ElsV-transfonued B-cell
line producing b78 huAb, which has been reported to recognize amino acid residues
between 532-540 on GAD-65 but not on GAD-67 (Schwartz et al., I <)<)9). was kindly
supplied by Dr J Paul Banga (Department of Medicine, King' s College School of
Medicine. London, UK).
The epitope of b78 huAb (532-540 aa) may be very close to the proposed GAD-6
epitope (523-528 aa: see section 3.2). In addition. the footprint pattern of protected
trypsinized GAD-65 fragments with GAD-6 is similar to that with h7X (Tremble et
al.. 1997). Thus, cross-inhibition of binding to GAD-65 between GAD-() and b78 was
examined in terms of b78 huAb inhibition of GAD-6 binding to GAD-65 as well as
the converse ofGAD-6 inhibition ofb78 huAb binding to GAD-()).
In circular dichroism studies, the structure of GAD seems to change significantly
according to whether it has bound to pyridoxal phosphate or not (Chen. et al., 1998).
Furthermore. the rat brain preparation probably contains GAD in various forms, i.e.
monomeric. dimeric and also multimers (Trigwell et al., in preparation). The different
monoclonal antibodies (b78 or b96.11 huAb and GAD-6) may react preferentially
with different GAD fractions of the preparation. If so. cross-inhibitions may not work
very well. Thus. the results of the cross-inhibition studies were confirmed by exposing
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b78 or b96.11 huAb to rat brain GAD which was captured by (;;\1)-6 in the solid
phase.
It is noteworthy that I did attempt to screen the b78 hu.Ab with M IJ pili (linear 12-
mers) phage library following similar procedure as with b96.11 bUI 110 b78 hu/cb-
specific clones were selected, since the number of phage plaques increased from
round to another. The possible reason is no b78 hllAb-specific peptides in this library
as happened with GAD-6 screened with Ml3 pili phage library. While the increasing
number of the plaques is possibly due to specificity of these plaques In anti-human
19G antibody, Fe portion ofb78 huAb or BSA (blocking reagent).
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4.1.2.2 Materials and Methods
-1.1.2.2.1 Direct Binding of b78 and b96.11 Human Monoclonal Autihodies and GAD-
6 to Rat Brain GAD by Direct and Capture ELISA
,/.1.2.2.1.1 Direct ELISA (Rat Brain GAD Coating)
Semi-purified rat brain GAD was prepared as previously described (I )avcnport et al.,
19(8). The GAD preparation was diluted to 40~lg total protein per ml in O.05M
sodium carbonate/sodium bicarbonate buffer pH 9.6 (coating butler). and coated onto
wells (50~LI/well) of maxisorp ELISA plates. Plates were incubated at 4°(, overnight.
Wells were washed 3 times (200lll/well) in phosphate buffer saline (PBS) containing
O.I(Yo Tween-20 (PBS-T) (each time the plates were incubated ~ minutes at room
temperature), and then blocked with 2% BSA in PBS (2% I3SA/PBS) (200~d/well) for
one hour at room temperature. Blank wells, which were not coated with GAD65, were
also blocked with 2% BSA/PBS, as above. Then. GAD-6 (20. 10. 5. 2.5 or 1.25
ug/ml) or a supernatant of cultured EBV-transformed B-cell line producing human
monoclonal antibody b78 or b96.11 (diluted I :2. 1:4. 1:8. I: 16 or I :.\ 2). in 1% BSA in
PBS- T (I % BSA/PBS- T) was added to the wells. Each d ilut ion was applied
(50~lllwell) to antigen-coated and blank wells for 2 hours at 1"00m temperature on a
shaker. Following 3 washes in PBS-T, sheep anti-mouse Ig(j (whole molecule)
alkaline phosphatase conjugate or goat anti-human IgG (Fe specific) alkaline
phosphatase conjugate (diluted I: 1000 in 1% BSA/PBS- T) was added to all wells
(50~d/well) and incubated for one hour at room temperature on a shaker. Wells were
washed ~ times in PBS-T and pNPP substrate in diethanolarninc butler was added to
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temperature on a shaker. Wells were washed 3 times in PBS-To and pNpp substrate in
diethanolamine buffer was added to all wells (I OO~d/well) and incubated at room
temperature. Plates were read at 30 and 60 minutes at 405 nm Oil a microtitre plate
reader (Molecular Devices). The mean OD of the test wells was corrected by
subtracting the mean OD of the equivalent blank wells.
4.1.2.2.2 Competition between GAD-6 and b78 or b96.11 Human Monoclonal
Antibody for Binding to GAD in ELISA
Inhibition of GAD-6 Binding by h 78 or "%.11 Hutnau Monoclonal
Antibody
N-terminal MoAb (diluted 1:200) in coating butler, was coated onto wells
-1.1.2.2.2.1
(I OO~L1/well)of maxisorp ELISA plates. Plates were incubated at 4°(, overnight.
Wells were washed 3 times in PBS-T and then blocked with 2% BSA/PBS
(200~lllwell) for one hour at room temperature. Blank wells. which were also coated
with N-terminal MoAb. were also blocked with 2% BSA/PBS, as above. Then. semi-
purified rat brain GAD (40~g/ml) in 1% BSA/PBS- T was added to all wells and
incubated for 2 hours at room temperature on a shaker. Following 3 washes in PBS- T,
the supernatant of cultured EBV -transformed B-cell Iine producing human
monoclonal antibody b78 or b96.11 (diluted 1:2). in 1% BSA/PBS-T. was applied
(I OO~L1/well)to all wells for 2 hours at room temperature on a shaker. Then. without
washing the wells. GAD-6 (0.25 ug/ml) mixed with the supernatant of cultured EBV-
transformed B-cellline producing human monoclonal antibody b7R or b96.l1 (diluted
I :2). in 1% BSA/PBS- T. was applied (lOO~lIwell) in duplicate to test (not blank)
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wells for 2 hours at room temperature on a shaker. One percent or BSA/PBS-T was
applied (l Ouul/well) in duplicate to the blank wells (i.e. without (iAD-6) for 2 hours
at room temperature on a shaker. Following 3 washes in PBS-T, rat anti-mouse IgG2a
monoclonal antibody alkaline phosphatase conjugate (diluted I:1000 in 1%
BSA/PBS- T) was added to all wells (I OOfll/well) and incubated for 0111: hour at room
temperature on a shaker. Wells were washed 3 times in PBS-T, and pNPP substrate in
diethanolamine buffer was added to all wells (lOOllllwell) and incubated at room
temperature. Plates were read at 30 minutes at 405 nm on a microtitrc plate reader
(Molecular Devices). The mean OD of the test wells was corrected by subtracting the
mean OD of the equivalent blank wells. The results were compared with the ODs
given for binding of GAD-6 in the absence or b78 or b96.11 .
.J 1.2.2.2.2 lnhihition of h78 or b96. J J Human Monoclonal Antibocli Binding by
GAD-(j
N-terminal MoAb (diluted I :200) in coating buffer, was coated onto wells
( 1Otlul/well) of maxisorp ELISA plates. Plates were incubated at 4°(, overnight.
Wells were washed 3 times in PBS-T and then blocked with 2'Yo BSA/PBS
(200~d/well) for one hour at room temperature. Blank wells, which were also coated
with N-terminal MnAb. were also blocked with 2% BSA/PBS. as above. Then, semi-
purified rat brain GAD (40~tg/ml) in 1% BSA/PBS-T was added 10 all wells and
incubated for 2 hours at room temperature on a shaker. Following J washes in PBS- T,
GAD-6 (0.5 ug/rnl). in 1% BSA/PBS-T, was applied (IOO~tl/well) to all wells for 2
hours at room temperature on a shaker. Then, without washing the wells. GAD-6 (0.5
ug/rnl) mixed with the supernatant of cultured EBV -transformcd B-ccll line
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producing human monoclonal antibody b78 or b96.11 (diluted 1:2). in I(Yo BSA/PBS-
T. was applied (IOOpl/well) in duplicate to test (not blank) wells lor 2 hours at room
temperature on a shaker. One percent of BSA/PBS- T was applied (I OO~L1/well) in
duplicate to the blank wells (i.e. without b78 or b96.11) for 2 hours at room
temperature on a shaker. Following 3 washes in PBS- T. goat anti-human IgO (Fe
specific) alkaline phosphatase conjugate (diluted 1:1000 in I(Yr) BS/\/PBS-T) was
added to all wells ( 1OO~L1/well)and incubated for one hour at room temperature on a
shaker. Wells were washed 3 times in PBS-T, and pNPP substrate in dicthanolarnine
buffer was added to all wells (lOOJll/well) and incubated at room temperature. Plates
were read at 30 minutes at 405 nm on a microtitre plate reader (Molecular Devices).
The mean OD of the test wells was corrected by subtracting the mean OD of the
equivalent blank wells. The results were compared with the ODs given tor binding of
h7S or b96.11 in the absence ofOAD-6.
4.1.2.2.3 Direct Binding of b78 and b96.11 Human Monoclonal Antibodies to Rat
Brain GAD Captured by GAD-6 in ELISA
CiAD-6 (I ug/rnl) or N-terminal MoAb as a control (diluted J::WO) in coating buffer.
was coated onto wells ( IOO~lllwell) of maxisorp ELISA plates. Plates were incubated
at 4°(, overnight. Wells were washed 3 times in PBS-T and then blocked with 2%
BSA/PBS (200~d/well) for one hour at room temperature. Blank wells. which were
also coated with GAD-6 or N-terminal MoAb, were also blocked with 2% BSA/PBS.
Then. semi-purified rat brain GAD (40~g/ml) in 1% BSA/PBS-T \\<lS added to all
wells and incubated for 2 hours at room temperature on a shaker. Following 3 washes
in PBS-T, a supernatant of cultured EBV-transformed B-ccl! line producing human
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4.1.2.3 Results
-l.1.2.3.1 Direct Binding of GAD-6 Mouse Monoclonal Antibody or h7R or b96.11
Human Monoclonal Antibody to Native or Denatured Rat Brain ( i/\ D
Supernatants of cultured EBV -transforrned B-cell lines producing human monoclonal
antibodies, b78 and b96.11, did not bind to semi-purified rat brain GAD after
applying these human monoclonal antibodies (huAb) to the GAD-coatl:d wells even
in low dilution (I :2) (Table 4.1 ). Also, there was no significant di ffercnccs within the
serial dilutions of b78 or b96.11 huAb. In contrast, GAD-6 bound to the (iAD-coated
wells even in low concentration (1.25 ug/ml) with significant di ffercnces within the
serial dilutions of GAD-6 (Table 4.1). This is probably because direct binding of
GAD to the plastic wells partially denatures the GAD such that the cpitopes of b78
and b96.11 (but not GAD-6) are disrupted.
On the other hand, b78 and b96.11 huAb, bound to semi-purified rat brain CiAO after
applying these human monoclonal antibodies (huAb) to the GAD-Cl5 that was
captured by N-terminal MoAb-coated wells, even in high dilution ( I :()4). Also there
was significant differences within the serial dilutions of b78 (not h96.II) huAb.
Whereas, GAD-6 bound also to the native GAD even in very low concentration
(0.625 ug/ml) (Table 4.1), also with significant differences within the serial dilutions
of GAD-6. This indicates that b78 or b96.11 huAb recognize conform.uional epitopes
at the C-terminus on native GAD since capturing the GAD with Nvterminal MoAb
should maintain its conformation, but not on denatured GAD. GAD-Cl recognizes an
epitope at the C-terminus on native GAD more etliciently than on denatured GAD.
Another difference between the two ELISAs is that the capture system will purify the
GAD in the rat brain preparation by binding to the N-terminal MnAb. whereas the
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(,AD will have to compete for binding to the wells with other brain proteins in the
direct-coating system.
.-L 1.2.3.2 Competition between GAD-6 Mouse Monoclonal Antibody and b78 or
b96.11 Human Monoclonal Antibody Directed to the Cvtenuinus of Native Rat
Brain GAD
(iAD-6 did not greatly inhibit b78 and b96.11 huAb binding to native semi-purified
rat brain GAD, which was captured by N-terminal MoAb: inhibition was only 14%
and 13%, respectively, in a competition ELISA (Table 4.2). Conversely, b78 and
h96.ll huAb did not greatly inhibit GAD-6 binding to native (JAD-65 by 18% and
~2%, respectively, in a competition ELISA (Table 4.2). This indicates that b78 and
h96. I I may not recognize epitopes which are very close to that of (iA f)-(l.
The different monoclonal antibodies (b78 or b96.l1 huAb and (,AI)-6) may react
preferentially with different GAD fractions of the preparation (monomeric, dimeric
and also multimers). This could be an alternative explanation as to why the cross-
inhibitions did not work very well. Therefore, the results of the cross-inhibition
experiments were confirmed by exposing b78 or b96.11 huAb to rat brain CiAO which
was captured by GAD-6, to avoid false negative results. SMS serum bound equally to
(,AD captured either by GAD-6 or captured by N-terminal MoAb (Table 4.3). b78
huAb bound slightly better with GAD-6 as the capture McAb. but b96.1 I bound
much better with GAD-6 as the capture MoAb (Table 4.3). This suggests that the
UAD-6 and b78 or b96.11 epitopes are not directly overlapping.
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Table 4.1 Optical Densities for Direct Binding of b78 or b96.11 Human Monoclonal
Antibodies or GAD-6 to coated Rat Brain GAD and GAD Which Captured by N-
terminal Monoclonal Antibody in ELISA.
Concentr- GAD-6 GAD-6 Dilution b78 h78 h%.1 I h96.11
aion Direct Binding to Direct Binding to Direl'I Binding to
(pg/ml) Binding to Captured Binding to Captured Binding 10 Captured
GAD (;AD GAD GAl> (;.\ J) GAD
20 0.266 05:12 1:2 0.023 O ..IIK (I 111.\ 022K
10 O.IM 0.514 1:4 0.015 0.2X4 II (lllh 0.232
S 0.124 0.41) I 1:8 0.009 0.2.'(' (I (I(I~ 0.260
2.5 0.0')5 0.4(,3 1:16 0.006 OIIU 11.001 0.226
1.25 0.076 0.435 1:32 0.005 0.151 II II(lX o IXI)
0.(,25 0.412 1:64 O. I II) IUOX
Another
Plate
0.5 O.SOO 1:2 0.4.'4 (271)
0.25 0.413
0.125 0 ..143
00625 0.244
0.03125 0.141
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Table 4.2 Optical Densities for Direct Binding and Competition between GAD-6 and
Human Monoclonal Antibodies (b78 or b96.11) Directed to the (,-terminus of Native
GAD captured by N-terminal Monoclonal Antibody in ELISA.
Table 4.3 Optical Densities for Direct Binding of b78 or b96.11 Human Monoclonal
Antibodies or SMS Serum (DH) to Native GAD captured by either N-terminal
Monoclonal Antibody or GAD-6 in ELISA.
Polyclonal Antibody Direct Binding to Native Direct Binding to Native (;.\ U-t./i\-h·rminal MoAb
GA D Captured by GAD Captured by (';Ipllln' 1(;ltiofor Binding
N-terminal MoAb GAD-6 MoAb
It 15 min incubation
SMS Scrum (DH) O.l)) I 1.024 1.111
h7S (I :2) O.66S 0.826 I.~·I
11%.11 (1:1) o I 17 0.!96 ~.:'i.l
I, 30 min Incubation
SMS Serum (DII) 2.521 2.710 1.117
h7S (I :2) I.M,) 2.201 1.32
"96.11 (I: I) ()..10l) 0.849 2.7'
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4. 1.2.4 Discussion
GAD-6 recognizes the C-terminus of both native and denatured GAD-65. indicating
that the GAD-6 epitope may have both conformational and linear properties. b78 and
b96.11 huAb recognize the C-terminus of native (not denatured) (rAD-65, indicating
that these huAbs recognize conformational (not linear) epitopes on (jAD-65.
GAD-6 inhibited the binding of b78 and b96.l1 hu/vb to native GAD-65 by only 14%
and 13%, respectively. Conversely, b78 and b96.ll hliAb inhibited the binding GAD-
6 to native GAD-65 by 18% and 32%, respectively. in a competition ELISA (Table
4.2). This indicates that b78 and b96.11 may recognize an epitope, at the C-terminus
of native GAD-65, which is not very close to the GAD-6 epitope since the inhibition
is not high.
According to Schwartz et al., 1999, the huAb b78 recognizes amino acid residues
between 532-540 on GAD-65 which is very close to the GAD-6 epitope (523-528 aa)
proposed in this thesis. In addition, the footprint pattern of protected trypsinized
fragments of GAD-6 is similar to that of the b78 (Tremble et al.. 19(7). It is possible
that the three amino acids between the epitopes of GAD-6 and b78 may give different
orientations to the epitopes which do not give strong steric hindrance (only 14-18% of
binding inhibition).
The b78 huAb bound slightly better with GAD-6 as the capture MuAb. but b96.11
bound much better with GAD-6 as the capture MoAb (Table 4.3). This might suggest
that the GAD-6 does interfere with b78 huAb binding to GAD-65 more than it does
with b96.11 huAb binding. Alternatively, it could suggest that the N-terminal MoAb
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inhibits b96.11 huAb binding to some extent. However. it must also suggest that the
CiAD-6 and b78 huAb epitopes are not directly overlapping. or the ratio of OD for
binding to GAD-6 captured GAD divided by OD for binding to N-terminal MoAb
captured GAD should be well below 1.00.
The epitope of b78 huAb is present at the extreme C-terminus of «-hclix S in the
three dimensional model of the C-terminus of GAD-65 (Schwartz et al., 1999). It is
noteworthy that the mutation V532K disrupts the binding of b78 to (ii\D-65, while
other mutations in the same region of b78 epitope, R536L and Y540S. do not disrupt
the binding of b78 to GAD-65. This indicates that V532 is a critical amino acid
residue for the b78 epitope and there are neighbouring amino acid residues which are
not essential for b78 binding to GAD-65. Also, it has been suggested that V532 may
only be involved in a surface patch of the b78 epitope. which is lormed by other
amino acid residue(s) from different region(s).
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4.1 Human po/ye/ona/ antibodies
4.2.1 SMS Patients' Sera
4.2.1. 1 Introduction
GAAs are present in 89% of SMS sera. GAAs of SMS and APS sera. which are
present at high titre. are less dependent on the conformation ofthe (jAI) than in type
I OM and commonly target GAD-67 as well as GAO-65 (Tremble cl al., 1997).
Preincubation of GAAs of SMS sera with 188-442 aa/GAD65 can block the hinding
of GAAs67 with GA067. whereas preincubation with GAD67 cannot block the
binding of GAAs65 with GA065 (Oaw et al., 1996). This indicates that the GAAs in
SMS sera recognize a specific epitope in GAD67. which is highly homologous to
188-442 aa/GA065. whereas other GAAs65 recognize epitopes which arc not
present in GAO-67. Furthermore, preincubation of SMS sera with 354-368
aa/GAD65 inhibits the binding ofSMS sera with GA065. In the 354-."j()5 aa/GAD65.
there are four amino acid residues K-KI-M which differ from E-NL-1. (ll" (JA067 (Li
et al., 1994). This suggests that these four amino acid residues (K-KI-M) may
contribute to the binding of SMS sera with GAD65. In SMS sera. (jAi\s recognize
some epitopes on GA065 not recognized by GAAs in 100M sera. c.g. an N-terminal
epitope within 1-16 aa and/or 1-95 aa (SMS E2) (Hagopian d al.. 1995: Bjork ct al.,
1994) as a major antigenic determinant, a middle region epitope 390-40."j aa (Daw et
al., 1996; Li et al., 1994). and a C-terminal epitope 475-585 aa (SMS 1:1) as a minor
antigenic determinant. The binding of GAAs of some SMS sera with SMS E2 is
much higher than with SMS El.
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An immunodominant epitope of T cell -reactivity with GAD-65 in non-diabetic SMS
patients is 341-351 aa residues. Also. in non-diabetic SMS patients. T cells can react
with N-terminal regions (61-90 and 191-220 aa) and C-terminal regions (491-520 aa)
of GAD-65 (Schloot et al., 1999).
The sequences obtained by screening M13 pIlI (linear 12-mers) phage peptide library
with supernatant of cultured EBV-transformed B-cell line producing h96.11 huAb,
suggested that this was a good library to screen with SMS patients' sera containing
human polyclonal antibodies to GAD. The protocol adopted for screening the library
with SMS patients' sera is shown schematically in Fig. 4.5.
Since SMS patients' sera contain polyclonal antibodies. these sera have
autoantibodies which recognize GAD but also many other antibodies which are also
present in normal human sera (NHS). Some of the input phage might be specifically
recognized by the GAD-65-specific autoantibodies binding to their peptide sequences.
but others might be bound via their inserted peptide sequences to polyclonal
antibodies which are also present in NHS. Thus. first of all. NHS pooled from
different donors was incubated overnight with M13K07 killed phage (wild-type
phage) to block any phage-reactive antibodies. Then. the phage-blocked NHS was
exposed to the input phage library through three rounds of biopanning to deplete
phage bearing peptides reactive with normal polclonal antibodies. The depleted phage
were then exposed to SMS patients' sera, which had also been pre-incubated with
killed wild-type phage to block the binding of phage-reactive antibodies. which could
be present in patients' sera as well as NHS.
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The patients' sera or NHS were captured on the immunotubes by goal anti-human IgU
polyclonal antibody, which may itself recognize some phage peptides non-
specifically. However, since the input phage were depleted with NilS antibodies, as
described above, which were themselves captured by goat anti-human IgO, this may
also have depleted input phage reactive with the goat anti-human IgU (Fig. 4.5).
Several SMS patients' sera were used in consecutive biopannings of the phage library
to try to select publicepitopes. OH, PM, LB. .10 and PT sera wen: obtained from
CrAAs+ SMS patients. LB was the only diabetic SMS patient.
Rat brain GAD was used during biopanning to elute the bound phage (rather than acid
elution) to try to increase the specificity of the selection. Also. the (iAD elution was
performed to select for peptides mimicking conformational epitopes.
IRc)
Human Antibody
Figure 4.5 Schematic Diagram Showing the Protocol for Immuno-panning of SMS
patients' Sera with M 13 pIlI (linear 12-mers) Phage Peptide Library. preceded by the
Negative Selection of these Sera.
I Input phage library
Absorbed
:; limes
PoolofNHS Blocked with killed
wild-type phage
_j Blocked ...captured by goat l"l NHSanti-human IgG Ab J
Phage not reactive
with NHS-Abs or
goal anti-human
Ig( i Ah
SMS sera uo: Blocked with killed
wild-type phage Blocked SMS """'-captured by goat ...
...
sera (10)anti-human IgG Ab
l'hage eluted
with GAD
Blocked with killedSMS sera (PT)
wild-type phage Blocked SMS ....
captured by goat .. ...
... sera (PT)
anti-human IgG Ab
l'hage eluted
with GAD
SMS sera (OH) Blocked with killed Blocked SMS ~
wild-type phage
captured by goat
~
sera (OH)
anti-human IgG Ab
Phage eluted
with GAD
SMS sera (LB) Blocked with killed
wild-type phage Blocked SMScaptured by goat ~
anti-human IgG Ab
...
sera (LB)
Phage eluted
with GAD
SMS sera (PM) Blocked with killed
wild-type phage Blocked SMS ...
captured by goat sera (PM) ~
anti-human IgG Ab
..
~
Phage eluted with GAD
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4.2.1.2 Materials and Methods
4.2.1.2.1 Screening of SMS Patients' Sera with MI3 pili (linear 12-mers) Phage
Peptide Library
,/,2.1.2.1.1 Preparation of Killed Wild-type Phage
One hundred microlitres of M13K07 wild-type phage were added to 300mls of an
early-log phase E.coli ER 2537 culture (OD600=0.05) and incubated on a shaker at
37°C lor 4.5 hours for amplification of the M13K07 wild-type phage. The amplified
phage were precipitated and purified as described in section 2.2.I.X. The purified
MI3K07 phage were spotted onto a Petri-dish as drops (25~tI each drop) and then
exposed 3 times to lJV=120,OOO JlJ(micro Jolel/crn (Prezzi et al., I()%). to kill the
phage which were then tested by plating them as described them in section 2.2.1. 7.
·./.2.1.2.1.2 Preparation of Semi-purified Rat Brain UAD
Rat brain homogenate was prepared as described previously (Davenport et al., 1998)
and enriched for GAD by using fast protein liquid chromatography (FPLC) system
(by Miss S Hyde of the Institute of Infections and Immunity. Queen s Medical
Centre. Nottingham). A Q Sepharose Fast Flow column was connected to a FPLC
system and washed with 20mM Tris HCI pH:7.5 at 4°C. Then. -lrnls of rat brain
GAD was applied to the column. A salt gradient was set up by eluting in 20mM Tris
HCI pH:7.S. 1M Nael to give 61 2mls fractions. The last 26 fractions. which show
high concentration of proteins. were tested for GAD by direct ELISA (direct binding
or GAD-6 to these 26 fractions, which were coated onto wells or a maxisorp ELISA
(9(
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plate). The fractions. which showed the highest concentration of (iAn. were pooled
and used to elute the SMS patients' antibodies specific for M 1:-'pili phage peptides.
-1.2.12.1.3 Bio-panning (?fSMS Patients' Sera with !vi13 pi J/ (linear 12-lIIer.\) Phag«
Peptide Library
Goat anti-human IgG (Fe specific) (Sigma) (0.5~lg/ml) in coating buffer. was coated
onto four Nunc immuno-tubes. Following overnight incubation at 4°(, Oil a rotator. all
the Nunc immuno-tubes were washed 5 times in 0.1 (Yo TBS-T and blocked with 0.5%
BSA and 0.02% NaN3 in TBS (blocking solution) for one hour at room temperature
on a rotator. Following 6 washes, 25~1 of three different pools of NHS (nine different
NHS in each pool) (diluted I: 100 in 0.1% BSArrBS) were added to three of these
Nunc immuno-tubes (called first. second, or third tube), i.e one pool in each tube, and
incubated at 4°C overnight on a rotator. Twenty live microlitrcs of a SMS patient's
serum (diluted I: I00 in 0.1% BSA/TBS) were added to the fourth Nunc immuno-tube
(test tube) and incubated overnight at 4°C on a rotator.
After 6 washes of the four Nunc immuno-tubes. l ul of UV light killed phage
M 13K07 «(1 x 1012 pfu/I ~I) (prepared as described above in section 4.2.1.2.1.1)
diluted in 0.1% TBS-TIO.Ol% BSA was added to each of them and incubated at 4°C
for 4 hours on a rotator. Ten microlitres of the MI3 pIli (linear 12-mers) phage
library (lxIO" pfu/IOul), as an input phage, were added to the first tube. coated with
a pool of NHS. and incubated at 4°C overnight on a rotator. The pre-absorbed M 13
plll phage were transferred from the first Nunc irnmuno-tube to another Nunc
immuno-tube (second tube), which was coated with a different pool of NIlS and also
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incubated at 4°(, overnight on a rotator. The pre-absorbed M I:; pili phage were
transferred from the second Nunc immuno-tube to another Nunc immuno-tube (third
tube). which also was coated with a different pool of NHS. and incubated at 4°(,
overnight on a rotator. The pre-absorbed M13 pili phage were transferred from the
third Nunc irnmuno-tube to the test Nunc immuno-tube (test tube). which had SMS
patient's serum coated on it. and incubated at 4°C overnight on u rotator (Fig. 4.5).
Following 10 washes of the test tube, l ml of rat brain GAD (prepared as described
previously in section 4.2.1.2.1.2) was added and incubated on a rotator at room
temperature for one hour. The non-amplified eluate was collected. One microlitre of
the non-amplified eluate was taken for dilution and plating (as described in sections
2.2.1.6 and 2.2.1.7. respectively). The rest of the eluate was subjected to the next
(second) round of affinity selection with a different patient's serum following the
same procedure. without amplification. Following a third round of affinity selection.
the eluate was amplified by adding it to 20mls of early-log phase l..coli ER 2537
culture (OD6(}()=0.05) and incubated on a shaker at 37°(, for 4.5 hours for
amplification. The amplified eluate of the third round was concentrated and purified
(as described in section 2.2. I .8), and was subjected to the next round (fourth round)
of affinity selection with a different patient's serum following the same procedure
without amplification. Five rounds were carried out; each round employed a different
SMS serum.
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.J. 2. 1.2. I. -I Detection of" SMS Patients' Sera-specific N/ /3 filii (Linear 12-l11er.\")
Phage Peptide Clones by Immuno-blotting A.\".\"ay
This was performed as described in section 2.2.3 to detect the specific phage peptide
clones of the third. fourth and fifth rounds of the biopanning. Fitty rnicrolitres of
patient's serum diluted I: 100 in 5% BSA ITBS- T. which were pre-incubated with
IOO~L1of sonicated E.coli ER 2537 lysate (see section 2.2. 1.10) and I()~t1 of M I3K07
(I x IOU pfu/ul) at room temperature for two hours on a rotator. were added to the
membrane and detected by applying goat anti-human IgG (Fe specific) alkaline
phosphatase conjugate.
Also, the specificity of the assay was confirmed by using goat anti-human IgG and
NHS, which was detected by anti-goat IgG clone GT-34 alkaline phosphatase
conjugate and goat anti-human IgG (Fe specific), respectively, precisely as described
in section 3.3.2.2.2. This was to exclude the false positive binding of the SMS
patient's serum with plaques which showed binding with either NlIS, conjugated
goat anti-human IgG and/or unconjugated goat anti-human IgG (Fig. 4.2).
-1.2.1.2.1.5 Purification and Sequencing of ,r;,'N/51 patients Sera-specific MI3 pili
(linear 12-lIIer,< ;)Phage Insert
This was performed as described in section 2.2.4.
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Detection of" SMS Patients' Sera-specific M13 pl ll (linear l Z-mers)
Phage Peptide Clones hy Direct ELISA
The clones of selected phage. and unselected phage clones. were ampl ilied by adding
-1.2.1.2.1.6
them to Smls of the early-log phase E.coli ER 2537 culture (01)(,00=0.05) and
incubated on a shaker at 37°C for 4.5 hours. The amplified phage wen: concentrated
and purified as described in section 2.2.1.8.
The purified phage clones or helper M13, in coating buffer (50~Llphage with SO~d
coating buffer), were coated onto wells (1OOf.lllwell)of maxisorp UJS;\ plates (Life
Technologies, UK). Plates were incubated at 4°C overnight. Wells were washed 3
times (200l-lllwell) in 0.1% TBS- T. each time the plates were incubated ~ minutes at
room temperature. The wells were then blocked with 1% BSA/TBS ( 120~t1/well) for
one hour at room temperature. Blank wells, which were not coated with phage. were
also blocked with 1% BSA/TBS. as above. The SMS patients' sera or normal sera
diluted 1: 100 in 1% BSA/TBS and pre-incubated with I~L1of sonicated E.coli ER
2537 lysate, see above. and lul ofMI3K07 phage (IxlOIJ ptu/p.l) were applied
( IOO~tl/well) in duplicate to antigen-coated and blank wells for :2 hours at room
temperature on a shaker. Following 5 washes goat anti-human IgG alkaline
phosphatase conjugate (diluted I:1000 in 1% BSA/PBS- T) was added to all wells
( IOOl-ll/well)and incubated for one hour at room temperature on a shaker. Wells were
washed 3 times and pNPP substrate was added to all wells (I ()()~d/well) and
incubated at room temperature for one hour, Plates were read at 60 min at 405 nm on
a micromolecular plate reader (Molecular Devices).
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Rabbit anti-fd, sheep anti-M 13 or mouse anti-M 13 [gO were not used to capture the
phage due to strong cross-reaction of all human sera (either normal or patients' sera)
with these antibodies (either anti-fd or anti-M l3 antibodies), suggesting that there are
anti-idiotypes in human sera against anti-fd or anti-M 13 [gO (data not shown).
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4.2.1.3 Results
4.2.1.3.1 Sequences of Phagotopes Isolated by Bio-panning. of M 13 pili Phage Peptide
Library (linear 12-mers) and Immuno-blotting Assay with SMS Patients' Sera.
M13 plll phage library (linear 12-mers) was screened by 5 rounds of imrnunopanning
with SMS patients' sera as described in section 4.2.1.2.1.3. The number of plaques
obtained in each round during plating decreased consecutively. This may he due to the
loss of non-amplified phage which are specific to one paticnts scrum, but not to
another patient's serum. leading to a decrease in the number of the selected phage.
The specific plaques of 3 different rounds (third, fourth and fifth rounds) of M 13 pilI
phage library (linear 12-mers) to the SMS patients' sera were selected by immuno-
blotting assay as described in section 4.2.1.2.1.4. About 80(Yt, or these plaques
(clones) showed moderate affinity, giving pale blue spots on the nitrocellulose
membranes, to the SMS patients' sera in the third, fourth or fifth round. The plaques
showed high affinity neither to goat anti-human IgO nor to normal human sera.
Twenty clones derived from rounds 3,4 or 5 of bio-panning with SMS patients' sera
were sequenced successfully. The 20 clones specific to SMS patients' sera showed
two possible motifs depending on how the sequences were aligned. The tirst motif
showed leucine (13/20 clones), valine (1120 clones). glycine (2/20 cloucs) or alanine
(2/12 clones) followed by alanine (4/20 clones) or isoleucine (1/20 clones) followed
by cystine (2/20 clones) or methionine (1120 clones) followed by threonine (10/20
clones) or serine (7/20 clones) followed by histidine (5/20 clones). arginine (6/20
clones) or lysine (2/20 clones). Thus, one motif of these 20 clones is I.!i\-A-X- T/S-
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R/H/K. corresponding to amino acid residues 371-375 of GAD-65 (I.-L-M-S-R).
which showed conservative substitutions (Fig. 4.6. group I). Alanine. valine, glycine.
isoleucine and leucine have aliphatic side chains and thus are similar residues. In
addition. cystine and methionine have sulphur-containing side chains and thus are
similar residues. Also. threonine and serine have aliphatic hydroxyl side chains and
thus are similar residues. Furthermore, arginine, histidine and lysine have basic side
chains and thus are similar residues.
The second motif given by different alignment of the same sequences showed a motif
of threonine (5/20 clones) or serine (1/20 clones) followed by threonine (12/20
clones) followed by valine (2/20 clones), isoleucine (1/20 clones) or leucine (7/20
clones) followed by phenylalanine (2/20 clones) followed by glutamate (2/20 clones)
It1110wed by leucine (10/20 clones), glycine (2/20 clones). isoleucine (1120 clones).
valine (3/20 clones) or alanine (1120 clones) followed by histidine ( I 1120 clones) or
lysine (1/20 clones) followed by leucine (1120 clones) or glycine (1/20 clones)
followed by an amino acid residue followed by lysine (3/20 clones) or arginine (6/20
clones). Thus, the other motif of these 20 clones is T/S-T-V/l/L-F-E-L/Ci/I/V/A-H/K-
L/G-X-K/R, corresponding to amino acid residues 463-472 aa of GAD-ClS (T-T-G-f'-
E-A-H- V-D-K). which showed conservative substitutions. see above. (Fig. 4.6. group
II).
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4.2.1.3.2 Testing of SMS Patients' Sera-specific Phagotopes of M 13 pili Phage
Peptide Library (linear 12-mers) by ELISA
Sequenced phagotopes of Ml3 pIlI (linear 12-mers) phage library were selected for
investigation of their binding to the SMS patients' sera by direct ELISA as described
in section 3.2.1.2.4. Randomly selected 5 out of these 20 clones. which were screened
in EUSA, showed high binding with SMS patients' sera (.10. PT. DII and PT). not
LB SMS patient's serum compared to the negative control (normal human serum)
(data not shown). In particular. high optical density readings were given with negative
control phage (N-tenninal MoAb specific clone) as well as the selected phage clones.
Thus. because of this high background reactivity with the negative control phage, it
was not possible to demonstrate specific binding to the specific phage.
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Figure 4.6 Sequences of Peptides Selected from M 13 pili (linear 12-mers) Phage
Peptide Library by Binding to Antibodies of SMS Patients' Sera.
Group I:
GAD-65 (371-375) L L MS R
1-5 T L P L H P P L o S T H
6,7 r ypVrY~ A f HR,9 ILHKQi S lSi S p
10, II V I K T T V P LAS V R
12 N S ~ I E ~ J P C S J c
IJ S H L P R t N P ~ L T
14,15 b E T i F F H G P R V V
I I16,17 T t S A IV R P IT T T
18 H K A Y F T E A H YAK
19 T E C E ICGWRFS P
20 VK~PKPb~ J) /\ W I
Group II:
GAD-65 (463-472) T T G F [ A H V D K
10, II V I K T T V P L A S V R
12 1N n ~E P L P C S k C
14,15 E ~ + F F H t ~ k V V
19 I IT E C [ II C G WR F S III
1-5 T L P L H P P L D S T II
6,7 L H Y J ~ ~ Y L /\ S II' R
R,9 I L ~ K Q lA IS l IS ~ s P
16,17 T L S 1 S V k P Y lr II' II'
18 IH K A Y F T [ A H y A K
13 S ~ L P J L N II S L T
20 V k M Ip J p F S j, A W ~
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4.2.1.4 Discussion
Twenty clones. which were obtained from the third. fourth and Ii tth rounds of
successful biopanning of the M13 pIlI (linear 12-mers) phage library. were positively
imrnunostained in the blotting assay (moderate affinity) with the SMS patients' sera.
The 20 clones showed a motif of LlA-A-X-T/S-R/H/K (Fig. 4.6. group I). which
could correspond to 371-375 aa of GAD-65 (L-L-M-S-R). as a public epitope of
SMS patients' sera. Also. the 20 clones showed another motif of TlS-T-V/I/L-F-E-
L/G/I/V/A-H/K-L/G-X-KlR (Fig. 4.6. group II), which could correspond to 463-472
aa ofGAD-65 (T-T-G-F-E-A-H-V-D-K), as another public epitope or SMS patients'
sera.
Since SMS patients' sera-bound phage were eluted with rat brain GAD (native GAD)
rather than with acid. the phage peptide sequences may represent a conformational.
rather than linear, epitope.
Thus, a motif of SMS patients' antibodies may be 371-375 aa, which is present at the
C-terminal end of a-helix N in the three-dimensional model of the middle region of a
GAD-65 (Schwartz et al., 1999) (Fig. 4.7a). Alternatively. a motif of SMS patients'
antibodies could be 463-472 aa, which is present at the extreme N-terminal end of a-
helix R (467-486) and the loop region preceding it. in the three-dimensional model of
the C-terminal region of a GAD-65 (Schwartz et al.. 1999) (Fig. 4.7h. group II).
The proposed group II motif of SMS patients' sera (463-472) has a critical amino acid
residue H470 which. when mutated to Q470. affects the binding of MICA-8 and
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MICA-9 to GAD-65 (Schwartz et al., 1999). In addition. MICA-I. MICi\-3 and DPA
(huAbs of type 1 OM patients) are predicted to bind the backside or helix R (Schwartz
et al., 1999) which has the predicted public epitope of SMS patients' sera (463-472).
Thus. this predicted public epitope of SMS patients' sera may be a major antigenic
determinant of type I DM patients sera as well as SMS patients' sera.
It should also be noted that the two regions of GAD-65 identified here (371-375 aa
and 463-472 aa) are predicted to be very close together in the three-dimensional
model of GAD-65 due to the alignment of the middle and C-terminal regions of the
molecule.
Four out five sera of SMS patients (10, OH, PT and LB) showed higher binding than
negative control serum (NHS) to the selected phage in ELISA (data 110t shown).
However, these four SMS patients' sera gave high optical density readings with both
selected phage and the negative control phage (N-terminal MoAb specific clone). The
reason for this non-specific reactivity is unclear, but it is possible that the N-terminal
MoAb specific clone was not the proper negative control phage in this assay since
some SMS sera may recognize the N-terminus of GAD-65 as a major antigenic
determinant (Bjork et al., 1994; Kim et al., 1994). Another possibility is that the
selected phage may bind to GAD, since these phage were eluted by (iAD; this could
be tested by determining whether the selected phage bind to GAD itself. Also. it has
been suggested that one NHS was not sufficient to control for the specific binding of
SMS sera to the selected phage. Although, in immuno-blotting assay. XO% of clones
showed specific binding to SMS sera compared to NHS. we cannot be certain that the
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selected phage represent disease-specific sequences. Thus we cannot exclude that
other NHS might have shown high binding to the selected phage similar to SMS sera.
To investigate whether the selected phage represent disease-specific sequences, future
work could involve imruuno-precipitation assay by exposing the selected phage to the
antibodies of SMS sera in a fluid phase, rather than solid phase (which may denature
the exposed peptide or facilitate non-specific binding, followed by adding protein-A
sepharose to precipitate the antibodies of SMS sera, including the antibody-phage
immune complexes. The precipitated phage in the immune complexes could then be
detected by their ability to infect E.coli and generate the plaques. Also. other future
work could involve the mutation of the suggested regions of GAD to see if this affects
the binding of the SMS antibodies. Also, other future work could involve raising
mouse monoclonal antibodies (MoAbs) against the selected phage and see if these
MoAbs bind to GAD.
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Figure 4.7 The Three-dimensional Models of the Middle (a) and C-terminal (b)
Regions of GAD-65 (modified from Schwartz et al., 1999) showing the suggested
Public Epitopes of SMS Patients' Sera; a) 371-375, which is present in the C-
terminal end of a-helix N and b) 463-472, which is present in the Loop Region at the
extreme N-terminal end of a-helix R (Schwartz et al., 1999).
a)
b)
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General Discussion
5 General Discussion
5.1 Introduction
Type I diabetes mellitus (type 10M) is believed to have an autoimmune
pathogenesis with a multifactorial etiology leading to destruction of insulin-producing
pancreatic islet J3 cells and insulin deficiency. Many genetic loci arc involved in
determining genetic susceptibility to the disease. the most important of which is found
in the HLA, mainly HLA-OR3/DQ2 and HLA-DR4/0Q8. Environmental factors arc
also important, especially viruses. such as coxsackie virus B4 (CV£34). Humoral and
cellular autoimmune responses to the pancreatic islet p cells can damage these islet J3
cells and expose many autoantigens. Both subsets of T cells. ('04+ T helper I (Th I)
cells and CD8+ cytotoxic T cells (Tc), and macrophages are involved in the cellular
autoimmune response to the pancreatic islet p cells. Autoantibodies (lgG I). mainly
GAD autoantibodies (GAAs), anti-IA-2/ICA-512bdc autoantibodies (anti-IA-2 AAs).
anti-IA-2p/phogrin autoantibodies (anti-IA-2J3 AAs) and insulin autoantibodies
(IAAs), are produced to the autoantigens of the pancreatic islet 1\ cells and can be
used as markers of the pathogenesis of type 10M.
GAAs are important markers for type 10M. Individuals with other autoimmune
diseases such as stiff man syndrome (SMS) and autoimmune polyendocrine syndrome
(APS) also have GAAs. Diabetes is often a component of SMS and APS type II with
an incidence of about 30% (Bosi et al., 1991; Solimena et al., 1990) whereas it is not a
usual feature of APS type I (Riley 1992).
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While there is an autoimmune response to GAD-65 in type I DM. SMS and APS II. a
difference in the clinical frequency of diabetes suggests that the humoral and cellular
autoimmune response to GAO-65 may differ in these diseases. (,Ai\s in SMS have
both similarities and differences with those found in type I OM (Daw et al., 1996;
Kim et al., 1(94) and APS II. GAAs from patients with SMS or type 1 OM both
recognize determinants in the middle and carboxy (C) terminal regions of GAD65
but. predominantly in SMS patients, antibodies also recognize determinants in the
amino (N) terminal region of GAD-65 (Daw et al., 1996; KiIII et al., 19(4).
Furthermore. GAAs in patients with SMS recognize GAD on Western blots. whereas
GAAs in type 1 OM fail to detect GAD on Western blots (Baekkeskov et al., 1990).
indicating that GAAs of type 1 OM recognize only conformation-dependent epitopes
while some GAAs of SMS recognize linear epitopes. Although the locations of
epitopes of GAAs in APS type II have not yet been precisely mapped. GAAs of
diabetic APS patients' sera recognise a dominant linear epitope within 7-124 amino
acid residues (aa) of GAD65 which is also recognised by other patients' sera (type 1
OM. non-diabetic APS and SMS), but at a lower frequency than diabetic APS
(Sohnlein et al., 2000). Thus. there is considerable heterogeneity between anti-GAD
responses of these disorders, which may be due to GAD being presented to the
immune system through separate pathogenic mechanisms. In addition. (iAAs in SMS
and APS are present at high titre while GAAs in type 1 OM arc present at lower titre
(Bjork et al., 1994). GAAs are present in 89% of APS II patients wi th type 10M.
21% of APS II patients without type 10M, 89% of SMS patients (Morgenthaler et
al., 1997), 80% of newly diagnosed type I OM patients. 20% of non-diabetic identical
twins who are at low risk of diabetes (Christie et al.. 1(94) and X01Yc. of relatives of
diabetic patients who themselves developed type 1 OM (Bingley et al., 19(3).
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T cells of SMS patients recognize different immunodominant epitopes of GAO-65
compared with T cell from patients with type 10M. The region of GA065 amino
acids 339-352. which is recognised by the T cells of a non-diabetic SMS patient. has
110 reactivity with T cells of newly diagnosed type I OM patients (Schloot et al.,
1(99). In contrast. the GAD regions, 161-243 and 473-555 aa, induce a dominant T
cell response in type 10M. not in SMS; while the GAD regions. 81-171 and 313-403
aa. induce a dominant T cell response in SMS. not in type I DM (Lohmann et al.,
2000).
The prevalence of anti-1A-2 AAs is higher in acute onset 100M than in slowly
progressive lOOM (Yamada et al., 1997). The anti-IA-2 AAs are present in 56%
100M patients. 47% APS II patients with 100M. 14% SMS patients. 4% APS II
patients without IDOM (Morgenthaler et al., 1997). The maior antigenic determinant
of IA-2 in type I OM patients is localized within 762-887 aa. while the minor
antigenic determinant of IA-2 is localized within 601-762 aa. which is highly
homologous between IA-2 and phogrin. In addition. it has been suggested that some
of the anti-IA-2 AAs recognize a conformational epitope(s) associated with the C-
terminal region of native IA-2 (949-979 aa) (Kawasaki et al., 1(98).
A new approach to the identification of both linear and non-linear epitopes is antibody
probing of phage display peptide libraries which can reveal conformational epitopes
and also linear mimotopes that mimic the shape of conformational cpitopes (Scott and
Smith 1990). Conformational epitopes have been identified using monoclonal
antibodies (Cook et al., 1998: Felici et al., 1993; Luzzago et al.. 19(3) and also using
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polyclonal antibodies in immune sera from both animals and humans (Folgori et al.,
1994~ Osman et al.. 1(98). However, there have been lew definitive studies on
polyclonal antibodies in human sera using phage display libraries.
The aim of my studies was to determine the epitopes in GAD65 of three different
mouse monoclonal antibodies: GAD-6, N-terminal mouse monoclonal antibody
binding within 4-17 amino acids (aa) and C-terminal monoclonal antibody binding
within 572-585 aa: to determine the epitopes in IA-2 of two different mouse
monoclonal antibodies 768 and 76F; and to determine the epitopes of two different
human monoclonal antibodies, b78 and b96.11, on GAD-65. The determination of
epitopes recognized by these monoclonal antibodies might help us to understand the
antigenic nature of the GAD-65 and IA-2 autoantigens.
Furthermore, since epitope mapping is generally simpler with monoclonal antibodies
than with polyclonal antibodies, it was intended that these studies should indicate how
best to use the random phage peptide libraries to determine the epitope specificities of
patients' serum autoantibodies. The very high levels ofGAAs in SMS patients' sera,
indicates that phage display technology should be applicable to the identification of
mimotopes of GAD-65 that are reactive with GAAs of SMS patients' sera. Thus, a
further purpose of these studies was to determine the immunodominant epitopes
(public epitopes) in GAD65 ofSMS patients' serum autoantibodies.
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5.2 Antigenic Nature of GAD-65 defined by Binding of N-terminal and C-
terminal Specific Mouse Monoclonal Antibodies
N-terminal MoAb, GC 3208 (clone II), is a mouse (gG I MoAb which recognizes the
4-17 aa residues of GAD-65. C-terminal monoclonal antibody, GC 31O~ (clone III).
is a mouse (gG I monoclonal antibody which recognizes the 572-5X5 aa residues of
GAD-65.
In the present study the N-terminal MoAb was screened with two types of M 13
tilamentous phage-displayed library, gene III linear 12-mers and gene VIII 5C4C4. to
derive peptide mimotopes of N-terminal MoAb on GAD-65. All the clones of
phagotopes of Ml J, both gene III linear 12-mers and gene VIII 5C4C4 libraries. were
also tested for reactivity with N-terminal MoAb by using capture ELISA. thus
identifying a set of reactive phagotopes with sequences that represented mimotopes of
the epitope of the N-terminal MoAb on GAD-65. All the clones of the phagotopes
derived by biopanning of Ml3 gene VIII 5C4C4 library with N-terminal MoAb were
strongly reactive with the N-terminal MoAb by ELISA.
The clones, which were obtained from the successful biopanning of the M13 pili
linear 12-mers phage library with the N-terminal MoAb, showed a motif of P-G-X-X-
X-W-S-F, corresponding to 4-10 aa ofGAD-65 (P-G-S-G-F-W-S-F). The presence of
proline in the motif of the N-terminal MoAb may influence the binding of the N-
terminal mouse monoclonal antibody with the middle region of till: motif because it
induces a turn in the sequence. By contrast, the clones. which were obtained from the
successful biopanning of the M13 pVIII SC4C4 phage library with the N-terminal
MoAb, showed a motif of SeT-powhich does not correspond to amino acid residues 4-
209
General Discussion
17 of GAD-65 and does not overlap with the previous motif of the N-tenninal MoAb.
i.e. P-G-S-G-F-W-S-F (4-10 amino acid residues). Therefore. The MI3 pVIII 5C4C4
worked with N-terminal MoAb by expressing a relevant sequence for the N-terminal
MoAb but which is unlike its epitope in GAD-65. This shows that a dearly defined,
antibody-reactive motif selected from a phage peptide library may not necessarily
show sequence similarities with the epitope of the original protein antigen.
To further define the N-terminal MoAb epitope, in the present study the N-terminal
MoAb was screened with the T7 linear 9-mers phage-displayed library to derive
peptide mimotopes of N-terminal MoAb on GAD-65. Twenty clones. which were
obtained from the successful biopanning of the T7 linear 9-mers phage library with
the N-terminal MoAb, showed a motif of P-X-X-G, corresponding to amino acid
residues 4-7 of GAD-65 (P-G-S-G), which overlaps with the previous motif P-G-S-G-
F-W-S-F (4-10 amino acid residues). The other 6 clones did not show any significant
motif. This may be the result of a heteroclytic monoclonal antibody character. which
recognizes the related clones more strongly than the specific clones.
In the present study the C-terminal mouse monoclonal antibody was screened with
M13 filamentous phage-displayed library gene III linear 12-mers to derive peptide
mimotopes of C-terminal MoAb on GAD-65. The clones. which were obtained from
the successful biopanning of the M13 pIlI linear 12-mers phage library with the C-
terminal MnAb, showed a motif of F-L-I-X-E-IIV IL-D-X-L, corresponding to 573-
581 aa of GAD-65 (F-L-I-E-E-I-E-R-L), as an important epitopic determinant of the
C-terminal MoAb.
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The N'terminal MoAb reacts weakly with GA065 on blots. but does react with native
(jAD65. The Cstenninal MoAb reacts strongly on blots. but does 110tappear to react
with native GAD65 (data not shown). Therefore, the a-helix T. where the Cvterminal
MoAb binds. must be denatured for C-terminal MoAb to bind.
5.3 Antigenic Nature of GAD-6S defined by Binding of GAD-6 Mouse
Monoclonal Antibody
The murine IgG2a monoclonal antibody GAO-6 recognizes a spcci lie epitope on
GAD65 within 475-585 aa(SMS El) (Butler et al., 1993). The GAAs of type I OM.
SMS and APS II (diabetic and non-diabetic) sera recognize the region of the GAO-6
epitope on GAO-65. In addition, the extreme C-terminal sixteen amino acid residues
of GAD65 are not involved in the epitope ofGAD-6 (Davenport cl al., 19(7).
To further define the GAD-6 epitope, in the present study GAD-6 was screened with
two types of T7 phage-display library of random peptides, both constrained 9-mers
(C9C) and unconstrained 9-mers (linear 9-mers), expressed at the ("-terminus of gene
X coat protein of bacteriophage to derive peptide mimotopes of CiAD-()on GAO-6S.
Thirteen out of 16 clones of phago topes of the T7 C9C phage library or 217 clones of
phagotopes of the T7 linear 9-mers phage library showed a motif of R/K-LlA/I-X-K
or R-X-X-K, respectively. possibly corresponding to 525-528 aa of (jAD-65 (R-L-S-
K). as an important epitopic determinant of the GAD-6. The two amino acid residues
on the ends of the motif (arginine and lysine) are highly conserved. suggesting that
they are important in the paratope-epitope interaction between the (jAJ)-6 and GAD-
65. Another motif of GAD-6 obtained from 3 other clones. which were screened by
211
General Discussion
T7 (C9C) phage library, are M-X-X-A, possibly corresponding to 523-526 aa (M-S-
R-L) of GAD-65. The presence of methionine and leucine also appears to be
important in the paratope-epitope interaction between the GAD-6 and (iAD-65.
GAD-6 does not bind to GAD-67: it is therefore significant that the equivalent
residues of M-S-R-L-S-K, the motif of GAD-6 corresponding to 523-518 aa of GAD-
65, are R-E-K-L-H-R in GAD-67, which shows 5 amino acid substitutions that may
disrupt the GAD-6 epitope. Also, the equivalent residues of R-X-X-K. the motif of
GAD-6 corresponding to 525-528 aa ofGAD-65 obtained by T7 phage library. are K-
X-X-R in GAD-67: as an opposite direction of the motif (R-X-X-K) ill GAD-65. This
may prevent the binding of GAD-6 to GAD-67 or other changes to neighbouring
amino acids may affect the binding of GAD-6.
To further define the GAD-6 epitope, in the present study GAD-6 was screened with
three types of M 13 filamentous phage-displayed library of random peptides expressed
at the N-terminus of gene III protein, both constrained 7-mcrs (C7C) and
unconstrained 12-mers (linear 12-mers), or gene VIII protein constrained 13-mers
(5C4C4) to derive peptide mimotopes of GAD-6 on GAD-65. All the clones of the
two types of M 13 gene III library, which were sequenced and compared with one
another. did not show a clear motif. It was impossible to align them (data not shown)
and they did not show reactivity with GAD-6 by capture ELISA. A possible
explanation for this is that the peptides, which are specific to bind with GAD-6. are
not present in this type of library, M13 pIlI phage library, either linear l2-mers or
C7C. In contrast, all the clones of the phagotopes selected by biopanning of M 13 gene
VIII 5C4C4 library with GAD-6 were strongly reactive with GAD-Cl by capture
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ELISA. Interestingly. all these sequences were identical to each other, i.e. they
showed only one peptide. This indicates that the MI3 pVIII phage library may have
one dominant peptide specific to GAD-6. All the clones showed a motif of methionine
followed by two amino acids followed by alanine. Thus. the moti f of GAD-6
suggested from this library is M-X-X-A, which is identical to the motif selected from
3 clones of T7 (C9C) library. possibly corresponding to amino acid residues 523-526
(M-S-R-L) of GAD-65 which overlaps with the previous motif: R-L-X-K (525-528
aa). Other work from this laboratory has indicated that GAD-6 can recognize the
motif M-X-X-L (523-526 aa of GAD-65) by aligning 7/17 clones. which was selected
from a linear IS-mel's M 13 filamentous phage library (Davenport. 1(95).
Analysis of C-terminal deletion mutants shows that the removal of 41 aa at the C-
terminus of GAD65 (545-585 aa deletion mutant) abolishes the binding of MICA-2
(human monoclonal antibody) and GAD-6 on blots (Richter et al.. 1<)<)3).However,
the suggested GAD-6 epitope (523-528 aa) is present in cc-helix S of the model of
Schwartz et al. (1999). while the deletion of 545-585 aa removes the terminal o-helix
T and 2 lengths of ~-pleated sheet. Mapping of MICA-2 epitope within GAD-65 by
using an epitope cDNA library reveals that the MICA-2 can recognize an epitope
between 506-531 aa of GAD65 (Richter et al., 1996). which includes the GAD-6
epitope suggested from the libraries here. It is possible that the removal of 41 aa at the
C-terminus of GAD65 (545-585 aa deletion mutant) may lead to a conformational
change of GAD-6S which abolishes the binding of MICA-2 and GAD-6. Thus. 545-
585 aa deletion mutant would remove terminal a-helix (T) and 2 lengths of p-pleated
sheet. in the Schwartz model. which is likely to disrupt the conformation of u-hel ix S.
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In NOD mice. injection of GAD-65 peptide 524-543 aa. which also includes the
proposed GAD-6 epitope mapped here with phage libraries. activates diabetogenic T
cells (Zekzer et al., 19(8). Furthermore, T-cells in type I DM patients can react with
379-585 aa of GAD-65 (Rharbaoui et al., 1999). Binding of GAD-6 to this region of
GAD-65 may block antigen processing which generates the peptides required tor
stimulation of GAD specific TH I cells. Previous studies have shown that blocking the
T cell response to GAD by tolerisation with GAD antigen inhibits the response to
other islet antigens. in particular insulin and carboxypeptidase H (Kaufman et al.,
1993; Tisch et al., 19(3). Other studies have shown that injection of monoclonal
antibody against GAD into NOD mice leads to delay in the onset or diabetes and a
decrease in the severity of insulitis. The mechanism of diabetes prevention by
administration of anti-GAD antibody could be associated with an interference in
recognition of GAD by T cells (Menard et al., 1999). Indeed, autoreactive B cell may
act as APe for the T cell activation (Noorchashm et al., 1997). Also. incubation of a
T-cell hybridoma, which recognizes the GAD-65 274-286 epitope. with APe exposed
to recombinant human GAD-65 complexed with GAD-65+ autoantibodies led to the
stimulation of this T-cell hybridoma. This stimulation was most prominent using sera
from patients with GAD-65 autoantibodies. Uptake of antibody-complexed GAD-65
was Fe receptor-mediated. i.e. macrophages and/or dendritic cells. not antigen-
specific B-cells. These findings support the idea that GAD65 autoantibodies modulate
presentation of GAD-65 to T cells (Reijonen et al., 2000). In addition. the NOD
mouse fails to develop diabetes if the B cell compartment is inactivated. suggesting a
crucial role of B cells. probably as essential antigen presenting cells. It has been
suggested that the membrane bound IgG may playa crucial role in antigen uptake.
Thus, B cell presentation of GAD-65 may play an important role in
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immunopathogenesis of type I OM by shaping the autoreactive 1 cell repertoire
(Ouhindan et al., 20(0).
To further determine whether the phage peptides which were selected by
immunopanning with UAD-6 were acting as true mimotopes of (;;\1)-65 epitopes,
mice should be immunized with OAO-6 reactive clones. Immunizing with rnimotope
peptides presented on filamentous phage is an appropriate method to produce peptide-
specific antibodies which also bind to the native antigen (Meola er al.. 19(5).
5.4 Antigenic Nature of IA-2: Binding of 768 and 76F Mouse Monoclonal
Antibodies
768 (unknown IgO isotype) and 76F (lg02b), supernatants of two mouse monoclonal
antibodies, recognize epitopes in the extracellular domain and Nvtenninal region of
the cytoplasmic domain of lA-2, respectively.
In the present study the 768 or 76F MoAb were screened with 17 ('9C phage-
displayed library to derive peptide mimotopes of 768 or 76F MoAb epitopes on IA-2.
To further define the 768 or 76F MoAb epitopes, in the present study the 768 or 76F
mouse monoclonal antibodies were also screened with M 13 gene III Iinear 12-mers
phage-displayed library to derive peptide mimotopes of 7()B (Ir 76F mouse
monoclonal antibody on IA-2.
The sequences of 768-specific clones obtained from both libraries. T7 ('l)(' and M 13
pill linear l2-mers. showed homologies amongst themselves and with the original
IA-2 sequence. Thus. the main motif of 768 is D-X-K-P-L-S. corresponding to 477-
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482 aa of IA-2 (D-()-K-P-L-S). The sequences of 76F-specitic clones obtained from
hath libraries. T7 <,'9(' and M 13 pIlI linear 12-mers. show homologies amongst
themselves and with the originaIIA-2 sequence. Thus. the main motif or 76F is F-X-
Y-Q. corresponding to 626-629 aa of IA-2 (F-E-Y-Q). Since the minor antigenic
determinant of IA-2 is localized to 601-762 aa (Kawasaki et al.. 1(98) and huAb
t 03/5 recognizes 603-686 aa of IA-2 (Kolm-Litty et al.. 20(0) which includes the
predicted region recognized by 76F huAb (626-629 aa), the 76F MuAb might be
used to block antigen processing which generates the peptidcs required for
stimulation of IA-2 specific TH I cells by binding of 76F to this region of IA-2.
5.5 Antigenic Nature of GAD-65 by Binding of b96.11 and b78 Human
Monoclonal Antibodies
b78 and b96.11. supernatant of cloned cells of two human monoclonal antibody
producing cell lines derived from a human APS patient. recognize epitopes on GAD-
65. 532-540 aa and 308-365 aa, respectively.
In the present study b96.11 huAb was screened with M13 gene III linear 12-mers
library to derive peptide mimotopes of b96.l1 huAb on GAD-65. The clones, which
were obtained from the successful biopanning of the M 13 pili linear 12-mers phage
library with the b96.11. showed a motifoflN-T/S-A/G/L-T/S-A/L (Fiu. 4.1a), which
might correspond to 332-336 aa of GAD-65 (V-S-A-T-A). and another motif of S-
T/S-G/A/LII (Fig. 4.1 b). which also might correspond to 338-340 aa or GAD-65 (T-
T-V) as epitopic determinants of the b96.11 huAb. Thus. the overall motif of b96. t 1
might correspond to 332-340 aa of GAD-65, which is within the region of GAD65
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308-365 aa. Deletion of this region is known to abolish the binding of b96.11 to
GAD65 (Schwartz et al., 1999).
The b78 and b96.11 huAb recognize native (not denatured) UAO-65. indicating that
these hUAb. b78 and b96.11, can recognize conformational (not linear) epitopes on
GAD-65.
It is noteworthy that the b78 huAb bound slightly better with GAO-6 as the capture
MoAb (rather than the N-terminal MoAb), but b96.11 bound much better with GAD-6
as the capture MoAb (Table 4.3). This might suggest that the GAD-6 does interfere
with b78 huAb binding to GAD-65 more than it does with b96.1 I huAb. However. it
must also suggest that the GAD-6 and b78 huAb epitopes are not directly overlapping.
The b78 huAb recognizes amino acid residues between 532-540 on GAD-65
(Schwartz et al.. 1999) which is very close to the proposed GAO-6 epitope (523-528
aa). In addition. the footprint pattern of protected trypsinized fragments of GAD-6 is
similar to that of b78 huAb (Tremble et aI., 1997).
The mutation V532K disrupts the binding of b78 huAb to GAO-65. while other
mutations in the same region of b78 epitope, R536L and Y540S. do not disrupt the
binding of b78 to UAO-65. This indicates that V532 may be involved in the surface
patch of the b78 epitope which then includes other amino acid rcsiduets) from
different region(s).
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S.6 Antigenic Nature of GAD-6S defined by Binding of GAD
Autoantibodies of SMS Patients' Sera
To further define the epitopes of GAAs of SMS sera. in the present study SMS sera
were screened with an M 13 linear 12-mers phage-displayed Iibrary of random
peptides to derive peptide mimotopes of SMS sera on GAD-Cl5. All the clones of
phagotopes of M 13 gene III linear 12-mers library were tested for reactivity with
SMS sera by capture ELISA, but they did not show reactivity.
The clones. which were obtained from the third. fourth and fifth rounds of successful
hiopanning of the Ml3 pIlI (linear 12-mers) phage library and were positively
irnmunostained in the blotting assay (moderate affinity) with the SMS patients' sera
showed a motif of L/A-A-X-T/S-RfH/K. This could correspond to 371-375 aa of
(iAD-65 (L-L-M-S-R), as a public epitope of SMS patients' sera.
The 20 clones showed another motif of T/S-T-VIIIL-F -E-L/G/IIV! A-H/K-L/G-X-
K/R. This could correspond to 463-472 aa of GAD-65 (T-T-G-F-E-A-H-V-D-K), as
another public epitope of SMS patients' sera.
S.7 The Importance of Using Different Phage Libraries with Different
Features Screened with either Monoclonal or Po/yc/onal Antibodies
The differences in the sequences of the peptides selected using the M13 PVIII
filamentous phage library and T7 phage library with N-terminal MoAb may be due
to the differences in their capacity to express their displayed peptide. either at the N-
terminus of gene VIII ofM13 filamentous phage library or at the C-tcrminus of gene
X of T7 phage library. Also, the conformation of the expressed peptides may be
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different between these two phage libraries due to differences in the number of
amino acid residues and due to the presence of the cysteine-cysteine bridge in the
M13 pVIII phage library. However, similar sequences were selected from these
libraries with OAD-6.
The number of copies of the displayed peptide expressed by M 13 pVTIl (300 copies
per phage) compared with the lower number of copies expressed by M 13 pIlI (3-5
copies per phage). may account for the reactivity of the N-tcrminal MoAb with
specific clones of phagotopes derived from the MI3 pVIIl library rather than MI3
plll. due to the higher avidity of binding with the M13 pVIII library.
Polyclonal IgO includes a myriad of antibodies so that. even after extensive rounds of
negative selection. the phagotopes will include many that react with other antibodies
that are either specific or non-specific to the disease. The difficulty in discriminating
between sequences that are specific or non-specific for any disease has greatly
hampered the use of phage-displayed technology with polyclonal sera. In addition.
some of the non-disease specific phagotope sequences would include either nuisance
peptides intrinsic to the biopanning process itself. or mimotopes of bacterial or viral
antigens for which antibodies were absent from the particular pool or 19G used for
negative selection (data not shown).
S.B Conclusion
In conclusion. amalgamate findings for different mouse monoclonal antibodies
(GAD-6. 76B. 76F and N-terminal and C-terminal mouse monoclonal antibodies).
human monoclonal (b96.11) and polyclonal antibodies (SMS patients' sera) have
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been presented for the screening of different peptide libraries with different features
[T7 gene X (C9(' and linear 9-mers), M13 gene 1II (C7C and linear 12-mers) and
M13 gene VIII (5('4('4)]. These peptide sequences have been compared with the
known structure of immunodominant regions of the autoantigenic molecules. GAO-65
and IA-2, to locate precisely conformational epitopes on these major autoantigens in
type 10M, SMS and APS patients.
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APPENDICES
Appendix I: Abbreviations for Amino Acids
Amino Acid Th ree- Letter One-Letter
Abbreviation Abbreviation
-_ ...-.._-_ ....._ ...... _ .......
Alanine Ala A
Arginine Arg R
Asparagine Asn N
Aspartic Acid Asp D
Cysteine Cys C
Glutamine Gin Q.
Glutamic Acid Glu E
Glycine Gly G
Histidine His H
Isoleucine lie
Leucine Leu L
Lysine Lys K
Methionine Met M
Pheny lalanine Phe F
Proline Pro P
Serine Ser S
Threonine Thr T
Tryptophan Trp W
Tyrosine Tyr y
Valine Val V
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Appendix 2: Amino Acids grouped according to Chemical Properties
Chemical Nature of Side Chain Amino Acids
Aliphatic Side Chains Glycine
Alanine
Valine
Leucine
Isoleucine
Aliphatic Hydroxyle Side Chains Serine
Threonine
Basic Side Chains Lysine
Arginine
Histidine
Aromatic Side Chains Phenylalanine
Tyrosine
Tryptophan
Acidic Side Chains Aspartic Acid
Glutamic Acid
Amide Side Chains Asparagine
Glutamine
Sulfur-containing Side Chains Cysteine
Methionine
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